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Introduction 1 
1 Introduction 
1.1 Oral cancer treatment 
Cancer therapy has traditionally been dominated by intravenously administered agents [1]. A 
few oral anticancer drugs have been used for a long time such as chlorambucil, methotrexate, 
cyclophosphamide and 6-mercaptopurine [2]. However, during the previous decade many orally 
administered anticancer drugs have been developed. The mechanisms of action of these agents 
are heterogenous including oral cytotoxic drugs as well as targeted therapies which have a high 
specificity for a cancer-specific molecular target structure, e.g. cell surface receptors or other 
proteins [2, 3]. The National Comprehensive Cancer Network predicts that the percentage of 
anti-cancer treatment given as oral agents will rise up to 20 to 25% over the next years. 
Although oral anti-cancer drugs are unlikely to substantially substitute intravenous treatment, 
they will become more important in the combination with intravenous therapy [2]. 
Approximately one-quarter of all anti-cancer drugs under development are orally administered 
medicinal products [1]. 
The acceptance of oral treatments by cancer patients is widespread. Convenience is the most 
important advantage of oral anti-cancer therapy among patients. Medicines can be taken at 
home without the need for time-consuming appointments at treatment sites [2, 4]. Further 
benefits are the avoidance of venipuncture and paravasates as well as a greater patient 
autonomy. Patients appreciate the decrease of daily presence of the psychologically very 
distressing disease by use of oral administered anti-cancer therapy (better coping) [5]. 
Additionally, the reduction of institutionally triggered adverse drug reactions like e.g. 
psychogenic nausea or vomiting and the avoidance of confrontations with other patients which 
might cause high emotional involvement are benefits of an oral treatment. However, patient 
preference for an orally administered treatment might decrease if the alternative intravenous 
therapy is superior in efficacy or toxicity [2, 5, 6]. Even with such advantages and if similar 
efficacy and tolerability profiles are assumed, the use of oral anti-cancer agents does involve 
many challenges which have to be addressed to achieve best possible outcome for the patient. 
Due to less intense contact between patient and health care providers, responsibilities in terms 
of managing the course of treatment are transferred to the patient such as monitoring of doses 
and toxicity [2, 7]. In contrast to intravenously administered anti-cancer treatments, health care 
providers cannot always assume that the patients are adherent to their treatment which is, 
however, the key prerequisite for treatment success (see 1.3). Multidisciplinary patient care and 
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specific patient education regarding all aspects of the treatment regimen are crucial to maintain 
adherence [5, 7–10]. 
1.1.1 Capecitabine 
Patients of the present study were treated with the chemotherapeutic agent capecitabine, an 
orally administered prodrug of cytotoxic fluorouracil (5-FU). Capecitabine belongs to the 
pharmacological group of antimetabolites and is a non-cytotoxic fluoropyrimidine carbamate. 
The development was driven by the idea of increased drug concentrations inside the tumour 
cells through tumour-specific conversion to the active drug [11]. Capecitabine is activated via 
several enzymatic steps. The enzymes involved in the catalytic activation of capecitabine 
usually exhibit higher activity in tumour tissue than in normal tissue. Thus, sequential 
enzymatic biotransformation of capecitabine to 5-FU leads to higher concentrations within 
tumour tissue. The registered product Xeloda® received approval in the United States of 
America in April 1998 [2]. In Germany it was approved in February 2001 [12]. Xeloda® is 
available as 150 mg or 500 mg film-coated tablets. Capecitabine is indicated for the adjuvant 
treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer, for the 
treatment of metastatic colorectal cancer and for first-line treatment of advanced gastric cancer 
in combination with a platinum-based regimen. In combination with docetaxel, capecitabine is 
indicated for the treatment of patients suffering from locally advanced or metastatic breast 
cancer after failure of cytotoxic chemotherapy. An anthracycline should have been part of a 
previous therapy. Capecitabine is also indicated as monotherapy for the treatment of patients 
with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-
containing chemotherapy regimen or for whom further anthracycline therapy is not indicated 
[12, 13]. 
In the present investigation, capecitabine was most frequently used as single agent treatment. 
Table 1-1 gives an overview of all applied treatment regimens. 
Capecitabine tablets should be taken in the morning and in the evening with a glass of water up 
to 30 minutes after a meal. In case of disease progression or intolerable adverse drug reactions 
the treatment should be discontinued. Prescribed as single agent treatment, the recommended 
starting dose for capecitabine in the treatment of metastatic colorectal cancer, adjuvant 
treatment of colon cancer or of locally advanced or metastatic breast cancer is 1250 mg/m2 
administered twice per day for two weeks separated by twelve hours, followed by a one-week 
medication-free interval. Usually capecitabine is given in three-week cycles. Dose calculations 
are provided in Table 1-2. In case of toxicity, dose reduction to 75% or 50% according to 
toxicity grade is recommended [12, 13]. 
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Table 1-1: Treatment regimens used in the present study 
Cancer entity Treatment regimen 
Breast cancer Capecitabine [12, 13] 
 Capecitabine/bevacizumab [12, 14, 15] 
 Capecitabine/lapatinib [12, 14, 15] 
 Capecitabine/vinorelbin [16] 
 Capecitabine/trastuzumab [16] 
 Capecitabine/fulvestrant 
 Capecitabine/vinorelbin/letrozole 
Colorectal cancer Capecitabine [12, 13] 
 Capecitabine/bevacizumab [12, 14] 
 Capecitabine/bevacizumab/oxaliplatin [17] 
 Capecitabine/oxaliplatin [12, 14] 
 Capecitabine/mitomycin C [18] 
Gastric cancer Capecitabine [19] 
Pancreatic cancer Capecitabine [11] 
Endometrial cancer Capecitabine 
Cancer of unknown primary (CUP) Capecitabine 
Oesophageal cancer Capecitabine/oxaliplatin [20] 
 Capecitabine/oxaliplatin/trastuzumab [20] 
Ovarian cancer Capecitabine [11] 
 Capecitabine/bevacizumab 
Table 1-2: Standard and reduced capecitabine dosing according to body surface area for a 
starting dose of 1250 mg/m2 twice daily [12, 13] 
 
Full dose 
(100%) 
1250 mg/m2 
Reduced dose 
(75%) 
950 mg/m2 
Reduced dose 
(50%) 
625 mg/m2 
Body Surface Area 
[m2] 
Dose per 
administration [mg] 
Dose per 
administration [mg] 
Dose per 
administration [mg] 
≤1.26 1500 1150 800 
1.27 - 1.38 1650 1300 800 
1.39 - 1.52 1800 1450 950 
1.53 - 1.66 2000 1500 1000 
1.67 - 1.78 2150 1650 1000 
1.79 - 1.92 2300 1800 1150 
1.93 - 2.06 2500 1950 1300 
2.07 - 2.18 2650 2000 1300 
≥2.19 2800 2150 1450 
Safety and efficacy data in patients with hepatic impairment are unavailable. Close monitoring 
in patients with mild to moderate liver impairment is mandatory. Capecitabine therapy should 
be interrupted in case of treatment-related elevations in bilirubin of >3.0 x the upper limit of 
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normal (ULN) or treatment-related elevations in hepatic aminotransferases (alanine 
transaminase (ALT), aspartate transaminase (AST)) of >2.5 x ULN. Capecitabine monotherapy 
may be restarted as soon as bilirubin decreases to ≤3.0 x ULN or hepatic aminotransferases 
decrease to ≤2.5 x ULN. Severe renal impairment at baseline (Creatinine Clearance (CLCR) <30 
ml/min, Cockroft and Gault) is a contraindication for capecitabine. The recommended starting 
dose for patients with moderate renal impairment at baseline (CLCR 30-50 ml/min) is 75% of a 
starting dose of 1250 mg/m². No modification is recommended in patients with mild renal 
impairment (CLCR 51-80 ml/min at baseline) [12, 13]. 
Adverse drug reactions 
The development of capecitabine as a prodrug of 5-FU was aimed to increase efficacy and 
tolerability by selectively targeting the active drug to tumour cells with the convenient 
secondary effect of sparing healthy cells. Oral capecitabine proved to achieve superior response 
rates, equivalent time to disease progression and equivalent survival compared with 
intravenously administered 5-FU. A secondary aim during development was a superior safety 
profile when compared to 5-FU. This has been achieved with capecitabine. The incidence of 
alopecia, nausea, stomatitis, diarrhea, and neutropenia requiring medical intervention was found 
to be significantly lower in patients treated with capecitabine. Capecitabine does, however, 
cause a higher incidence of hand-foot syndrome (HFS, 53.5%). Most frequently occurring 
adverse effects apart from HFS are diarrhea (47.7%), nausea (37.9%), stomatitis (24.3%), 
vomiting (23.3%) and fatigue (21.1%). Thus, in patients treated with capecitabine HFS and 
diarrhea are the most common adverse events leading to treatment interruptions or dose 
reductions [11, 21, 22]. 
Capecitabine toxicity can be managed with symptomatic therapy, treatment interruption or 
decrease of the dose. Table 1-3 provides recommended dose adjustments for toxicity according 
to the toxicity grade [12, 13]. The Cancer Therapy Evaluation Program (CTEP) within the 
National Cancer Institute (NCI) developed the “Common Terminology Criteria for Adverse 
Events” (CTCAE, current version: 4.03). The CTCAE are standards for the description of 
toxicity grades and help to find the extent of the required dose reduction. The descriptive 
terminology provides standards for the description and exchange of safety information in 
oncology research. It is used for adverse event reporting and a grading (severity) scale is 
provided for each term. The grading scale implies the adverse event severity descriptions “mild” 
(grade 1), “moderate” (grade 2), “severe” (grade 3), “life-threatening” (grade 4) and “death” 
(grade 5) [23]. Once the dose of capecitabine has been reduced, it should not be increased again. 
Omitted doses due to adverse effects should not be replaced by a further dose [12, 13]. 
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Table 1-3: Scheme for reducing capecitabine dose in case of adverse drug reactions [12, 13] 
Toxicity grades Dose changes during a treatment cycle 
Dose adjustment for 
next cycle/dose 
(% of starting dose) 
Grade 1 Maintain dose level Maintain dose level 
Grade 2 
1st appearance Interrupt until resolved to grade 0-1 100% 
2nd appearance Interrupt until resolved to grade 0-1 75% 
3rd appearance Interrupt until resolved to grade 0-1 50% 
4th appearance Discontinue treatment permanently Not applicable 
Grade 3 
1st appearance Interrupt until resolved to grade 0-1 75% 
2nd appearance Interrupt until resolved to grade 0-1 50% 
3rd appearance Discontinue treatment permanently Not applicable 
Grade 4 
1st appearance 
Discontinue permanently 
OR 
If physician deems it to be in the patient's best 
interest to continue, interrupt until resolved to 
grade 0-1 
50% 
Patients treated with capecitabine who require a treatment interruption or a dose reduction, 
frequently fear a decrease or loss of efficacy of their anti-cancer therapy. However, it has been 
shown that toxicity-associated interruptions or dose modifications are not accompanied by 
reduced efficacy. No increase in risk of disease progression or mortality has been observed [11, 
22, 24]. Therefore, dosing flexibility allows an effective management of adverse drug reactions 
leading to improved tolerability and fewer treatment interruptions [24]. Thus, it should be 
explained to patients that there is no need to tolerate toxicity in order to achieve optimal efficacy 
[25]. They should promptly report occurring adverse drug reactions to their physician. The 
physician may then conduct a dose adjustment which might ensure long-lasting capecitabine 
treatment. 
Hand-foot syndrome (HFS) 
As mentioned above, HFS is the most common adverse effect in patients treated with 
capecitabine chemotherapy. This toxicity might be dose- and treatment limiting. HFS was first 
reported in 1974 by Zuehlke in patients treated with intravenously administered mitotane. 
Patients developed a syndrome of “erythematous eruption on the palms and soles” [26]. HFS is 
a cutaneous skin reaction and also referred to as palmar-plantar erythrodysesthesia (PPE) or 
chemotherapy-induced acral erythema. The median time to first occurrence is 79 days with a 
range of 11 to 360 days [11]. It is defined as “a disorder characterised by redness, marked 
discomfort, swelling, and tingling in the palms of the hands or the soles of the feet” [23]. The 
first HFS symptoms usually are dysesthesia and tingling in the palms, fingers and soles of feet 
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connected with erythema. Over several days the HFS may progress to burning pain with rash, 
dryness, cracking, ulceration, oedema and desquamation [27, 28]. Other symptoms can be 
pruritus, paresthesia or sensory impairment [29]. HFS can significantly affect a patient’s quality 
of life (QoL) [30]. The severity grades of HFS can be classified according to CTCAE (see Table 
1-4) [23]. Hospitalisation and death due to HFS is rare [31, 32]. Other anti-cancer drugs causing 
HFS are docetaxel, doxorubicin and the tyrosine kinase inhibitors sorafenib and sunitinib [27]. 
Table 1-4: Severity grades of hand-foot syndrome according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03 [23] (the severity grades “life-threatening” 
(grade 4) and “death” (grade 5) are not applicable in the context of HFS) 
Grade 1 Grade 2 Grade 3 
Minimal skin changes or 
dermatitis (e.g., erythema, 
edema, or hyperkeratosis) 
without pain 
Skin changes (e.g., peeling, 
blisters, bleeding, edema, or 
hyperkeratosis) with pain; 
limiting instrumental ADL* 
Severe skin changes (e.g., 
peeling, blisters, bleeding, 
edema, or hyperkeratosis) 
with pain; limiting self-care 
ADL* 
* ADL=Activities of Daily Living (Instrumental ADL refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc. Self-care ADL refer to bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not bedridden.) 
Pathomechanisms of the hand-foot syndrome 
The pathogenesis of HFS and the causes for increased incidence with capecitabine are unknown 
but various theories exist [29, 30, 33]. HFS occurs under the treatment of miscellaneous anti-
cancer drugs with diverse mechanisms of action. The explaining theory of HFS 
pathomechanisms could hence be broad [27]. A direct toxic effect caused by the 
chemotherapeutic agent on the skin is considered to be one explanation. However, this 
assumption does not provide an explanation for the occurrence of HFS especially at the hands 
and feet [28]. Another explanation for the toxicity indicates an involvement of eccrine sweat 
glands in the pathogenesis. Anti-cancer agents causing HFS are thought to accumulate in 
eccrine sweat ducts and thus cause local damage. Since the palm of the hands and the sole of the 
feet exhibit more sweat ducts, this theory would explain the typical anatomical distribution of 
this adverse event [30, 33]. Further reports consider HFS to be a type of inflammation due to an 
overexpression of cyclooxygenase 2 in the skin as a result of chemotherapy [30, 34]. Hands and 
feet are usually exposed to a high degree of mechanical pressure during everyday life. Capillary 
damage and leakage of chemotherapeutic agents from the blood vessels into the acral tissue may 
occur [27]. A further pathomechanism postulated implies the involvement of thymidine 
phosphorylase. Thymidine phosphorylase is one of the capecitabine-metabolising enzymes and 
shows an elevated expression in the palms. This increased expression may result in higher 
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concentrations of cytotoxic metabolites in this area and in skin damage. Additionally, an 
elevated proliferation rate has been observed in the epidermal basal cells of the palm area which 
might sensitise this skin area to the elevated amount of locally produced cytotoxic metabolites 
[30, 35]. 
Management of hand-foot syndrome 
No evidence-based effective possibility to prevent or to treat this toxicity exists. The current 
mainstays of HFS management are temporary treatment interruption and dose reductions [12, 
13, 34]. Table 1-3 shows the recommended schedule for capecitabine treatment interruptions 
and dose reductions in case of HFS (grade 4 “life-threatening” is not applicable in terms of 
HFS). As mentioned before, interruptions and dose reductions of capecitabine treatment do not 
diminish efficacy and will most likely lead to a relief of adverse effects [25]. Thus, health care 
professionals should use this evidence to educate their patients and to tell them that a toleration 
of HFS is not necessary. However, it should be avoided that this information leads to an 
underestimation of capecitabine therapy by the patient and accordingly to an increased non-
adherence. 
All attempts of prophylaxis and treatment of HFS besides dose reduction and therapy 
interruption are basically limited to a relief of the patient’s clinical symptoms. As long as the 
pathomachnisms of HFS are not fully understood, a causal prevention and therapy of this 
toxicity is not possible. However, various interventions are available, both pharmacological and 
non-pharmacological [30]. 
As denoted already, patient education and effective patient management strategies play a key 
role in HFS management to ensure correctly executed treatment interruptions and dose 
reductions. This is especially important since capecitabine is administered in the outpatient 
setting. Patients should be educated on how to use the drug properly. The importance of taking 
the correct dose and duration of treatment should be stressed. In terms of toxicity it should be 
highlighted that it is essential to adhere to the seven day rest period and not continue treatment. 
Moreover, patients need to know how to identify HFS as a toxicity of their cancer treatment. 
For this purpose they need to know nature and severity grades of HFS and when to contact their 
health care team for advice. Written information material and continuous care might complete 
patient education [24, 25]. 
Empirical interventions that are recommended for prophylaxis and treatment of HFS are the 
avoidance of hot water, excessive rubbing, pressure and constrictive footwear. Moreover, the 
patients might wear cotton gloves or socks and air their skin regularly to avoid severe sweating. 
Full-body skin examination, pedicure or evaluation by an orthotist (e.g. in terms of providing 
padded shoes) are further non-pharmacological interventions. To relieve HFS symptoms, hands 
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and feet can be immersed in cool water or cooled with cold compresses. Moisturising emollients 
and creams should be applied to the skin regularly both to prevent and to relieve HFS symptoms 
(e.g. containing 20-40% urea or petroleum-lanolin based ointment with antiseptic 
hydroxyquinoline sulphate). Sore areas should be padded with appropriate cushions and, in case 
of blisters or ulcers, topical wound care as well as consultation with a dermatologist should be 
considered [30, 32, 36]. 
The use of topically applied creams in HFS is not evidence-based. Corticosteriods have been 
described to be useful for prevention and treatment of HFS, e.g. clobetasol 0.05% ointment. The 
anti-inflammatory properties of corticosteroids might explain their beneficial effect in HFS. 
However, long-term use can be connected with thinning of the skin and this is likely to worsen 
HFS symptoms [30, 32, 36]. Moreover, uridine hand-foot ointment might be an option for the 
treatment of patients suffering from HFS. Nevertheless, a broader application or a controlled 
trial has to show the real value of this intervention [37]. The application of urea cream was 
found to be valuable in the prevention of HFS by Hoesly et al. [30]. This conflicts with the 
findings of a randomized, double-blind phase III trial evaluating 137 patients receiving 
capecitabine. Patients were treated with an urea/lactic acid–based cream or placebo. The results 
did not strengthen evidence of a beneficial effect of the cream for prophylaxis of HFS. There 
was no significant difference in HFS symptoms between the treatment and control group [38]. 
Topical anaesthetics can be applied for symptom relief [32]. Since October 2011, an ointment 
containing several antioxidants (Mapisal®) is available on the German market. It is advertised to 
prevent and to treat HFS effectively [39]. Further phase III studies are in progress to provide 
evidence for its efficacy [40]. 
Systemic medications for prevention and treatment of HFS include celecoxib [34], pyridoxine 
(vitamin B6) [41] and vitamin E [31] and can be tried in combination with topical interventions 
or alone. Zhang et al. conducted a single-centre, prospective randomised clinical trial to evaluate 
if HFS can be prevented by additional intake of celecoxib, a selective cyclooxygenase-2-
inhibitor. They found a reduced occurrence of HFS in the capecitabine/celecoxib group 
compared to the capecitabine group and concluded that celecoxib can be applied for the 
prevention of capecitabine-related HFS [34]. Studies investigating the use of pyridoxine for 
prevention of HFS caused by capecitabine do not show a beneficial effect on incidence or 
severity [41, 42]. However, pyridoxine might be beneficial in the treatment of HFS and can 
provide symptom relief once HFS develops [41]. Patients treated with a combination of 
capecitabine and cisplatin should not take pyridoxine for symptomatic or secondary 
prophylactic treatment of HFS. There have been reports that pyridoxine can impair the efficacy 
of cisplatin [12, 13]. 
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HFS is not life-threatening, but without an appropriate management this adverse drug reaction 
can be extremely painful and debilitating for the patient [36]. Moreover, non-adherence might 
be enhanced. Further randomised-controlled trials are needed to establish an evidence base for 
the prevention and treatment of HFS. 
The occurrence of HFS in patients treated with capecitabine might be associated with a better 
clinical outcome [43]. Upon request of the European Medicines Agency (EMA), Roche 
performed a meta-analysis of 14 clinical trials with data from over 4,700 patients suffering from 
multiple cancer entities treated with capecitabine monotherapy or combination chemotherapy. 
The development of HFS was connected with a longer overall survival [12, 13]. Thus, HFS 
might possibly be a valuable marker for the evaluation and monitoring of the efficacy of 
capecitabine treatment [43]. 
1.2 Pharmaceutical care 
The term pharmaceutical care has been used in pharmacy in one context or another for many 
years [44]. Pharmaceutical care was first formally defined in 1990 by Hepler and Strand as “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality of life” [45]. Since the definition of 1990 seemed incomplete in 
terms of the practitioner’s responsibility, Strand stated in 1997 that “pharmaceutical care is a 
practice in which the practitioner takes responsibility for a patient’s drug-related needs and 
holds him or herself accountable for meeting these needs” [44]. In 1998, the Fédération 
Internationale Pharmaceutique (FIP) published an extended definition of pharmaceutical care 
which stresses the collaborative approach and the continuous care process. They defined 
pharmaceutical care as “the responsible provision of pharmaco-therapy for the purpose of 
achieving definite outcomes that improve or maintain a patient’s quality of life. It is a 
collaborative process that aims to prevent or identify and solve medicinal product and health-
related problems. This is a continuous quality improvement process for the use of medicinal 
products” [46]. Since the pharmacist is not especially mentioned in the definitions of 
pharmaceutical care, this health care service might basically be delivered by every health care 
provider like e.g. the physician, pharmacist or a nurse. However, the pharmacist has a 
comprehensive qualification and a broad knowledge regarding drugs, adverse effects, drug 
administration and so on. These prerequisites make him predestined for the provision of 
pharmaceutical care. According to this, it was proposed for pharmacists to provide 
pharmaceutical care just like nurses provide nursing care and physicians provide medical care 
[45]. Through the systematic process of pharmaceutical care for an individual patient, the 
pharmacist develops, implements and monitors a therapeutic plan in collaboration with the 
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respective patient and other health care professionals. This plan helps to achieve predefined 
health outcomes. Three main competencies of the pharmacists are demanded: identifying 
potential and actual drug-related problems, resolving actual drug-related problems and 
preventing drug-related problems. By performing pharmaceutical care the pharmacist is a 
provider of quality of care and directly responsible for the benefit of the patient [45, 47–49]. 
1.2.1 Pharmaceutical care for cancer patients 
Cancer diagnosis is connected with psychological stress and a high disease burden for the 
patient concerned. Additionally, the patient is strained by complex treatment regimens. Surgery, 
radiation and antineoplastic pharmacotherapy form the three pillars of cancer treatment. Besides 
the use of classical cytotoxic chemotherapies, the availability of so called targeted therapies has 
recently increased. The development of modern, highly effective, and individually tailored 
treatment options has led to the circumstance that cancer has largely become a chronic condition 
[50]. The patient’s treatment regimen is complicated by supportive therapies to limit treatment-
associated toxicity, complementary therapy options, additional medication against other 
underlying conditions, and self-medication [51, 52]. The consequence of complex treatment 
regimens is an increased risk of drug-related problems such as adverse drug reactions, drug-drug 
interactions, non-adherence, and medication errors. Consequences of drug-related problems in 
the treatment of cancer can be severe since they emerge from a high toxicity and narrow 
therapeutic range of anticancer agents [53]. Through the establishment of central services for 
compounding of anti-cancer drugs or the offering of therapeutic drug monitoring for critical 
agents, the pharmacist began to play a more important role in oncology [51]. Moreover, it has 
been shown that a pharmacist integrated in the health-care team can improve drug use on an 
oncology ward. The pharmacist can contribute to risk minimisation with a systematic focus on 
the patient from a drug perspective [54]. The pharmacist is the only health care provider who 
might have a complete overview of the drugs a patient is taking. In addition to drugs prescribed 
by general practitioners, patients receive prescriptions from consultants or purchase over-the-
counter medicines themselves in community pharmacies. The pharmacist can use his specific 
drug-related knowledge to optimise individual drug therapy [51, 53]. Therefore, the detection 
and solution of drug-related problems can be facilitated by the integration of a pharmacist into 
the health care team. Multidisciplinary provision of care is highly appreciated by patients and 
the pharmacist is valued as an information source. In addition, physicians and nurses 
acknowledge the pharmacist’s contribution to improved drug use [54, 55]. 
Published studies conducted at the department of clinical pharmacy, University of Bonn verified 
the positive influence of pharmaceutical care on outcome parameters. Complete response to 
antiemetic prophylaxis was significantly improved amongst breast and ovarian cancer patients 
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receiving pharmaceutical care consisting of detailed patient counselling on the management of 
treatment-associated toxicity and optimisation of supportive medication compared to patients 
receiving usual care [56]. The provision of intensified pharmaceutical care to colorectal and 
breast cancer patients achieved a significant increase in mean daily adherence (proportion of 
days with correct drug intake), prolonged treatment with capecitabine, and reduced deviations of 
drug intake intervals. Detailed patient education before and during anti-cancer treatment 
combined with patient counselling regarding drug therapy, adverse drug reactions, and 
complementary treatment options were part of this intervention [51, 57]. Furthermore, a 
multiprofessional cancer medication management model was developed allocating tasks to 
physicians, pharmacists and nurses which was appreciated nationwide by the professions. The 
pharmacist was integrated with responsibilities in patient education and counselling as well as 
the prevention of drug-related problems. Such a model can improve effectiveness and efficiency 
of the provision of health-related services [58]. These results underline the potential of 
pharmaceutical care to contribute significantly to a safe and effective anti-cancer treatment. 
Further projects conducted at the department of clinical pharmacy, University of Bonn and parts 
of the projects mentioned above respectively could show significant beneficial effects of 
pharmaceutical care for cancer patients on important outcome and process parameters like cost-
effectiveness, detection and solution of drug-related problems, patient satisfaction with 
information on cancer treatment, and quality of life [55, 59–62]. 
1.3 Adherence 
Referring to the literature, one can find diverse terms for the description of medication taking 
behaviour of patients (see Table 1-5). The term ‘adherence’ is increasingly used due to the fact 
that it implies the best relationship between patient and health care provider, while using the 
abilities of each party [63]. Therefore, the term ‘adherence’ will be used in this thesis. The 
World Health Organization (WHO) defines adherence as “the extent to which a person’s 
behaviour – taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider” [63]. The term ‘persistence’ 
describes the duration from treatment initiation to discontinuation [64]. There is no overarching 
term that combines the two concepts [65]. Since to date there is no uniform terminology to 
describe insufficient medication taking behaviour, Vrijens et al. recently proposed a taxonomy 
which is supposed to be focused on promoting consistency and quantification in terminology 
and methods to aid in the conduct, analysis and interpretation of scientific studies of medication. 
Adherence to medication, management of adherence and adherence-related sciences are the 
three elements this taxonomy is consisting of [66]. 
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Table 1-5: Definition of different terms describing patient medication taking behaviour 
Term Definition 
Compliance 
Extent to which a person’s behaviour – taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider [63, 67, 68]. 
Adherence 
Same definition and synonymic use like compliance [65], however 
disconnection of the patient being a passive, acquiescent recipient of expert 
advice and of a hierarchical relationship between the patient and the health 
care provider [69, 70]. 
Concordance 
Equal, cooperative relationship between patient and health care provider, 
respect for the patient’s views, open exchange of information, mutual 
confidence, cooperative decisions concerning treatment [69, 70]. 
Persistence Time elapsed between first dose taken and time of treatment discontinuation, no information about correctness of intake [64, 65]. 
A patient who does not adhere to his treatment regimen is referred to as non-adherent. Non-
adherence may be divided into two different types, intentional and unintentional non-adherence. 
Intentional non-adherence is associated with the patient’s motivation and views in terms of his 
disease and pharmacotherapy. If a patient does not accept his diagnosis or treatment, the patient 
may not begin or correctly administer therapy. This lack of patient desire to continue the 
medication may also lead to discontinuation of therapy. Furthermore, personal preferences of 
the patient which have not been taken into account regarding drug treatment can lead to 
intentional non-adherence. 
Unintentional non-adherence is not planned by the patient and in most cases practical barriers 
are the problem. The patient omits dosages throughout the whole duration of his treatment 
without any obvious pattern [71, 72]. 
Moreover, particular patterns of non-adherence may be understood as cross forms of intentional 
and unintentional non-adherence, e.g. in a phenomenon known as ‘white-coat adherence’, i.e. an 
improvement of patient adherence shortly before and after an appointment with the health care 
provider [73]. 
1.3.1 Causes and identification of non-adherence 
The literature knows about 200 factors which may influence patient adherence. According to the 
WHO “adherence is a multidimensional phenomenon determined by the interplay of five sets of 
factors” or dimensions [63]. 
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Social and economic factors 
Examples for social and economic factors known to significantly influence adherence are a low 
level of education, unemployment, high cost of medication, culture and lay beliefs about illness 
and treatment, illiteracy and family dysfunction. 
Health care team and system-related factors 
These factors e.g. imply lack of knowledge and training for health care providers on managing 
chronic diseases, overworked health care providers, short consultations, lack of incentives and 
feedback on performance, weak capacity of the system to educate patients and provide follow-
up and lack of knowledge on adherence and of effective interventions for improving it. 
Therapy-related factors 
Therapy-related factors that most notably affect adherence are those related to the complexity of 
the medication treatment, such as duration of treatment, previous treatment failures, frequent 
changes in treatment and adverse drug reactions. The adherence to a once-daily intake is 
significantly higher than to a three or four times daily intake [73, 74]. 
Patient-related factors 
Examples for patient-related factors are forgetfulness, anxieties about possible adverse effects, 
low motivation, inadequate knowledge and skills in managing the disease symptoms and 
treatment, lack of self-perceived need for treatment, lack of perceived effect of treatment, lack 
of acceptance of monitoring and low attendance at follow-up. 
Condition-related factors 
Condition-related factors that strongly determine adherence include severity of symptoms, level 
of disability of any kind, rate of progression, severity of the disease and availability of effective 
treatments. Consequences depend on these factors’ influence on patients’ risk perception, the 
importance of following treatment, and the priority placed on adherence. Co-morbidity (e.g. 
depression in HIV/AIDS or diabetes) and drug as well as alcohol abuse are central modifiers of 
medication taking behaviour. 
1.3.2 Adherence measurement 
The detection of extent, pattern, and cause of low adherence is very important for the selection 
of an appropriate adherence-enhancing strategy. Thus, detailed information on the exact nature 
of patient medication behaviour is required.  
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Adherence-measuring methods can be divided into direct and indirect methods, for detailed 
information see Table 1-6 [73, 75]. 
Concerning all methods for measuring adherence that actively include the patient, it should be 
taken into account that the patient’s knowledge of the adherence measurement may influence 
his behaviour [75]. Thus, methods that imply a questioning of the patient tend to overestimate 
patient adherence. Rates of refilling prescriptions are an objective measure of overall adherence. 
This chronological medication history considers a defined period of time and shows all 
prescribed drugs of the patient. However, a complete and central documentation either by the 
physician or the pharmacist of all refilled prescriptions is a mandatory requirement. Electronic 
medication monitors like the Medication Event Monitoring System (MEMS®) are medication 
bottles with a screw cap containing a microprocessor. These bottles can be filled with orally 
administered dosage forms and are capable of recording and displaying date and time of bottle 
openings [76]. Thus, special behavioural patterns can be tracked, e.g. if a patient mostly forgets 
his evening dosage or does not take his medication mostly on the weekends, see also 3.7.2. A 
disadvantage of these devices is the non-documentation of the actual ingestion of the drug. The 
patient might have opened the bottle without taking his drug, taking his medication from 
another source (other medication container, medication package) or taking multiple doses at the 
same time. Furthermore, costs for electronic medication monitors are not covered by the health 
insurance and the execution of this method is relatively complex. Patients need to visit their 
therapy site more often than normally required and the healthcare provider needs to read data 
from medication vials using special software. Thus, electronic monitoring of adherence is not 
used in daily routine so far. But despite existing disadvantages, this measure provides the most 
accurate and valuable data on patient medication intake behaviour [73, 75]. 
Table 1-6: Direct and indirect methods for measuring patient adherence including advantages 
and disadvantages [73, 75] 
  Advantages  Disadvantages 
Direct methods   
Direct supervision of  
the intake 
 Most precise  Impractical for routine use  
 Prone to Hawthorne effect [75], see 
1.3.3 
 Patients can hide tablets in the mouth 
and discard them 
Measurement of the 
level of drugs or 
metabolites in plasma 
 Objective  Variations in metabolism and white-
coat adherence can give a false 
impression of adherence 
 Expensive 
 Blood samples required 
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Table 1-6: continued 
  Advantages  Disadvantages 
Indirect methods   
Patient questionnaires, 
patient self-reports 
 Generally easy to 
perform 
 Inexpensive 
 Most useful method 
in the clinical 
setting 
 Susceptible to errors with increases in 
time between visits 
 Easily altered by the patient 
Patient diaries  Help to correct for 
poor recall 
 Easily altered by the patient 
Pill counts  Objective 
 Quantifiable 
 Easy to perform 
 Easily altered by the patient (e.g., pill 
dumping) 
Rates of prescription 
refills 
 Objective 
 Easy to obtain data 
 A prescription refill is not equivalent 
to ingestion of medication 
 Requires a closed pharmacy system  
Electronic medication 
monitors  
 Precise 
 Quantifiable 
 Tracks patterns of 
taking medication 
 Expensive 
 Requires return visits and reading 
data from medication vials 
 No proof of actual intake 
Assessment of the 
patient’s clinical or 
pharmacodynamic 
response (e.g., blood 
pressure in hypertensive 
patients) 
 Simple 
 Generally easy to 
perform 
 Factors other than medication 
adherence can affect clinical response 
 Marker may be absent for other 
reasons (e.g., increased metabolism, 
poor absorption) 
 Often no appropriate marker available 
1.3.3 Adherence enhancement 
In short-term drug treatments, patient counselling and written patient information helps to 
improve adherence [77]. In chronic disease patients, adequate medication use is harder to 
achieve. Interventions are complex and require a combination of different measures [77]. They 
have been divided into four categories [73, 77]: 
Educational interventions 
Patient education, counselling and written information material contribute to a better 
understanding of the disease and therapy. These interventions are appropriate for the 
improvement of intentional non-adherence. Patients who better understand their disease and 
their pharmacotherapy are more apt to follow their treatment plan. Decker et al. identified that 
the misunderstanding of the intended duration of treatment was the main reason for premature 
discontinuation of clopidogrel treatment in myocardial infarction patients [78]. Such 
information appears trivial and thus, may not be passed on to the patient by the prescribing 
physician or the delivering pharmacist. Dosing instructions need to be communicated in a 
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precise, definite and unambiguous manner. Abbreviations which may not be clear to the patient 
should be avoided. Simple advice should always be given, e.g. regarding nasal sprays or the 
shaking of aqueous suspensions before use [69]. 
Behavioural interventions 
Such interventions are treatment diaries, medication dosette boxes, reminder cards pinned at a 
distinctive spot, alarm clocks, and/or the inclusion of family members into the process of care. 
Behavioural interventions aim to improve unintentional non-adherence and remind forgetful 
patients of their medication intake. “Cue-dosing” is also a behavioural intervention. It is the 
linking of drug intake with a certain activity in daily life such as dental hygiene or watching a 
certain TV programme. 
Monitoring interventions 
The regular monitoring of patients’ blood pressure or other health outcomes increases the 
patients’ motivation to take their medication as prescribed. Furthermore, measurement of 
adherence itself may have a potential effect on the medication taking behaviour and improve 
adherence. This beneficial effect of the observation itself on the outcome is termed the 
“Hawthorne effect” [75]. 
Pharmacotherapeutic interventions 
This group of interventions comprises the simplification of treatment regimens such as the 
prescription of extended release or combination formulations. Information regarding the 
divisibility of tablets is lacking frequently. Thus, half or quartered tablets should be prescribed 
as rarely as possible. Additionally, faith in treatment and adherence can decrease in patients who 
are instructed to split their tablets [71, 79]. 
1.3.4 Adherence of cancer patients 
Long-term adherence in patients with chronic, non-oncologic conditions is estimated at 50% 
[63, 80]. Since cancer is a distressing and life-threatening disease, cancer patients’ medication 
taking behaviour is presumed to be particularly precise and adherent [73, 81–84]. For oral anti-
cancer agents, adherence rates from 16 to 100 % have been reported. The variability can be 
explained by the different anti-cancer agents, the definition of adherence and the method of 
measurement [82, 85]. The adherence to oral capecitabine treatment has been explored by 
several recent studies.  
Partridge et al. used MEMS® for adherence assessment in 161 older women (aged from 65 to 89 
years) with early-stage breast cancer. Adherence was defined as the number of doses taken 
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divided by doses expected. Patients were considered adherent if ≥80% of the expected doses 
were recorded by MEMS®. 124 patients (83%) persisted with capecitabine up to the completion 
of the planned protocol (six cycles). 75% of participants performed more than 80% of expected 
openings and were regarded as adherent. Average adherence was 78% across all cycles, and 
adherence did not vary by cycle. This study was part of a clinical trial and might not reflect 
usual care [86, 87]. 
Winterhalder et al. used participant self-reports in 143 gastrointestinal and 34 breast cancer 
patients to assess adherence to capecitabine. Patients recorded their capecitabine intake each day 
in patient diaries. Ninety-one percent (161/177) of the participants were found to be fully 
adherent, whereas only 9% (16/177) participants reported some kind of adherence error which 
was defined as any violation of the recommended regimen. Reasons for non-adherence included 
forgetfulness (n=9), adverse drug reactions (n=4) and misunderstanding of instructions (n=3) 
[81]. 
Mayer et al. explored adherence amongst metastatic breast cancer patients by means of MEMS® 
vials (n=13) as well as self-reports using a daily drug diary completed by each patient (n=12). 
Adherence was defined as observed divided by expected doses. An adherence of >80% was 
used to define acceptable adherence. Adherence measured by MEMS® ranged from 75% to 
100% and both median and mean adherence accounted for 96%. Self-reported adherence ranged 
from 89% to 100% and median adherence was 97% (mean adherence: 99%) [88]. 
The authors of another study recruited breast and colorectal cancer patients treated with 
capecitabine in a UK teaching hospital and assessed self-reported patient non-adherence using 
the Medication Adherence Report Scale (MARS). Respondents were asked to report whether 
any divergence to treatment originates from dose alteration, omission, intentional termination, 
or forgetting. Non-adherence was stated by 10 of the 43 patients (23%). Four patients reported 
several types of deviation. Forgetting to take a capecitabine dose was the most commonly stated 
reason for a deviation [89]. 
Adherence to capecitabine was also assessed using a qualitative approach in 42 patients. 
Adherence was defined as being against not taking their treatment. The results of group and 
individual interviews did not suggest deliberate non-adherence but poor observance of the 
dosing schedule. Most frequently, patients deviated from the instruction to take capecitabine 
after a meal [90]. 
A Canadian study from 2007 surveyed 25 patients treated with capecitabine. Adherence was 
measured using pill counts and patient self-reports and defined as any indication of not having 
100% adherence. Patients were randomly assigned to either receive capecitabine provided in 
convention pill bottles or pre-filled per patient’s prescription into daily pill boxes. After the 
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completion of one cycle the patients switched over to the alternate packaging method. It could 
not be demonstrated that daily pill boxes improved adherence to capecitabine. Adherence rates 
were similar when using daily (81%, 17/21) and conventional pill bottles (86%, 18/21) [91]. 
1.3.5 Adherence and pharmaceutical care 
Continuous pharmaceutical care has been shown to be particularly suitable to enhance 
medication adherence. Several studies proved that the integration of a pharmacist in patient care 
has a beneficial effect on adherence.  
A community pharmacist-led intervention in heart failure patients improved their adherence to 
loop diuretics. The effect of monthly consultations in the community pharmacy led to a 
significant better outcome in MEMS® recordings compared to usual care without community 
pharmacist consultations. Non-adherence was expressed as the number of days without any loop 
diuretic although at least once daily was prescribed. Over the six-month study period, patients in 
the intervention group (n=74) exhibited 140/7656 days without use of loop diuretics compared 
with 337/6196 days in the usual care group (n=78) [92]. 
A Belgian study investigated the effect of a pharmaceutical care programme provided by 
community pharmacies on the adherence of once-daily atorvastatin treatment in patients with 
elevated cholesterol levels. Electronically measured adherence was defined as the proportion of 
days with correct administration. The intervention resulted in a 6.5% increase in post-baseline 
adherence (p<0.001). Furthermore, only 25/194 (13%) subjects in the intervention group 
discontinued medication, in contrast to 51/198 (26%) subjects in the control group [93]. 
The efficacy of a comprehensive pharmaceutical care programme to improve medication 
adherence and its associated effects on blood pressure and low-density lipoprotein cholesterol 
was evaluated in a randomised controlled trial conducted in a US military medical center. After 
a run-in phase, patients entered an intervention phase. Following the six-month intervention 
phase, patients were randomized to continued pharmaceutical care versus usual care for 
additional six months. Adherence was calculated as the proportion of drugs taken for all chronic 
medications and measured by pill counts. Mean baseline medication adherence was 61.2%. 
After six months of intervention, medication adherence increased to 96.9% (p=0.001) and was 
associated with significant improvements in systolic blood pressure and low-density lipoprotein 
cholesterol. Six months after randomisation, adherence decreased to 69.1% among usual care 
patients, whereas it was sustained at 95.5% under pharmaceutical care (p=0.001). This was 
associated with significant reductions in systolic blood pressure in the pharmaceutical care 
group versus the usual care group, but did not result in significant differences in low-density 
lipoprotein cholesterol levels [94]. 
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Adler et al. conducted a randomised controlled trial and studied 533 depressed patients in 
primary care. Intervention patients received consultations in person and by telephone performed 
by a clinical pharmacist. Adherence was measured using self-reported six-month antidepressant 
use rates. Intervention patients exceeded controls (57.5% vs. 46.2%, p=0.03). The pharmacist 
intervention also improved antidepressant use rates for patients not taking antidepressants at 
enrollment (32.3% versus 10.9%, p=0.001) [95]. 
Klein et al. examined the influence of a pharmaceutical care programme on liver transplant 
patients’ adherence to immunosuppressive therapy. Adherence was defined as the percentage of 
days with the correct number of bottle openings and was measured using MEMS®. The 
intervention group (n=26) receiving pharmaceutical care in addition to traditional patient care 
showed a mean adherence of 90% compared with 81% in the control group (n=24; p=0.015) 
[96]. 
A British study reports the adherence-enhancing potential of a telephone-based pharmacy 
advisory service which was provided to patients of the intervention group by community 
pharmacists. Self-reported non-adherence to newly prescribed medicines for chronic conditions 
was significantly lower in the intervention group (10/87, 11%) when compared to the control 
group (23/118, 19%; p<0.05) [97]. 
A randomised, controlled trial from Hongkong showed an association between adherence of 
patients receiving polypharmacy and mortality. Patients receiving five or more drugs for chronic 
disease and showing an adherence of less than 80% were included. Throughout the study period 
of two years, patients allocated to the intervention group received a telephone call from a 
pharmacist at the midpoint between clinic visits (six to eight conversations lasting 10 to 15 
minutes). Telephone counselling improved adherence and reduced mortality by 41% which was 
mainly attributed to the decrease of cardiovascular events in the intervention group. The number 
needed to treat to prevent one death during two years accounted for 16 [98]. 
In Switzerland, several adherence-enhancing interventions are even anchored in the health care 
system. After prescription by a physician, weekly dosing systems, polymedication checks or 
intake controls provided by the pharmacist are reimbursed by the health insurances [99]. 
A first step in Germany was the publication of a future concept to optimise patient care by the 
Federal Union of German Associations of Pharmacists (ABDA) and the Associations of 
Statutory Health Insurance Physicians (KBV) in April 2011. Through continuous care of 
multimorbid patients provided by both a physician and a pharmacist (medication management) 
it is aimed to enhance adherence and reduce costs. A shared reimbursement is intended. In 
practice, a general practitioner could send his patient to the collaborating pharmacy where the 
pharmacist compiles an individual medication plan and conducts an interaction check [100]. 
20 Introduction 
The legislative basis for a practical implementation of this concept is provided since January 
2012 [101] and a definite start of the model in two German test regions is intended for the 
second half of 2013 [102]. 
To the author’s knowledge, only one study investigated the influence of pharmaceutical care on 
the adherence of cancer patients treated with any kind of oral anti-cancer agent. The effect of an 
intensified multidisciplinary pharmaceutical care programme on the adherence of cancer 
patients treated with capecitabine was investigated by Simons et al. Adherence was measured 
using MEMS® and was defined as the percentage of days with correct medication taking 
behaviour. Patients who received pharmaceutical care showed a higher mean daily adherence 
compared to the control group who received standard care (96.8% vs 87.2%, p=0.029) [57]. 
Thus, adherence rates of patients treated with capecitabine are relatively high compared to non-
oncologic oral drugs but can still be increased by specific measures [57]. Conversely, this 
implies that only some patients treated with capecitabine are in need of an adherence-enhancing 
intervention and the limited resources could be used more efficiently. Certain patients manage 
their oral treatment regimen independently and do not benefit from a specialised patient care. 
Since lack of time is a restricting factor in daily practice, it is important to know which patients 
especially take advantage of such an intervention and which patients do not benefit. In this 
study, we screened cancer patients for their adherence during their first cycle of capecitabine to 
detect potential non-adherers. Initially adherent as well as non-adherent patients received basic 
pharmaceutical care and adverse event management. Specific adherence support, however, was 
only provided to initially non-adherent patients. 
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2 Aim 
The aim of the present study was to assess medication adherence over time of initially adherent 
as well as initially non-adherent cancer patients treated with the chemotherapeutic agent 
capecitabine and receiving a modular medication management. 
In the present project a strategy to identify non-adherent patients at an early stage of their anti-
cancer treatment (adherence screening) was developed as well as a special adherence-enhancing 
intervention for these patients (adherence support). 
It was hypothesised that adherence of initially adherent patients would remain high over time 
without a special adherence supporting intervention and that initially non-adherent patients 
would benefit from such an intervention. 
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3 Patients and Methods 
The present study was conducted to evaluate medication adherence and further patient-relevant 
outcomes in initially adherent as well as initially non-adherent cancer patients treated with the 
oral chemotherapeutic agent capecitabine under the provision of modular medication 
management. 
3.1 Legal status of the study 
The legal classification of this study resulted under consideration of § 4, 40 and 67 of the 
German drug law (Arzneimittelgesetz, AMG) and the recommendations of the Federal Institute 
of Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) 
and the Paul-Ehrlich-Institut (PEI) from 07 July 2010. The patients’ treatment including 
diagnosis and monitoring was not based on a pre-determined study protocol. The participating 
physicians’ decision on diagnosis, prescribing capecitabine, and monitoring was not influenced. 
All patients included in the study were treated according to clinical routine. Therefore, this 
study was classified as ‘non-interventional trial’ [103]. 
On 06 May 2009 the ethics committee of the Faculty of Medicine of the University of Bonn, 
Germany voted positively for this study (consecutive number 042/09). In September 2009 an 
amendment to the study protocol to include patients treated with capecitabine suffering from 
further tumour entities besides breast cancer was approved by the ethics committee. A further 
amendment to include three additional study centres was approved in November 2010. 
3.2 Participating study centres and cooperation partners 
The study was conducted in two oncology outpatient wards and two oncology practices in the 
area of Bonn and Cologne (Table 3-1). 
Table 3-1: Participating study centres 
Treatment setting Study centres 
Oncology outpatient ward 
Johanniter Hospital Bonn, Department of Internal Medicine 
St. Elisabeth Hospital Cologne-Hohenlind,  
Specialist Breast Unit/Senology 
Oncology practice 
Dr. Peter F. Schwindt, Bonn 
Dr. Helmut Forstbauer, Troisdorf 
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The provided patient care (modular medication management) was delivered by a 
multidisciplinary team consisting of physicians, nurses and pharmacists. Physicians and nurses 
employed at the respective study centre carried out usual patient care (standard care). Two 
pharmacists of the Department of Clinical Pharmacy, Institute of Pharmacy of the University of 
Bonn accomplished the pharmaceutical services, including the author of this thesis and an 
additional research pharmacist (in the following referred to as ‘study pharmacists’). Data 
collection was carried out by the study pharmacists in the respective study centre. The analysis 
of the collected data was accomplished at the Department of Clinical Pharmacy, University of 
Bonn (in the following to be called ‘central study office’). 
In addition, the following cooperation partners supported the project: 
 Dr. Rolf Fimmers, Institute of Medical Biometrics, Computer Sciences and Epidemiology, 
University of Bonn (advice on statistical methodology) 
 Prof. Dr. Steve A. Hudson, Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow, Scotland (advice on cancer care) 
 Klaus Ruberg, Pharmacy Kronen-Apotheke Marxen, Wesseling (advice on palliative care) 
 Roche Pharma AG, Basel (breast cancer patients were recruited and studied in association 
with the non-interventional study ML 21725, see 3.3) 
3.3 Study design 
The study was designed as a prospective, multi-centred, two-arm observational cohort study. 
One study arm consisted of patients classified as initially adherent (baseline daily adherence 
≥90%), the other arm of initially non-adherent patients (baseline daily adherence <90%), see 
Figure 3-1. This classification was based on an ‘adherence screening’ during the first 
capecitabine cycle. Since no standard for the definition of sufficient adherence exists [73], the 
threshold of 90% was defined empirically based on the results of an earlier research project 
[57]. Modular medication management consisted of three modules: module 1 (basic 
pharmaceutical care), module 2 (adverse event management) and module 3 (adherence support). 
Every recruited patient received module 1 and 2 which were initiated after inclusion and 
provided by physicians, nurses and the study pharmacists. If a patient was found to be initially 
non-adherent, module 3 (adherence support) was provided additionally by the study 
pharmacists. Adherence screening plus adherence support is referred to as ‘adherence 
management’. Details regarding the course of the study and the three patient care modules are 
given in 3.6. 
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Figure 3-1: Study design 
In terms of breast cancer patients, the present study was conducted in association with the non-
interventional study with capecitabine (Xeloda®) ML 21725 executed by Roche Pharma AG, 
Basel [104, 105]. Patients suffering from breast cancer were included in both studies. The 
assessment of the following outcome parameters overlapped: 
 Patient satisfaction with information at the time of inclusion (t0) assessed by the Patient 
Satisfaction with Cancer Treatment Education (PSCaTE) questionnaire 
 Cancer-specific quality of life at the time of inclusion (t0), after the third capecitabine cycle 
(t3) and after the sixth capecitabine cycle (t6) assessed by the European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-
C30) questionnaire 
 Self-assessed adherence after each conducted capecitabine cycle (t1, t2, t3, t4, t5, t6) assessed 
by the adherence questionnaire I 
 Self-assessed adherence after the last conducted capecitabine cycle (t6) assessed by the 
adherence questionnaire II 
For detailed information regarding outcome assessment see section 3.7. 
3.4 Patient selection 
To obtain a sufficient number of patients during the study period the following inclusion and 
exclusion criteria were defined. 
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Inclusion criteria: 
 Patient suffered from a cancer entity which required an oral chemotherapy with capecitabine. 
 Patient received chemotherapy with capecitabine as single agent or combination therapy for 
treatment of cancer. 
 Patient was therapy-naïve concerning capecitabine. 
 Patient was at least 18 years old. 
 Patient gave written informed consent. 
 Patient was able to speak, read and write German. 
Exclusion criteria: 
 Patient suffered from a disease or mental state compromising full understanding of purpose 
and course of the study (e.g. Alzheimer’s disease). 
 Patient had the intention to change his site of treatment. 
 Patient showed a contraindication to capecitabine. 
3.5 Patient recruitment 
Data were collected between July 2009 and March 2012.  
After the identification of eligibility by the collaborating oncologists, patients were briefly 
informed about the study. In case of patients’ agreement on a further briefing conversation, the 
physician informed the patient that his name and his contact details would be referred to the 
study pharmacists. The physician passed on the contact details to the study pharmacists via fax 
(see Appendix A), e-mail or telephone. If a study pharmacist was present at the study centre at 
this particular time, the physician transmitted the information on the eligible patient personally 
and the further briefing conversation between the patient and the study pharmacist took place 
immediately. Otherwise a study pharmacist contacted the patient as soon as possible to arrange 
a meeting for further conversation. The first personal meeting usually took place at the oncology 
outpatient ward/oncology practice. If this was not suitable (e.g. long time until next visit of the 
patient in the study centre) the meeting took place at the patient’s home. During the first 
conversation with the study pharmacist the patient was explicitly informed on the aim, content 
and course of the study. The patient received a written patient information brochure (see 
Appendix A) and had the opportunity to ask questions regarding the trial. After an appropriate 
amount of time the patient was asked to decide on his participation in the study. In case of 
acceptance, each participant signed a written informed consent (see Appendix A). 
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3.6 Course of the study 
The study protocol defined a maximum observation period of six capecitabine cycles for every 
participant. Since each capecitabine cycle consists of 21 days (14 days with twice daily 
capecitabine intake and seven days without capecitabine intake) the observation period covered 
a maximum of 126 days or 18 weeks respectively. The observation period could exceed 126 
days, if e.g. the physician prescribed a temporary treatment discontinuation for a certain patient. 
The outcome assessment was orientated at the course of the patients’ anti-cancer treatment with 
capecitabine. During the full study period patients’ adherence was assessed by electronic 
monitoring (see 3.7.2). After written informed consent the study pharmacist handed over the 
MEMS® container to the patient and explained its features in detail. The study pharmacists 
executed the first refill of the MEMS® container together with the patient. If this was not 
possible (e.g. the patient was not in possession of his capecitabine chemotherapy yet) the study 
pharmacist explained exactly how to fill and refill the container. The patient was advised to 
store his capecitabine chemotherapy in the container only and to only withdraw his twice daily 
dose out of the container. The correct usage of MEMS® was illustrated by the written MEMS® 
patient information (compare Appendix C, see also 3.7.2). The MEMS® monitor of every 
patient was read out after the completion of the first capecitabine intake period plus first day of 
treatment break. According to the result, the patients were defined as initially adherent (baseline 
daily adherence ≥90%) or initially non-adherent (baseline daily adherence <90%). This 
particular period was chosen for evaluation of participants’ baseline daily adherence as a longer 
observation period (21 days) was not feasible. If adherence screening resulted in a participant 
being defined as initially non-adherent, the adherence supporting module had to be initiated 
before the start of the second intake period. It was not feasible to schedule an appointment with 
every participant exactly on day 21 of the first capecitabine cycle in order to guarantee a timely 
initiation of the adherence support. 
Concerning initially adherent patients, further readout of the MEMS® monitor was performed 
after the sixth cycle of capecitabine treatment (t6). Regarding initially non-adherent patients, the 
MEMS® monitor was read out after each chemotherapy cycle (at t1, t2, t3, t4, t5, and t6). These 
regular readouts were the central requirement for the accomplishment of module 3 ‘adherence 
support’ (for details see 3.6.3). 
Before the first (t0), after the third (t3) and after the sixth (t6) capecitabine cycle, patients 
completed two questionnaires on quality of life (EQ-5D and EORTC QLQ-C30, see 3.7.3) and 
the questionnaire on patient satisfaction with information (for more details see 3.7.4). After each 
cycle (t1-6) the patients filled in the questionnaire on hand-foot syndrome (compare 3.7.5) and 
the one on adherence regarding the preceding chemotherapy cycle (see 3.7.2). At t6 additionally 
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the adherence questionnaire regarding the capecitabine cycles 1 to 6 (compare 3.7.2) and the 
patient evaluation questionnaire (see 3.7.7) was completed. General and disease-related patient 
data were collected by means of a special questionnaire (compare 3.7.1) and on the basis of the 
patient file. The study pharmacists had access to the patient files during the full study period on 
a regular basis. 
After each capecitabine cycle a personal interview between patient and study pharmacist took 
place (for details see 3.6.1, 3.6.2 and 3.6.3). During these visits the respective questionnaires 
were delivered to the patient personally by the study pharmacist. The patient had the 
opportunity to fill in the questionnaires without being observed. After completion the study 
pharmacist collected the questionnaires. 
All questionnaires are shown in Appendix B. Figure 3-2 shows the course of the study 
schematically and the outcome measurement during the observation period. 
 
Figure 3-2: Course of the study and outcome measurement 
t=time point; EQ-5D=generic questionnaire on quality of life; QLQ-C30=cancer-specific 
questionnaire on quality of life; PSCaTE=questionnaire on patient satisfaction with information; 
GenPatData=questionnaire on general patient data; MEMS®=reading of MEMS® (Medication 
Event Monitoring System); Adh I=adherence questionnaire regarding preceding chemotherapy 
cycle; Adh II=adherence questionnaire regarding all chemotherapy cycles; QHFS=questionnaire on 
hand-foot syndrome; PatEv=questionnaire on therapeutic success and adverse drug reactions. 
* At this time point MEMS® was read out in initially non-adherent patients only. 
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3.6.1 Module 1 – Basic pharmaceutical care 
Every patient received module 1 (basic pharmaceutical care) which was provided by physicians, 
nurses, and the study pharmacists. Module 1 started after signing the informed consent during 
the first personal meeting of the study pharmacist and the patient (t0). During the initial visit the 
study pharmacist discussed the following issues with the patient: 
 Medication history including all prescribed and over-the-counter (OTC) drugs. 
 Education concerning cytotoxic capecitabine (e.g. pro-drug and tumour selectivity, 
administration, drug-drug interactions). 
 Education concerning further anti-cancer therapy (e.g. administration, mechanism of action). 
 Education concerning supportive therapy (e.g. administration, mechanism of action). 
Additional issues depending on the individual patient were discussed and questions brought up 
by the patient were answered. To complete the counselling session the patient received written 
information material as follows: 
 Appropriate information brochures (“Blaue Ratgeber”) published by the German Cancer Aid 
(Deutsche Krebshilfe). 
 A patient brochure on frequently asked questions regarding the chemotherapy with 
capecitabine („Meine Therapie mit Xeloda® - Fragen und Antworten zu Ihrer 
Krebsbehandlung“) developed by Roche Pharma AG. 
Since it was part of the attending physician’s usual patient care, the patients of one study centre 
received a treatment diary („Persönliches Therapietagebuch - Begleitheft für Xeloda Patienten 
während der Therapie“). 
All issues of the initial visit were documented in the first consultation documentation form 
(Appendix C). Following this counselling session, the study pharmacist checked the patient’s 
current medication in terms of contraindications, dosages and interactions. The computer-based 
interaction check was conducted using the data bases DrugDex® and DIMDI SmartSearch® 
which were also used for information search regarding contraindications and dosages. The 
summary of product characteristics (SPC, Fachinformation) of the respective drugs served as an 
additional source of information. In case of drug-drug interactions or further identified drug-
related problems (e.g. contraindication), necessary changes of the medication were made in 
collaboration with the responsible physician. Every patient received an individual information 
letter from the study pharmacist repeating important issues, answering remaining questions and, 
if necessary, additional written information brochures. Furthermore, the letter contained the 
result of the interaction check and an individual medication plan for the patient (Appendix C). 
At the end of each capecitabine intake period (every three weeks, at t1, t2, t3, t4, t5 and t6) a 
further scheduled counselling session took place. During these follow-up visits the patient was 
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asked if changes regarding his medication had been performed during the last cycle or if he have 
had any problems regarding his medication. The patient had the possibility to ask questions or 
discuss individual issues. If necessary, advice was given, written information material was 
handed out and the attending physician was contacted. If the patient was prescribed a new drug 
or took additional OTC products, the interaction check was repeated. The results were 
documented and passed on to the patient. If necessary, the physician was contacted. In addition 
the patient’s medication plan was updated. Contents of the follow-up discussions with the study 
pharmacist, the patient and, if applicable, the attending physician were documented using the 
further consultation documentation form (Appendix C). In case of urgent questions the patient 
had the possibility to call the study pharmacist in the central study office or on a special study 
mobile phone. 
Figure 3-3 shows schematically the general course of module 1 (basic pharmaceutical care). 
3.6.2 Module 2 – Adverse event management 
In addition to module 1, every study patient received module 2 (adverse event management). 
Module 2 was carried out by physicians, nurses and the study pharmacists. The start of module 
2 was in parallel to module 1 after the patient had signed the informed consent sheet. Module 2 
was conducted during the initial visit of the study pharmacist (t0) and the further scheduled 
counselling sessions (t1, t2, t3, t4, t5 and t6). 
In module 2, the patient received written information material as follows: 
 A general information sheet on prophylaxis and treatment of important adverse effects of 
anti-cancer drugs (Appendix C). This leaflet was developed at the Department of Clinical 
Pharmacy at the University of Bonn in cooperation with participating physicians. 
 A patient brochure on advice in terms of prophylaxis and management of typical adverse 
effects of capecitabine („Richtiges Verhalten bei Nebenwirkungen – Eine Information für 
Xeloda® Patienten“) developed by Roche Pharma AG. 
During the initial visit of module 2, patients were educated regarding common adverse effects 
(e.g. HFS and diarrhoea). Prophylaxis, detection and treatment were discussed in detail. If 
patients took other drugs or were prescribed a concomitant anti-cancer treatment, they were 
counselled regarding the adverse effects of these drugs as well. During the follow-up scheduled 
counselling sessions, the patient was questioned about adverse drug reactions he had 
experienced during the last cycle of capecitabine. He was given advice in terms of treatment and 
had the opportunity to ask questions or discuss problems. Generally, in case of issues that 
needed further clarification the treating physician was contacted. The first consultation 
documentation form and the follow-up consultation documentation form were used for the 
Patients and Methods 31 
documentation of all issues discussed during the initial visit or further sessions (see 
Appendix C). 
 
Figure 3-3: Flow diagram of module 1 (basic pharmaceutical care) 
3.6.3 Module 3 – Adherence support 
As the two other modules, module 3 (adherence support) was developed on the basis of 
currently available evidence. Module 3 was only applied to those patients who were found to be 
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initially non-adherent (for details regarding adherence screening compare 3.3). Module 3 was 
started after cycle 1 and personal follow-up visits took place at least once during every 
capecitabine cycle. Module 3 contained detailed discussion of the patient’s individual adherence 
results on the basis of cycle 1 adherence data. Adherence support focussed on the identification 
of reasons for non-adherence in order to define a feasible adherence-enhancing strategy. Since 
various types of non-adherence exist, strategies to overcome individual barriers to adherence 
were designed individually. Strategies to improve unintentional non-adherence (e.g. due to 
forgetfulness) included treatment diaries or linking drug intake with a certain act of daily routine 
(cue dosing). In contrast, intentional non-adherence had to be approached in a completely 
different manner. If an adverse drug reaction was the reason for not taking capecitabine, 
management and prevention of further adverse drug reactions were addressed in accordance 
with module 2. Patients’ expectations and experiences were included in all considerations. 
Moreover, an increase of the patient’s awareness of the importance of adherence to capecitabine 
treatment was aimed. Routinely, beginning and end of the current and next capecitabine cycle 
were explicitly discussed and noted down. After each cycle further detailed discussions of the 
patient’s adherence results on the basis of the preceding cycle MEMS® data were undertaken. 
The content and course of the adherence-supporting sessions was adapted according to the 
patient’s medication taking behaviour. If the patient’s adherence accounted for ≥90%, a 
shortened conversation was performed. Due to the pleasant adherence result, compliment and 
support of the behaviour during the preceding cycle was given by the study pharmacist. 
Moreover, the proper functioning of the adherence-enhancing strategies was discussed and the 
patient was asked for problems that needed further clarification. If necessary, the patient was 
given appropriate advice. If the patient showed a daily adherence value of <90%, the content of 
the first counselling session of module 3 was repeated and adherence-enhancing strategies were 
reassessed, discussed and adapted. 
Between scheduled appointments every participant had the possibility to reach individual advice 
in person, by telephone or by email. All contents of module 3 discussions were documented 
using the adherence support documentation forms (either the one for use after cycle 1 or the one 
for use after cycle 2 to 6, see Appendix C). If necessary, the attending physician was contacted 
in order to report relevant issues or discuss problems. 
3.7 Outcome measurement 
The primary endpoint in the present study was daily total adherence to capecitabine 
chemotherapy determined by electronic monitoring. Additional endpoints were self-assessed 
adherence, overall adherence, persistence, dosing intervals, health-related quality of life, patient 
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satisfaction with information, the occurrence of the adverse effect hand-foot syndrome, 
pharmacist’s working time for pharmaceutical care and patients’ evaluation of capecitabine 
treatment. 
3.7.1 General patient data 
A questionnaire on general patient data (see Appendix B) was handed out to the study subjects 
to record their marital status, current living situation, education, responsibility for 
pharmacotherapy, education, current employment situation, activity in self-help groups and time 
required to reach treatment site. 
3.7.2 Adherence 
Patient adherence to capecitabine was assessed by means of electronic monitoring using the 
Medication Event Monitoring System (MEMS® by Aardex® Group Ltd., Zug, Switzerland). 
MEMS® consists of a medication container made from high-density polyethylene (HDPE) and a 
screw cap containing a microprocessor (MEMS® monitor). Every participant was provided with 
a MEMS® container and asked to use it for storage of capecitabine medication during study 
participation. Patients were instructed to open the containers only when taking their 
capecitabine dose and for no other reason. In case of required refills, patients were requested to 
schedule refill and regular capecitabine intake at the same time in order to avoid additional 
openings. If this was not possible or in case of further extraordinary openings, patients were 
asked to document the respective information on a special documentation sheet every 
participant was provided with. The MEMS® technology is illustrated in Figure 3-4. 
Each MEMS® monitor was delivered in the so called ‘sleeping mode’. Before use, the monitor 
was activated by a special software called MEMS® WakeUp (Aardex® Group Ltd., Zug, 
Switzerland). After activation the monitor was usable for 36 months. 
The microprocessor contained in the caps recorded date and time of each opening of the 
container. Using the hardware component MEMS® reader, data could be transferred from the 
monitor to the web-based application medAmigo® which was used to read out, visualise and 
store patients’ dosing history data. If no internet access was available, data could alternatively 
be transferred from the monitor to a personal computer using the MEMS® reader and the 
software PowerView®. PowerView® was able to visualise drug dosing histories as well. A 
subsequent transfer of all data from PowerView® to medAmigo® was performed. Table 3-2 
shows details of the MEMS® components used. 
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Figure 3-4 Medication Event Monitoring System (MEMS®) 
Table 3-2: Components of the MEMS® technology used 
Element Version 
Monitor MEMS® 6 TrackCap, screw cap 45 mm 
Container 250 cc HDPE container 
Software medAmigo® (online display of MEMS® data) 
MEMS® 6 WakeUp Version 2.3.1 (initialising of MEMS® monitors) 
PowerView® Version 3.5.1 (offline display of MEMS® data) 
Hardware MEMS® 6 reader USB 
Both medAmigo® and PowerView® were able to create patients’ medication taking profiles. 
Figure 3-5 shows the drug dosing history of one initially adherent patient displayed by 
medAmigo®. The medication taking profile of the same patient displayed by PowerView® is 
shown in Figure 3-6. In each case the profile describes one capecitabine cycle of the patient 
which consisted of 21 days (14 days with twice daily capecitabine intake followed by seven 
days of break). MedAmigo® and PowerView® allowed the setting of a twice daily drug intake. 
Thus, the software expected two MEMS® openings per day for the removal of the capecitabine 
tablets. A blue dot represents an opening of the screw cap in dependence of clock time on the y-
axis and date on the x-axis. MedAmigo® represents omitted doses by a grey bar. PowerView® 
represents two omitted openings of the screw cap as a red bar which covers the whole day. One 
omitted dose is shown as a red triangle. Subsequent corrections of the medication taking profiles 
were possible in both softwares. Since uncensored MEMS® data might overestimate non-
adherence [106], adherence data were censored according to information derived from patients 
notes (e.g. documented in MEMS® patient information or treatment diary) and interviews. 
Reasons for exclusions of openings or time periods were e.g. extra openings due to MEMS® 
reader
medication container
monitor
medAmigo® software
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container refills or self-reported non-monitoring intervals (e.g. due to hospital stays). Insertions 
were undertaken e.g. because of doses taken from another source than MEMS®. Reported 
divergences of opening and drug intake (e.g. earlier opening than intake due to an invitation, 
opening without intake) were corrected. In medAmigo® as well as in PowerView®, a blue cross 
depicts an excluded opening (event). In medAmigo®, a square represents a subsequently added 
opening. An added event is shown as a blue star in PowerView®.  
After the readout of all MEMS® data to medAmigo®, the raw data were converted and 
transferred to Excel® 2007 and SPSS® Version 20 for further data analysis. 
 
Figure 3-5: Graphical view of adherence data in medAmigo® 
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Figure 3-6: Graphical view of adherence data in PowerView® 
Observation period 
The observation period comprised days with drug intake as well as days without medication 
intake and started at the first day of patient’s capecitabine intake or the morning after the day 
the study pharmacist delivered the MEMS® vial to the patient, respectively. 
If the first capecitabine intake took place in the evening and thus the last drug intake took place 
in the morning, these two days were excluded from the observation period. 
Observation period ended at the end of the last day of the intake period of the patient’s sixth or 
last cycle (if the patient was prescribed less than six cycles). If days of the patient’s sixth or last 
drug intake break were observed by MEMS®, they were added to the observation period. A 
further possibility for the observation period to end was the final discontinuation of treatment on 
doctor’s order. The number of observed days had to be a whole number. 
The day of an either temporary or final discontinuation of treatment on doctor’s order was 
counted as a whole observation day. Since most frequently discontinuations were initiated 
sometime during the day (after breakfast and before dinner), the morning of this day counted as 
half a day with drug intake and the evening of this day counted as half a day without 
capecitabine intake. 
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Daily adherence 
Daily adherence (DA) was selected as primary endpoint in this study. It was defined as the 
percentage of days with correctly administered capecitabine doses and was calculated according 
to Equation 3-1: 
ܦܣሾΨሿ ൌ  ൬݊ݑܾ݉݁ݎ݋݂݀ܽݕݏݓ݅ݐ݄ܿ݋ݎݎ݁ܿݐ݀ݎݑ݃݅݊ݐܽ݇݁݊ݑܾ݉݁ݎ݋݂݋ܾݏ݁ݎݒ݁݀݀ܽݕݏ ൰ ൈ ͳͲͲ Equation 3-1 
Adherence and non-adherence was assessed regarding the correct administration of capecitabine 
on days with drug intake as well as days during the rest period. Generally a day was considered 
as adherent, if the patient exactly followed the instructions for his prescribed chemotherapy. A 
day was considered as adherent only, if two openings of the MEMS® monitor were recorded on 
a day during the drug intake period (dosing interval greater or equal six hours) or if no openings 
were recorded during the rest period. In case of ambiguity, adherence assessment was discussed 
and decided by a group of experts of the Department of Clinical Pharmacy, Institute of 
Pharmacy of the University of Bonn. 
Different daily adherence parameters were calculated: 
 Daily total adherence was calculated for each individual cycle referring to days with and 
days without capecitabine intake. 
 Daily intake adherence was calculated for each individual cycle on the basis of the drug 
intake interval only (excluding capecitabine-free days). 
 Daily break adherence was calculated for each individual cycle on the basis of treatment-
free days only (excluding days with drug intake). Daily intake and break adherence were 
calculated to investigate the influence of the rest period on the adherence. 
 Baseline daily adherence was calculated for cycle 1 referring to the intake period of the first 
cycle plus the first day of the first therapy-free interval. This parameter was used for the 
classification of a participant as initially adherent or non-adherent. 
 Daily adherence was calculated for the whole observation period of every patient including 
each intake and break period. 
Moreover, daily total adherence of patient subgroups which were built according to gender, 
tumour entity, therapy regimen and treatment intention was calculated. 
Self-assessed adherence 
Furthermore, adherence was assessed from the patients themselves by means of two adherence 
questionnaires (adherence questionnaire I and II, see Appendix B).  
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The adherence questionnaire I was handed out to the patients after every conducted capecitabine 
cycle (t1, t2, t3, t4, t5, and t6). It asked for the number of days (during the last 14 days) on which 
the patient took his capecitabine tablets both in the morning and in the evening. If the patient 
stated that he did not take his capecitabine tablets in the morning and in the evening on one or 
more days, he was asked for the reason. The adherence parameter was referred to as self-
assessed daily intake adherence. To compare MEMS®- and patient self-assessed adherence 
(results of the adherence questionnaire I), the questionnaire was converted from the parameter 
‘patient-stated number of days with full adherence’ to daily adherence expressed as percentage. 
Table 3-3 illustrates this conversion. 
Table 3-3: Conversion of patient self-assessed adherence measured by adherence 
questionnaire I to daily adherence expressed as percentage 
Response options question 1  
of the adherence questionnaire I 
Conversion to  
daily adherence range [%] 
0/14 days 0.0 
1/14 to 7/14 days >0.0-50.0 
8/14 to 10/14 days >50.0-71.4 
11/14 to 12/14 days >71.4-85.7 
13/14 to 14/14 days >85.7-100.0 
Patients were asked to fill in the second adherence questionnaire after the last cycle of their 
capecitabine treatment (normally after the sixth cycle at t6). They were supposed to assess their 
adherence to capecitabine during the whole intake period on a scale from 0% (never) to 100% 
(always). This adherence parameter was referred to as self-assessed total adherence. 
Overall adherence 
Overall adherence (OA) was determined for each cycle and throughout the whole observation 
period (including days without drug intake). It was defined as the percentage of correctly 
conducted openings of the MEMS® container and calculated according to Equation 3-2: 
ܱܣሾΨሿ ൌ  ൬ ݊ݑܾ݉݁ݎ݋݂ܽܿݐݑ݈ܽ݋݌݁݊݅݊݃ݏ݊ݑܾ݉݁ݎ݋݂݁ݔ݌݁ܿݐ݁݀݋݌݁݊݅݊݃ݏ൰ ൈ ͳͲͲ Equation 3-2 
Persistence 
Additionally, adherence data were analysed in terms of persistence and non-persistence. 
Duration of physician’s capecitabine prescription was compared with the duration of the actual 
treatment performance by the patient. 
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Dosing intervals 
Dosing intervals (time in between two capecitabine intake events) were examined as all 
registered time intervals between two openings of the MEMS® vial were downloaded and 
analysed. Dosing intervals >24 hours were excluded from analysis. 
3.7.3 Quality of life 
EORTC QLQ-C30 questionnaire 
A modified version of the cancer-specific EORTC QLQ-C30 (European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) questionnaire, 
version 3.0 (German language) was completed by the patients at t0, t3 and t6 (for version 3.0 and 
modified version 3.0 see Appendix B). Changes have been reported to the EORTC and 
comprised the insertion of a question regarding hand-foot syndrome (question 16, “Have you 
had symptoms of hand-foot syndrome?”). Consequently, the modified version 3.0 consisted of 
31 questions instead of 30 questions and the numbering from question 16 onwards was changed, 
accordingly. Furthermore, patient’s initials were not asked and design as well as layout of the 
questionnaire was changed. The modified version 3.0 comprised three pages instead of two. 
The modified version 3.0 of the questionnaire consisted of five functional scales, ten symptom 
scales (originally nine symptom scales, hand-foot syndrome was added) and the global health 
status [107], see Table 3-4. 
To answer each item, patients could score on a four-point Likert-scale from “not at all” (1) to 
“very much” (4). At first the raw scores were calculated for all scales and for the global health 
status as the mean of the component items (see Equation 3-3). Subsequently, a linear 
transformation was used to standardise the raw score. Thus, the scores ranged from 0 to 100. A 
higher numerical value of the score represented a higher (better) level of functioning, a higher 
(worse) level of symptoms and a higher (better) global health status, compare Equation 3-4, 3-5 
and 3-6. The range represents the difference between the possible maximum and the minimum 
response to individual items. Most items take values from 1 to 4, resulting in a range of 3 [108]. 
Raw score ܴܽݓݏܿ݋ݎ݁ሺܴܵሻ ൌ  ଵ ൅ ଶ൅Ǥ Ǥ Ǥ ൅୬  Equation 3-3 
Functional scales ܵܿ݋ݎ݁ ൌ  ቊͳ െ ሺ െ ͳሻ ቋ ή ͳͲͲ Equation 3-4 
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Symptom scales/items ܵܿ݋ݎ݁ ൌ  ቊሺ െ ͳሻ ቋ ή ͳͲͲ Equation 3-5 
Global health status/QoL ܵܿ݋ݎ݁ ൌ  ቊሺ െ ͳሻ ቋ ή ͳͲͲ Equation 3-6 
Table 3-4: Functional scales, symptom scales and global health status of the EORTC QLQ-C30 
questionnaire modified version 3.0 
 Scale Number of items 
Item numbers 
version 3.0 
Item numbers 
modified version 3.0 
Functional scales     
Physical function PF2 5 1 to 5 1 to 5 
Role function RF2 2 6, 7 6, 7 
Emotional function EF 4 21 to 24 22 to 25 
Cognitive function CF 2 20, 25 21, 26 
Social function SF 2 26, 27 27, 28 
Symptom scales/items     
Fatigue FA 3 10, 12, 18 10, 12, 19 
Nausea and vomiting NV 2 14, 15 14, 15 
Pain PA 2 9, 19 9, 20 
Dyspnoe DY 1 8 8 
Insomnia SL 1 11 11 
Appetite loss AP 1 13 13 
Constipation CO 1 16 17 
Diarrhea DI 1 17 18 
Financial difficulties FI 1 28 29 
Hand-foot syndrome HFS 1 - 16 
Global health status/QoL     
Global health status/QoL QL2 2 29, 30 30, 31 
EQ-5D-3L questionnaire 
Additionally patient’s quality of life was measured at t0, t3 and t6 using the EQ-5D-3L (EuroQol 
– five dimensions – three levels) questionnaire, a standardised generic measure of health status 
which is applicable to a wide range of health conditions and treatments (see Appendix B). The 
first part of the questionnaire comprises a descriptive system of health-related quality of life 
states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression). Each dimension can take one of three responses on a three-point Likert-
scale representing three levels of severity. These levels are no problems (level 1), some or 
moderate problems (level 2) or extreme problems (level 3). The second part of the EQ-5D 
questionnaire consists of a vertical, visual analogue scale (VAS) on the patient’s self-rated 
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health state. The scale’s endpoints are labeled “best imaginable health state” (100) and “worst 
imaginable health state” (0) [109]. 
3.7.4 Patient satisfaction with information 
The Canadian Patient Satisfaction with Cancer Treatment Education (PSCaTE) questionnaire 
was translated into German in the year 2002 and version 1.0 was used in patients with various 
cancer entities [59, 60, 110, 111]. In collaboration with the Department for Psychology of the 
University of Mannheim version 1.1 of the PSCaTE questionnaire was developed (compare 
Appendix B). The aim of the revision was an enhancement of the questionnaire’s 
comprehensibility for the patients [61]. In the present study patient satisfaction with information 
among initially adherent and initially non-adherent patients was measured before the first 
capecitabine cycle (t0), after the third cycle (t3) and after the sixth cycle (t6) using a modified 
version of the PSCaTE questionnaire version 1.1 (03/2006, see Appendix B). The first two 
pages of the PSCaTE questionnaire version 1.1 were used only (questions 1 to 16), design and 
layout were modified, date and date of birth were asked and the questionnaire’s introduction 
was worded differently. 
The 16 items of the PSCaTE questionnaire can be combined in four different scales (see Table 
3-5). In addition to the individual items and the different scales, overall satisfaction (OV) can be 
calculated. As a response scale a five-point Likert-scale was utilised. Patients had the possibility 
to score each item either strongly disagree (1), disagree (2), uncertain (3), agree (4) or strongly 
agree (5). 
Table 3-5: Scales of the PSCaTE questionnaire version 1.1 
PSCaTE Scale Number of items 
Item number 
version 1.1 
Satisfaction with information...     
…on cancer therapy CT 5 1, 5, 6, 8, 14 
…on adverse effects SE 4 2, 3, 9, 15 
…on vitamins, herbal medicines and 
complementary treatment options VC 3 4, 10, 16 
…sources RS 4 7, 11, 12, 13 
According to Equation 3-7, individual patient’s answers (item values) were utilised to calculate 
each individual scale of the PSCaTE questionnaire. To calculate the overall satisfaction of a 
patient at a certain time point, the mean scale values were used (Equation 3-8). If at least half of 
the items from a scale were answered, the respective scale was calculated. Regarding the 
calculation of the overall satisfaction, if at least half of the scale values were available, the 
overall satisfaction was calculated. As a basic principle, for ordinal data like answers to a 
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Likert-scale the calculation of the mean is not an adequate method as the distances between the 
scale values are not even. However, if one and the same person answered the items of the 
respective questionnaire the distances between the individual scale values of the different items 
are supposed to be equal for this individual. 
ɖത ൌ σ ɖ୧  
ɖത ൌ  
ɖ୧ ൌ   
 ൌ  
Equation 3-7 
ɖത ൌ σ ɖ୧  
ɖത ൌ  
ɖ୧ ൌ   
 ൌ  
Equation 3-8 
3.7.5 Hand-foot syndrome (HFS) 
After each conducted capecitabine cycle (at t1, t2, t3, t4, t5, and t6) patients were requested to fill 
in the questionnaire on HFS (see Appendix B). By ticking the respective box, patients 
documented if they experienced HFS and, if yes, how severe it was. The questionnaire on HFS 
was developed by the Department of Clinical Pharmacy of the University of Bonn in 
cooperation with oncologists. The description of the HFS severity grades was based on the 
Common Terminology Criteria for Adverse Events of Cancer Therapy Evaluation Program 
from the National Cancer Institute and reached from mild skin reactions at the hands and feet 
(grade 1) to major skin reactions with bleeding, ulceration and severe pain (grade 3) [23]. 
3.7.6 Pharmacist’s working time 
The study pharmacists documented the duration of patient interviews and counselling sessions 
(see Appendix C). Also, the time needed for extra work was recorded. Extra work included e.g. 
literature search, time needed to provide written patient information, e.g. medication plan, and 
discussions with other health care professionals. The duration of the initial counselling session 
was documented separately from the time needed for follow-up visits. The time required for 
module 3 was added to the duration of follow-up visits. 
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3.7.7 Patient evaluation 
Upon completion of the patients’ last capecitabine cycle, they were requested to evaluate their 
capecitabine therapy by means of a specific questionnaire (see Appendix B). The questionnaire 
consisted of three questions asking for the patients’ assessment of the therapy outcome 
compared with their expectations. This included experienced adverse drug reactions and overall 
experience with capecitabine therapy. 
3.7.8 Further analyses in the entire patient cohort 
The whole patient cohort was analysed concerning two different aspects. An existing 
relationship between overall adherence and hand-foot syndrome was explored. Moreover, 
potential predictors of adherence were evaluated. Therefore, the relationship and correlation, 
respectively, between daily total adherence during the first cycle of capecitabine treatment and 
diverse socio-demographic and disease-related characteristics were tested. For detailed 
information regarding applied statistical analyses see 3.9. 
3.8 Working hypotheses and sample size determination 
The following working hypotheses were investigated in the present study: 
 Patients who show a baseline adherence of ≥90% do not require a special adherence 
supporting intervention. 
 Patients who show a baseline adherence of <90% require a special adherence supporting 
intervention. 
 Patient adherence to capecitabine chemotherapy is increased by a special adherence 
supporting intervention. 
 Quality of life and patient satisfaction with information can be maintained during therapy 
with capecitabine by means of a multiprofessional, modular medication management. 
Regarding the primary outcome measure daily adherence two hypotheses were phrased: 
Hypothesis 1 
Null hypothesis H0: ≤75% of initially adherent patients remain being adherent without 
adherence supporting intervention. 
Alternative hypothesis H1: >75% of initially adherent patients remain being adherent without 
adherence supporting intervention. 
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Hypothesis 2 
Null hypothesis H0: ≤80% of initially non-adherent patients are adherent after the adherence 
supporting intervention. 
Alternative hypothesis H1: >80% of initially non-adherent patients are adherent after the 
adherence supporting intervention. 
Sample size determination 
Sample size determination was conducted for the primary endpoint ‘daily adherence’ and was 
based on available adherence data of 44 cancer patients collected in a prospective, multi-centred 
observational cohort study between 05/2006 and 04/2008 [57]. These patients had a diagnosis of 
breast or colorectal cancer and were treated with capecitabine. Patients’ adherence was 
monitored by MEMS® over a time period of six months. These data were analysed with regard 
to daily adherence of the patient’s first capecitabine cycle (compare 3.7.1): 59.1% were adherent 
(≥90%) during their first cycle and 40.9% were non-adherent (<90%).  
Regarding initially adherent participants a sample size of 45 patients was required to show with 
a power (1-β) of 80% that >75% of these patients remain being adherent (error of first kind (α) 
= 5%). The true population value of patients who persist being adherent was assumed to account 
for >90%. 
Regarding initially non-adherent patients, a sample size of 30 patients was required to show 
with a power (1-β) of 80% that >80% of these patients become adherent after receiving 
adherence support (error of first kind (α) = 5%). The true population value of patients who 
became adherent was assumed to account for >95%.  
Finally a dropout rate of 20% was estimated resulting in a total sample size of 90 patients 
(54 initially adherent patients and 36 initially non-adherent patients). 
3.9 Statistical analysis 
Data entry and statistical data analysis of the results were carried out using the software Excel® 
2007 (Microsoft, Redmond, USA) as well as SPSS® Version 20 (SPSS® Inc., Chicago, USA, 
Statistical Package for the Social Sciences). 
Data were mostly binary, nominal, ordinal, or failed to follow a normal distribution, thus, non-
parametric testing was utilised consistently. A p value of <0.05 was considered as statistically 
significant in all cases. Statistical evaluations were conducted separately for the groups of 
initially adherent and initially non-adherent patients. Only the analysis of the relationship 
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between overall adherence and hand-foot syndrome and the evaluation of potential predictors of 
adherence were conducted including the entire patient cohort. 
Descriptive statistics 
Appropriate descriptive statistics calculating mean, standard deviation (SD), median, 
interquartile range (IQR), range, absolute and relative frequency distribution was used to 
characterise the patient population and summarise the study results. Moreover, appropriate 
graphical presentation was carried out in terms of boxplots, bar charts, pie charts, scatter plots, 
line charts and histograms. Kaplan-Meier plots were used for graphical presentation of data 
regarding time until a particular event occurred (e.g. time to dose reduction of capecitabine, 
time to first occurrence of HFS) [112]. 
Inductive statistics 
Furthermore, inductive statistics was employed. The Mann-Whitney-U test for independent 
samples was employed to analyse existing differences between two samples regarding 
continuous (not normally distributed) data (e.g. daily adherence in initially adherent and initially 
non-adherent patients). 
The Kruskal-Wallis-H test for independent samples was used to test for differences between 
more than two independent samples in terms of continuous data (e.g. daily adherence in patients 
with breast cancer, colorectal cancer and other cancer entities). 
The Wilcoxon test was applied to look for differences regarding continuous data between two 
dependent samples (e.g. MEMS®- versus self-assessed adherence in initially adherent patients). 
To test whether two categorical variables were associated or independent the Chi-square test 
was employed (e.g. relationship of dichotomised adherence with adherence group membership). 
However, the Chi-square test is not appropriate when more than 20% of the cells of a cross 
tabulation exhibit an expected frequency less than five. Thus, when the expected frequencies 
were too low, the Fisher’s exact test for nominal data was used, a method for computing the 
exact probability of the Chi-square statistics that is accurate when sample sizes are small [113]. 
In this study differences regarding socio-demographic and disease-related characteristics 
between initially adherent and non-adherent patients were tested using the Fisher’s exact test. 
Cox regression models are used to investigate the influence of several variables on the time until 
a particular event occurred (predictive models for time-to-event data) [112]. In this study the 
effect of two overall adherence variables and the cancer entity on the time to first occurrence of 
HFS grade 1 to 3 and grade 2 to 3, respectively, was explored. 
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To explore the strength of relationship between adherence and potential predictors of adherence, 
Spearman’s rank correlation coefficient was utilised for comparing two ordinal or continuous 
(not normally distributed) data sets [113]. 
The log-rank test was used to compare time-to-event rates of independent samples, i.e. to test 
for statistically significant differences between Kaplan-Meier curves [112]. 
Missing data and study drop-outs 
If adherence data were missing, the corresponding days were not included in analysis. The 
number of observed days was reduced accordingly. In the event of missing data regarding 
further endpoints, available data of the respective patient were analysed. Study drop-outs due to 
withdrawal of informed consent, non-use of the MEMS® container or death before the 
containers could be read out were not analysed. Patient data collected until drop-out were not 
included in further analyses (per-protocol analysis). However, study drop-outs due to other 
reasons were included in analyses, e.g. because of premature treatment discontinuation as a 
result of an adverse drug reaction, if they completed at least one entire cycle. 
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4 Results 
4.1 Patient recruitment 
Patient recruitment took place on two oncology outpatient wards (one Department of Internal 
Medicine and one Specialist Breast Unit/Senology) and two oncology practices. Between July 
2009 and November 2011, participating oncologists assessed 97 patients for eligibility, 78 of 
these were enrolled in the study (80.4%). Figure 4-1 provides a detailed overview of patient 
recruitment. Nineteen patients were excluded from participation, because they did not fulfil 
inclusion criteria or declined participation. The main reason (seven out of eight refusals) for 
non-participation was perceived stress by the study in addition to their mentally and/or 
physically impaired condition. Other reasons for non-participation were capecitabine non-
naivity (five patients), participation in another trial (four patients), and insufficient knowledge 
of German language (two patients). Five patients who dropped out of the present study were not 
analysed. One patient withdrew his informed consent because he refused to fill in questionnaires 
and did not want to receive patient care provided by the study pharmacists. Two patients did not 
use their MEMS® container during the course of the study. Two patients died before it was 
possible for the study pharmacists to read out the MEMS® monitor. Study drop-outs due to other 
reasons than the reasons mentioned above were included in analyses. Finally, 73 patients were 
analysed. 
4.2 Patient characteristics 
Seventy-three patients were analysed for baseline daily adherence. Fifty-eight of them (79.5%) 
were found to be initially adherent and 15 initially non-adherent (20.5%). Table 4-1 and Table 
4-2 show that there was no statistically significant difference between initially adherent and 
non-adherent patients regarding socio-demographic and disease-related characteristics. A higher 
number of patients from oncology outpatient wards than patients from oncology practices were 
initially adherent (p=0.021, Fisher’s exact test). 
In initially adherent patients the mean age at t0 was 62.5 years (median 62.0, SD 12.6, range 36-
87, IQR 55.5-73.0). The mean age at t0 of the initially non-adherent patients was 66.6 years 
(median 65.0, SD 11.5, range 52.0-90.0, IQR 55.0-76.0). Therefore initially adherent patients 
were on average 4.1 years younger than initially non-adherent patients. This difference was not 
statistically significant (p=0.335, Mann-Whitney-U test). 
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The mean time for initially adherent patients to reach their treatment site was 23.1 minutes 
(median 20.0, SD 14.4, range 5.0-90.0, IQR 15.0-30.0). In initially non-adherent patients the 
mean time to treatment site accounted for 25.1 minutes (median 27.5, SD 7.7, range 10.0-36.0, 
IQR 20.0-30.0). No statistically significant difference between the two patient groups was 
observed (p=0.187, Mann-Whitney-U test). 
Concerning the number of additional drugs (regularly, orally administered) at time of inclusion 
(t0) the two patient groups did not differ either (p=0.062, Mann-Whitney-U test). In initially 
adherent patients, the mean number of additional drugs accounted for 3.5 (median 3.0, SD 3.2, 
range 0.0-13.0, IQR 1.0-5.0). Initially non-adherent patients took on average 5.1 additional 
drugs at t0 (median 5.0, SD 3.3, range 1.0-12.0, IQR 2.0-6.0). 
Mean time since diagnosis [months] at t0 in the group of initially adherent patients was found to 
be 30.2 months (median 12.5, SD 45.6, range 1.0-216.0, IQR 5.0-32.8). Initially non-adherent 
patients’ diagnosis was on average 74.9 months ago (median 16.0, SD 112.7, range 0.0-393.0, 
IQR 5.0-120.0). However, this difference between the two patient groups was not statistically 
significant (p=0.342, Mann-Whitney-U test). 
Figure 4-1: Patient recruitment flow diagram 
  
First patient in 07/2009, last patient in 11/2011, last patient out 03/2012
Assessed for eligibility (n=97)
Excluded (n=19)
 Did not meet inclusion criteria (n=11)
 Refused to participate (n=8)
Analysed (n=73)
Excluded from analysis (n=0)
Initially adherent (n=58)
Initially non-adherent (n=15)
Enrollment
Study drop-outs* (n=5)
Withdrew informed consent (n=1)
 Non-use of MEMS® (n=2)
 Died before reading MEMS® (n=2)
Follow-up
Analysis
Enrolled (n=78)
*  Excluding study drop-outs due to other reasons than the reasons mentioned above
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Table 4-1: Socio-demographic patient characteristics 
Socio-demographic characteristics 
initially 
adherent 
initially non-
adherent p value* 
n % n % 
Classified age [years] 
≤50  11 19.0 0 0.0 
0.203 
51-60  15 25.9 6 40.0 
61-70  17 29.3 3 20.0 
71-80  10 17.2 5 33.3 
>80 5 8.6 1 6.7 
Sex 
Female 44 75.9 10 66.7 
0.516 
Male 14 24.1 5 33.3 
Marital status 
Married/partner 33 56.9 8 53.3 
0.639 
Single 6 10.3 3 20.0 
Divorced 4 6.9 0 0.0 
Widow 8 13.8 3 20.0 
No answer 7 12.1 1 6.7 
Current living situation 
Living alone 8 13.8 3 20.0 
0.759 
With family/partner 42 72.4 11 73.3 
Living in institution 1 1.7 0 0.0 
No answer 7 12.1 1 6.7 
Education 
Elementary school 8 13.8 1 6.7 
0.650 
Secondary school 4 6.9 2 13.3 
O-levels 15 25.9 3 20.0 
Journeyman 4 6.9 1 6.7 
A-levels 6 10.3 2 13.3 
Master of a trade 2 3.4 2 13.3 
Bachelor 2 3.4 1 6.7 
University/College 8 13.8 1 6.7 
Higher university degree 1 1.7 1 6.7 
No answer 8 13.8 1 6.7 
Current employment 
situation 
Housewife/-man 5 8.6 1 6.7 
0.643 
Public servant 2 3.4 0 0.0 
Pensioner 27 46.6 7 46.7 
Employee 12 20.7 3 20.0 
Self-employed 3 5.2 3 20.0 
Worker 1 1.7 0 0.0 
No answer 8 13.8 1 6.7 
Number of additional 
drugs 
≤5 45 77.6 10 66.7 
0.514 
6-10 9 15.5 3 20.0 
>10 3 5.2 2 13.3 
No answer 1 1.7 0 0.0 
* Fisher´s exact test 
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Table 4-2: Disease-related patient characteristics 
Disease-related characteristics 
initially 
adherent 
initially non-
adherent p value* 
n % n % 
Tumour entity 
Breast cancer 21 36.2 7 46.7 
0.818 
Colorectal cancer 25 43.1 7 46.7 
Gastric cancer 3 5.2 0 0.0 
Oesophageal cancer 1 1.7 1 6.7 
Ovarian cancer 3 5.2 0 0.0 
Cancer of unknown 
primary (CUP) 1 1.7 0 0.0 
Pancreatic cancer 3 5.2 0 0.0 
Endometrial cancer 1 1.7 0 0.0 
Therapy regimen at 
inclusion1,2 
Cap 35 60.3 7 46.7 
0.313 
Cap Beva 11 19.0 4 26.7 
Cap Beva Ox 1 1.7 0 0.0 
Cap Lap 1 1.7 0 0.0 
Cap Ox 3 5.2 1 6.7 
Cap Vin 1 1.7 1 6.7 
Cap Mito 0 0.0 1 6.7 
Cap Trastu Ox 0 0.0 1 6.7 
Cap Fulve 2 3.4 0 0.0 
Cap Vin Letro 1 1.7 0 0.0 
Cap Trastu 3 5.2 0 0.0 
Treatment intention curative 8 13.8 3 20.0 0.686 palliative 50 86.2 12 80.0 
Classified time since 
diagnosis 
<½ year 15 25.9 4 26.7 
0.712 ½ to 2 years 22 37.9 4 26.7 
>2 years 21 36.2 7 46.7 
Treatment setting Oncology outpatient ward 51 87.9 9 60.0 0.021 Oncology practice 7 12.1 6 40.0 
Responsibility for 
pharmacotherapy 
Independently 46 79.3 13 86.7 
1.000 
Partner/family 3 5.2 1 6.7 
Nursing service 1 1.7 0 0.0 
Nursing service or 
partner/family 1 1.7 0 0.0 
No answer 7 12.1 1 6.7 
Activity in self-help 
group 
Yes 5 8.6 1 6.7 
1.000 No 44 75.9 13 86.7 
No answer 9 15.5 1 6.7 
Classified distance to 
treatment site [minutes] 
<15 9 15.5 1 6.7 
0.448 
15-29 25 43.1 6 40.0 
30-44 14 24.1 7 46.7 
≥45 2 3.4 0 0.0 
No answer 8 13.8 1 6.7 
* Fisher´s exact test 
1Therapy regimens: Cap=capecitabine monotherapy; Cap Beva=capecitabine+bevacizumab; Cap Bev 
Ox=capecitabine+bevacizumab+oxaliplatin; Cap Lap=capecitabine+lapatinib: Cap Ox=capecitabine
+oxaliplatin; Cap Vin=capecitabine+vinorelbine; Cap Mito=capecitabine+mitomycin; Cap Trastu Ox
=capecitabine+trastuzumab+oxaliplatin; Cap Fulve=capecitabine+fulvestrant; Cap Vin Letro=cape-
citabine+vinorelbine+letrozole; Cap Trastu=capecitabine+trastuzumab 
2Bisphosphonate and radiation therapies are not considered 
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4.3 Initially adherent patients 
Initially adherent participants were observed for a median time of 119.0 days (mean 100.5 days; 
SD 37.1; range 21.0-152.0; IQR=69.8-126.0). 
4.3.1 Daily adherence 
As described in 3.7.2, baseline daily adherence was calculated based on the first capecitabine 
intake period plus first day of treatment break for reasons of feasibility. According to this 
adherence parameter, patients were screened and classified as either initially adherent or non-
adherent. Moreover, daily total adherence was calculated based on the intake period plus the 
treatment-free interval. Values of baseline daily adherence and daily total adherence during 
cycle 1 might differ. Figure 4-2 compares median baseline daily adherence and median daily 
total adherence during cycle 1 of initially adherent patients and visualises that baseline daily 
adherence was marginally lower. 
Further adherence parameters calculated were daily intake and daily break adherence. 
 
Figure 4-2: Baseline daily adherence versus daily total adherence during cycle 1 of initially 
adherent patients (n=58) 
Figure 4-3 shows the individual daily total adherence profiles of each patient over the 
observation period. Although these participants did not receive specific adherence support, the 
modular medication management led to a consistently high daily total adherence in a majority 
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of these patients. Only in exceptional cases daily total adherence was observed to be lower than 
90%. One patient did not adhere to the minimum intake interval of six hours between two 
capecitabine doses on several days. A further patient took capecitabine for three weeks instead 
of two weeks. Hand-foot syndrome, epistaxis, gum bleeding, and mental disorders represented 
additional barriers to sufficient adherence in the presented patient group. In one patient, only 
three days were observed via MEMS® in cycle two and therefore minor deviations from the 
prescribed regimen caused low adherence parameters. 
One patient refused the receipt of modular medication management provided by the study 
pharmacist. The reason for this was extreme psychological stress of the patient caused by his 
life-threatening condition. Conversations, interviews, and questionnaires concerning cancer 
disease were perceived as additional stress. However, daily total adherence of this patient 
accounted for 100.0% during all observed capecitabine cycles. 
 
Figure 4-3: Individual daily total adherence of initially adherent patients during the course of 
the study; cycle 1: n=58, cycle 2: n=56, cycle 3: n=48, cycle 4: n=45, cycle 5: n=40, cycle 6: 
n=37, the black line represents median daily total adherence 
Average daily total adherence decreased by 1.6% points from cycle 1 to 6. Median daily total 
adherence was found to be 100% in each cycle. Table 4-3 shows the respective details. 
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Table 4-3: Daily total adherence of initially adherent patients (calculation based on intake and 
rest period) 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
Cycle 1 58 98.9 100.0 2.1 93.3-100.0 100.0-100.0 
Cycle 2 56 97.3 100.0 5.5 66.7-100.0 95.2-100.0 
Cycle 3 48 97.2 100.0 4.9 75.0-100.0 95.2-100.0 
Cycle 4 45 96.7 100.0 6.3 68.8-100.0 95.2-100.0 
Cycle 5 40 97.4 100.0 4.7 80.0-100.0 95.2-100.0 
Cycle 6 37 97.3 100.0 7.3 57.1-100.0 95.2-100.0 
Figure 4-4 demonstrates that variability with regard to daily total adherence increased 
marginally in further cycles compared to cycle 1. Outliers and extreme values during the 
different capecitabine cycles did not belong to the same patients (compare explanation given to 
Figure 4-3). One patient exhibited extreme values during three cycles for reasons of mental 
disorder and two patients during two cycles due to forgetfulness, hand-foot syndrome, epistaxis, 
and gum bleeding. 
 
Figure 4-4: Daily total adherence of initially adherent patients during cycle 1 to 6 
Compared to daily total adherence of initially adherent patients, values of daily intake adherence 
showed a higher variability, and more outliers and extreme values were observed (Figure 4-5). 
More detailed information on daily intake adherence of initially adherent patients during 
cycle 1 to 6 is presented in Appendix D, Table D-1. 
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Figure 4-5: Daily intake adherence [%] of initially adherent patients during cycle 1 to 6 
Daily adherence of initially adherent patients during capecitabine treatment-free intervals was 
found to be better than these patients’ daily total adherence and daily intake adherence, see 
Figure 4-6. More detailed information on daily break adherence is tabulated in Appendix D, 
Table D-2. 
 
Figure 4-6: Daily break adherence [%] of initially adherent patients during cycle 1 to 6 
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During all observed cycles, a high percentage of initially adherent participants showed a daily 
total adherence equal 100% and equal or greater 90% and 80%, respectively. After the sixth 
cycle, 36 of 37 (97.3%, confidence interval (CI) 88.8%-99.4%) initially adherent patients 
showed a daily total adherence of ≥90%. Since the CI does not include 75% it is shown with an 
error of the first kind of 5% that more than 75% of the initially adherent patients remained 
adherent without specific adherence support. Figure 4-7 illustrates the data as a bar chart and 
Appendix D, Table D-3 comprises more detailed information in tabular form. 
 
Figure 4-7: Percentage of initially adherent patients exhibiting a daily total adherence ≥90% 
during intake and rest periods of cycle 1 to 6; the numbers inside the boxes show the exact 
percentage (first row) and absolute patient numbers (second row) 
Figure 4-8 shows the percentage of initially adherent patients exhibiting a daily intake 
adherence (excluding therapy-free interval) ≥90%. The proportion of patients who showed a 
daily intake adherence ≥90% was lower compared to the proportion of patients who showed a 
daily total adherence ≥90%. This suggests that adherence is lower during intake than rest 
periods. 
Figure 4-9 shows intra-individual differences of daily total adherence between the end of study 
and baseline. Thus, initially adherent patients’ daily total adherence at the end of study was 
mostly found to be as high as at baseline. Adherence variation of more than ±10% was observed 
in 3.4% (2/58) of initially adherent patients only, and variation of more than ±5% was observed 
in 10.3% (6/58) of patients. Two patients’ adherence diminished by 37.9% and 33.3%. Reasons 
for this decrease were epistaxis and gum bleeding in one patient. Regarding the second patient, 
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only three days were observed in the second cycle. Two of three days were adherent, resulting 
in a daily total adherence of 66.7%. 
 
Figure 4-8: Percentage of initially adherent patients exhibiting a daily intake adherence ≥90% 
during the intake periods of cycle 1 to 6; the numbers inside the boxes show the exact 
percentage (first row) and absolute patient numbers (second row) 
 
Figure 4-9: Intra-individual difference in daily total adherence [%] between the last and first 
capecitabine cycle of initially adherent patients (n=58); every triangle represents one patient 
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After classification as either adherent (≥90%) or non-adherent (<90%), adherence patterns by 
cycle revealed that 12.1% (7/58) of initially adherent patients were at least one cycle non-
adherent, see Figure 4-10. Four of fifty-eight (6.9%) patients were non-adherent for one cycle 
and 3/58 (5.2%) patients for two cycles (either two subsequent cycles or two non-adherent 
cycles with one adherent cycle in between). Approximately half of all initially adherent patients 
were prescribed less than six capecitabine cycles (see 4.3.3). 
 
Figure 4-10: Individual daily total adherence of initially adherent patients (n=58); green bars 
indicate adherent cycles (daily total adherence ≥90%), red bars non-adherent cycles (daily 
total adherence <90%) and white bars non-use of MEMS® by the patient during the respective 
cycle; non-complete bars imply treatment duration of less than six cycles, for information on 
reasons for shortened prescription of capecitabine see 4.3.3 
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Influence of gender 
Daily total adherence was analysed separately in terms of female and male initially adherent 
participants. No statistical significant difference was observed between genders. Table 4-4 
summarises the respective results. Median daily total adherence of female and male patients was 
100.0% throughout all cycles. Mean daily total adherence of female patients ranged from 96.2% 
to 98.8% and of male patients from 95.0% to 99.3%. In both genders the highest value was 
observed during the first completed capecitabine cycle. 
Influence of tumour entity 
There were no statistically significant differences concerning daily total adherence at t1, t2, t3, t4, 
t5, and t6 between breast cancer, colorectal cancer, and other cancer subgroups. Median daily 
total adherence of the three mentioned subgroups at all six time points was 100.0% (Table 4-5). 
Influence of therapy regimen 
Between the two patient subgroups who were treated with capecitabine as single agent or with a 
combination of capecitabine and one or more further anti-cancer agents no statistically 
significant difference was found concerning daily total adherence at the first five time points. 
During cycle 6, mean daily total adherence of patients treated with capecitabine as monotherapy 
was 99.2% and the median accounted for 100.0%. Mean daily total adherence of patients who 
received combination anti-cancer treatment was 95.2% and the median was 98.2%. The results 
differed statistically significant between the two subgroups (p value=0.023, Mann-Whitney-U 
test). Table 4-6 summarises the findings. 
Influence of treatment intention 
Daily total adherence was analysed in terms of differences between patients who were treated 
with curative or palliative intention. Between these two subgroups no statistically significant 
differences were observed. Mean and median daily total adherence was high during the whole 
course of the study. For details see Table 4-7. 
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Table 4-4: Daily total adherence [%] of initially adherent female and male patients during the 
course of the study 
 Female Male p value* 
t1 
n 44 14 
0.411 
Mean  98.8 99.3 
Median 100.0 100.0 
SD 2.1 1.9 
IQR 97.7-100.0 100.0-100.0 
Range 94.7-100.0 93.3-100.0 
t2 
n 42 14 
0.244 
Mean  98.1 95.0 
Median 100.0 100.0 
SD 3.3 9.2 
IQR 95.2-100.0 95.0-100.0 
Range 90.5-100.0 66.7-100.0 
t3 
n 35 13 
0.611 
Mean  96.9 97.9 
Median 100.0 100.0 
SD 5.3 3.6 
IQR 95.2-100.0 95.2-100.0 
Range 75.0-100.0 90.9-100.0 
t4 
n 34 11 
0.378 
Mean  96.2 98.3 
Median 100.0 100.0 
SD 7.0 3.2 
IQR 95.2-100.0 95.5-100.0 
Range 68.8-100.0 90.5-100.0 
t5 
n 31 9 
0.298 
Mean  97.6 96.8 
Median 100.0 100.0 
SD 4.9 4.2 
IQR 95.2-100.0 95.0-100.0 
Range 80.0-100.0 90.5-100.0 
t6 
n 29 8 
0.912 
Mean  97.0 98.3 
Median 100.0 100.0 
SD 8.1 2.3 
IQR 95.2-100.0 95.8-100.0 
Range 57.1-100.0 95.0-100.0 
* Mann-Whitney-U test 
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Table 4-5: Daily total adherence [%] of initially adherent patients with breast cancer, 
colorectal cancer and other cancer entities1 during the course of the study (n=58) 
 Breast cancer Colorectal cancer Other1 p value* 
t1 
n 21 25 12 
0.242 
Mean  98.4 99.1 99.4 
Median  100.0 100.0 100.0 
SD  2.4 1.9 1.9 
IQR  95.2-100.0 100.0-100.0 100.0-100.0 
Range  94.7-100.0 95.0-100.0 93.3-100.0 
t2 
n 21 25 10 
0.304 
Mean  98.6 96.2 97.3 
Median  100.0 100.0 100.0 
SD  3.1 7.3 4.0 
IQR  100.0-100.0 95.2-100.0 95.4-100.0 
Range  90.5-100.0 66.7-100.0 90.5-100.0 
t3 
n 19 23 6 
0.617 
Mean  97.8 96.5 97.6 
Median  100.0 100.0 100.0 
SD  3.2 5.8 5.8 
IQR  95.2-100.0 95.2-100.0 100.0-100.0 
Range  90.5-100.0 75.0-100.0 85.7-100.0 
t4 
n 18 22 5 
0.513 
Mean  95.1 97.4 99.1 
Median  100.0 100.0 100.0 
SD  8.8 4.1 2.1 
IQR  95.2-100.0 95.2-100.0 100.0-100.0 
Range  68.8-100.0 89.3-100.0 95.2-100.0 
t5 
n 17 20 3 
0.327 
Mean  96.2 98.1 100.0 
Median  100.0 100.0 100.0 
SD  5.9 3.6 0.0 
IQR  95.2-100.0 97.5-100.0 100.0-100.0 
Range  80.0-100.0 90.5-100.0 100.0-100.0 
t6 
n 16 19 2 
0.514 
Mean  95.5 98.4 100.0 
Median  100.0 100.0 100.0 
SD  10.6 2.6 0.0 
IQR  95.2-100.0 96.4-100.0 100.0-100.0 
Range  57.1-100.0 91.7-100.0 100.0-100.0 
* Kruskal-Wallis-H test 
1Other cancer entities: gastric, oesophageal, ovarian, pancreatic, endometrial cancer and cancer of unknown 
primary 
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Table 4-6: Daily total adherence [%] of initially adherent patients who received capecitabine 
as single agent or in combination during the course of the study (n=58) 
 Single agent Combination p value* 
t1 
n 35 23 
0.257 
Mean  99.1 98.6 
Median  100.0 100.0 
SD  2.0 2.2 
IQR 100.0-100.0 95.2-100.0 
Range 93.3-100.0 95.0-100.0 
t2 
n 33 23 
0.520 
Mean  96.9 97.9 
Median  100.0 100.0 
SD  6.4 4.0 
IQR 95.2-100.0 95.2-100.0 
Range 66.7-100.0 85.7-100.0 
t3 
n 27 21 
0.755 
Mean  97.3 97.0 
Median  100.0 100.0 
SD  3.9 5.9 
IQR 95.2-100.0 95.2-100.0 
Range 85.7-100.0 75.0-100.0 
t4 
n 25 20 
0.384 
Mean  97.9 95.1 
Median  100.0 100.0 
SD  3.4 8.6 
IQR 95.2-100.0 93.6-100.0 
Range 90.5-100.0 68.8-100.0 
t5 
n 21 19 
0.375 
Mean  98.0 96.8 
Median  100.0 100.0 
SD  4.1 5.3 
IQR 100.0-100.0 95.0-100.0 
Range 86.4-100.0 80.0-100.0 
t6 
n 19 18 
0.023 
Mean  99.2 95.2 
Median  100.0 98.2 
SD  2.0 9.9 
IQR 100.0-100.0 95.2-100.0 
Range 92.9-100.0 57.1-100.0 
* Mann-Whitney-U test 
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Table 4-7: Daily total adherence [%] of initially adherent patients who received capecitabine 
with a curative or palliative treatment intention during the course of the study (n=58) 
 Curative intention Palliative intention p value* 
t1 
n 8 50 
0.988 
Mean  98.8 98.9 
Median  100.0 100.0 
SD  2.2 2.1 
IQR 97.7-100.0 100.0-100.0 
Range 95.2-100.0 93.3-100.0 
t2 
n 8 48 
0.336 
Mean  97.0 97.3 
Median  97.6 100.0 
SD  3.5 5.8 
IQR 95.2-100.0 95.3-100.0 
Range 90.5-100.0 66.7-100.0 
t3 
n 8 40 
0.472 
Mean  97.0 97.2 
Median  97.6 100.0 
SD  3.5 5.1 
IQR 95.2-100.0 95.2-100.0 
Range 90.5-100.0 75.0-100.0 
t4 
n 7 38 
0.673 
Mean  98.0 96.4 
Median  100.0 100.0 
SD  3.7 6.7 
IQR 95.2-100.0 95.2-100.0 
Range 90.5-100.0 68.8-100.0 
t5 
n 6 34 
0.092 
Mean  100.0 97.0 
Median  100.0 100.0 
SD  0.0 4.9 
IQR 100.0-100.0 95.0-100.0 
Range 100.0-100.0 80.0-100.0 
t6 
n 5 32 
0.108 
Mean  100.0 96.8 
Median  100.0 100.0 
SD  0.0 7.7 
IQR 100.0-100.0 95.2-100.0 
Range 100.0-100.0 57.1-100.0 
* Mann-Whitney-U test 
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MEMS®- versus self-assessed adherence 
Patient self-assessment in terms of adherence was compared with MEMS®-assessed daily intake 
adherence. Figure 4-11 illustrates a high daily intake adherence of initially adherent patients 
throughout the whole study period, more than 80.0% of the patients showed adherence values of 
>85.7% in each cycle. However, adherence self-assessment was found to be even higher, see 
Figure 4-12. Almost 100.0% of the studied patients stated that their daily intake adherence 
accounted for >85.7% during all observed capecitabine cycles. 
 
Figure 4-11: Percentage of initially adherent patients within MEMS®-assessed daily intake 
adherence ranges during the course of the study 
 
Figure 4-12: Percentage of initially adherent patients within self-assessed daily intake 
adherence ranges during the course of the study 
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Table 4-8 shows the comparison of MEMS®- versus self-assessed adherence concerning the 
whole capecitabine treatment period assessed after the sixth cycle (or after an earlier cycle in 
case of premature discontinuation of treatment). In the cohort of initially adherent patients, 
mean self-assessed total adherence was 97.9% and median was 100.0%. Mean MEMS®-
assessed daily adherence during the whole observation period accounted for 97.7% and the 
median was 98.4%. Thus, self-assessment came relatively close to a more objective method of 
measurement. No statistically significant difference was observed (p value=0.353, Wilcoxon 
test). 
Table 4-8: MEMS®-assessed [%] versus self-assessed adherence [%] during the whole study 
period (cycle 1 to 6) assessed at t6 in initially adherent patients 
MEMS®-assessed daily 
adherence [%] 
Self-assessed total adherence 
[%] p value* 
n 58 38 
0.353 
Mean 97.7 97.9 
Median 98.4 100.0 
SD 2.8 5.4 
IQR 96.5-100.0 100.0-100.0 
Range 85.7-100.0 75.0-100.0 
* Wilcoxon test 
4.3.2 Overall adherence 
Overall adherence of initially adherent patients under modular medication management was 
high throughout the complete observation period (see Figure 4-13). Variability of overall 
adherence was found to be minor. Median overall adherence was 100.0% in each cycle, mean 
overall adherence ranged from 98.2% to 100.5%. The extreme value in cycle 3 accounted for 
153.6%. This patient took capecitabine for three weeks (seven-day treatment break followed) 
instead of two weeks. More detailed information regarding mean, median, standard deviation, 
range, and interquartile range of overall adherence during individual cycles is summarised in 
Appendix D, Table D-4. 
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Figure 4-13: Overall adherence [%] of initially adherent patients during cycle 1 to 6 
4.3.3 Persistence 
All initially adherent patients were persistent during the whole period of capecitabine 
prescription. No patient performed an unauthorised discontinuation of his capecitabine 
treatment. 
However, in 17 of 58 initially adherent patients capecitabine therapy was discontinued 
prematurely by their physicians. In 12 patients this decision was taken due to tumour 
progression (one patient had to stop treatment on day three of the sixth cycle due to progression, 
so data for the sixth cycle were available for analysis). Five patients discontinued therapy 
because of adverse drug reactions (hand-foot syndrome and haemolytic anaemia), hospital 
admission, the toxicity of a co-administered drug, and the patient’s wish to stop treatment. The 
chronological sequence of treatment discontinuations is illustrated in Figure 4-14. Short vertical 
lines indicate censored patient data (patients who were not advised to discontinue treatment 
prematurely by their physician). Thirty-six patients completed six cycles as planned, two 
patients completed less than six capecitabine cycles as planned, one patient died after the 
completion of the third cycle, and two patients quit their study participation during the second 
cycle. 
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Figure 4-14: Duration of capecitabine prescription [days] for initially adherent patient, n=58; 
short vertical lines indicate censored patient data 
4.3.4 Dosing intervals 
Capecitabine tablets should be taken in the morning and in the evening with a dosing interval of 
twelve hours. In the cohort of initially adherent patients, 7064 dosing intervals were recorded by 
the MEMS® monitors during the observation period and the median dosing interval was 11:59 
hours. A detailed overview of the results of the interval analysis is shown in Table 4-9. For the 
analysis of dosing intervals, intervals ≥24 hours were not considered. 
Table 4-9: Dosing intervals [hours] <24 hours recorded by MEMS® in initially adherent 
patients (n=58) 
Dosing intervals [hours] 
n 7064 
Mean 11:59 
Median 11:59 
SD 2:13 
IQR 10:51-13:04 
Range 0:15-23:57 
Table 4-10 shows classified dosing intervals. For this consideration, a threshold of 12±2 hours 
was defined within which a dosing interval was regarded as adherent. The majority of the 
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registered dosing intervals was within this range (71.5%). Proportions of the dosing intervals 
<10 hours and >14 hours were lower and approximately equivalent (14.7% and 13.9%). 
Table 4-10: Classified dosing intervals <24 hours recorded by MEMS® in initially adherent 
patients (n=58) 
 Number of dosing intervals Proportion [%] 
<10 hours 1037 14.7 
10-14 hours 5048 71.5 
>14 hours 979 13.9 
Total 7064 100.0 
Dosing intervals in initially adherent patients are shown as a histogram in Figure 4-15. The 
main peak of the twice daily capecitabine regimen was located at twelve hours representing 
17.3% (1,219/7064) of all registered dosing intervals in initially adherent patients. 
  
Figure 4-15: Frequency of dosing intervals in initially adherent patients 
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4.3.5 Quality of life 
EORTC QLQ-C30 questionnaire 
High scores in functional scales of the EORTC QLQ-C30 questionnaire represent a better 
functioning in that category. In this study, no noticeable differences were observed in terms of 
physical, role, emotional, cognitive and social functioning during the course of the study. 
Compared to the reference values of the QLQ-C30 scoring manual [114], no distinctive 
divergence was found either. For details see Table 4-11. Reference values can be accessed in 
Appendix D, Table D-5. 
Table 4-11: EORTC QLQ-C30 (modified version 3.0) functional scales at t0, t3 and t6 in initially 
adherent patients (n=58) 
QLQ-C30 dimension n Mean  SD Median IQR 
Physical functioning (PF2) 
t0 50 65.9 25.5 73.3 53.3-86.7 
t3 41 69.1 19.7 73.3 53.3-86.7 
t6 33 72.5 23.6 73.3 53.3-93.3 
Role functioning (RF2) 
t0 49 55.4 36.1 66.7 16.7-83.3 
t3 41 58.1 33.8 66.7 33.3-100.0 
t6 33 56.1 34.8 66.7 33.3-83.3 
Emotional functioning (EF) 
t0 50 64.4 23.9 66.7 41.7-83.3 
t3 41 77.2 22.3 83.3 66.7-100.0 
t6 32 71.6 24.3 75.0 54.2-91.7 
Cognitive functioning (CF) 
t0 50 82.7 27.1 100.0 66.7-100.0 
t3 41 80.9 22.8 83.3 66.7-100.0 
t6 32 77.1 28.9 83.3 66.7-100.0 
Social functioning (SF) 
t0 50 63.7 35.1 66.7 33.3-100.0 
t3 41 71.1 29.8 83.3 66.7-100.0 
t6 32 75.0 28.7 83.3 66.7-100.0 
High scores in a symptom scale of the EORTC QLQ-C30 questionnaire stand for stronger 
symptoms of the patient in that category. Initially adherent patients had the same median values 
of symptom scales at t0 as the reference values of the QLQ-C30 scoring manual [114], apart 
from slightly worse fatigue and dyspnoea (Table 4-12). Median values of symptom scales did 
not vary during the course of the study, apart from worse pain at t6, worse hand-foot syndrome 
at t3 and t6, and improved dyspnoea at t6. High scores in global health status represent better 
quality of life. The global health status was slightly worse than the reference at t0 and t3 and 
increased to the level of reference at t6 (Table 4-12). Details on the reference values see 
Appendix D, Table D-5. 
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Table 4-12: EORTC QLQ-C30 (modified version 3.0) symptom scales and global health status 
at t0, t3 and t6 in initially adherent patients (n=58) 
QLQ-C30 dimension/QoL n Mean SD Median IQR 
Fatigue (FA) 
t0 50 48.9 27.7 44.4 33.3-66.7 
t3 41 48.0 28.5 44.4 22.2-66.7 
t6 33 47.5 30.3 44.4 22.2-66.7 
Nausea and Vomiting (NV) 
t0 50 7.7 14.0 0.0 0.0-16.7 
t3 41 11.8 21.2 0.0 0.0-16.7 
t6 32 5.7 11.7 0.0 0.0-0.0 
Pain (PA) 
t0 50 27.3 33.1 16.7 0.0-33.3 
t3 41 26.4 29.1 16.7 0.0-50.0 
t6 33 29.3 26.4 33.3 0.0-50.0 
Dyspnoea (DY) 
t0 50 35.3 35.3 33.3 0.0-66.7 
t3 41 30.9 32.0 33.3 0.0-33.3 
t6 33 26.3 32.0 0.0 0.0-33.3 
Insomnia (SL) 
t0 50 33.3 33.0 33.3 0.0-66.7 
t3 41 33.3 33.3 33.3 0.0-66.7 
t6 33 31.3 28.8 33.3 0.0-66.7 
Appetite loss (AP) 
t0 50 21.3 34.8 0.0 0.0-33.3 
t3 41 19.5 30.7 0.0 0.0-33.3 
t6 33 16.2 25.2 0.0 0.0-33.3 
Constipation (CO) 
t0 50 11.3 20.9 0.0 0.0-33.3 
t3 41 9.8 18.6 0.0 0.0-0.0 
t6 32 10.4 21.5 0.0 0.0-0.0 
Diarrhoea (DI) 
t0 49 19.0 31.2 0.0 0.0-33.3 
t3 40 18.3 33.7 0.0 0.0-33.3 
t6 32 15.6 26.8 0.0 0.0-33.3 
Financial difficulties (FI) 
t0 50 19.3 30.9 0.0 0.0-33.3 
t3 41 22.0 36.2 0.0 0.0-33.3 
t6 32 17.7 30.5 0.0 0.0-33.3 
Hand-foot syndrome (HFS) 
t0 50 21.3 34.8 0.0 0.0-66.7 
t3 41 53.7 37.9 66.7 33.3-100.0 
t6 32 58.3 34.9 66.7 33.3-100.0 
Global health status/ 
QoL (QL2) 
t0 50 53.5 22.8 50.0 41.7-66.7 
t3 40 59.2 21.1 58.3 45.8-79.2 
t6 33 64.1 19.8 66.7 50.0-75.0 
EQ-5D questionnaire 
Each of the five EQ-5D dimensions comprises three levels of perceived problems. Level 1 
indicates no problems, level 2 is a sign of some problems and level 3 indicates extreme 
problems. The results of the descriptive system of the EQ-5D-3L questionnaire are shown in 
Table 4-13. Generally, the EQ-5D dimensions ‘mobility’ and ‘self-care’ were least impaired in 
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the cohort of initially adherent patients. Most patients reported problems regarding ‘usual 
activities’ and ‘pain/discomfort’. Regarding the dimensions ‘mobility’, ‘usual activities’, and 
‘pain/discomfort’ the proportion of patients reporting no problems decreased during the course 
of the study, whereas it increased for the dimensions ‘self-care’ and ‘anxiety/depression’. Figure 
4-16 visualises this by means of a bar chart and shows the proportion of patients reporting 
problems (level 2 plus level 3) concerning the five EQ-5D dimensions at the three different time 
points. 
Table 4-13: Proportion of patients [%] reporting level 1, 2 or 3 of the EQ-5D-3L descriptive 
system at t0, t3 and t6 concerning the five EQ-5D dimensions 
EQ-5D dimension n Level 1 Level 2 Level 3 
Mobility  
t0 51 70.6 27.5 2.0 
t3 46 69.6 30.4 0.0 
t6 36 66.7 33.3 0.0 
Self-care 
t0 51 88.2 11.8 0.0 
t3 46 87.0 13.0 0.0 
t6 37 91.9 5.4 2.7 
Usual activities 
t0 51 54.9 37.3 7.8 
t3 46 58.7 34.8 6.5 
t6 37 43.2 56.8 0.0 
Pain/discomfort 
t0 51 45.1 49.0 5.9 
t3 46 45.7 54.3 0.0 
t6 37 35.1 64.9 0.0 
Anxiety/depression 
t0 51 54.9 43.1 2.0 
t3 46 67.4 32.6 0.0 
t6 37 75.7 24.3 0.0 
The median of most EQ-5D dimensions was found to account for level 1. Regarding the 
dimensions ‘usual activities’ at t6 and ‘pain/discomfort’ at all three time points, the median was 
on level 2. Mean, standard deviation, median and interquartile range of the EQ-5D dimensions 
at t0, t3 and t6 for initially adherent patients are tabulated in Appendix D, Table D-6. 
Interestingly, the mean EQ-5D visual analogue scale (VAS) value of initially adherent patients 
increased from 59.1 at t0, to 62.8 at t3 and to 67.5 at t6 (see Table 4-14). 
Table 4-14: EQ-5D-3L VAS values at t0, t3, and t6 (n=58) 
 n Mean SD Median IQR 
t0 50 59.1 18.8 60.0 49.0-75.0 
t3 46 62.8 17.8 60.0 50.0-80.0 
t6 37 67.5 15.5 69.0 55.0-80.0 
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Figure 4-16: Proportion of patients [%] reporting problems concerning the five 
EQ-5D dimensions (sum of proportion of patients reporting level 2 and 3) 
4.3.6 Patient satisfaction with information 
Patient satisfaction with information of initially adherent patients was found to be high at t0 and 
even increased during the course of the study for all PSCaTE dimensions. Patients could score 
strongly disagree (1), disagree (2), uncertain (3), agree (4), or strongly agree (5). The results are 
summarised in Table 4-15. Data shown in Table 4-15 are presented in Appendix D, 
Figures D-1, D-2 and D-3 additionally as boxplots. 
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Table 4-15: Patient satisfaction with information of initially adherent patients at t0, t3 and t6 
PSCaTE dimension n Mean SD Median IQR 
Satisfaction with information on 
cancer therapy (CT) 
t0 48 4.4 0.6 4.4 4.0-5.0 
t3 46 4.4 0.7 4.6 3.8-5.0 
t6 37 4.6 0.5 4.8 4.4-5.0 
Satisfaction with information on 
adverse effects (SE) 
t0 49 4.4 0.7 4.5 4.0-5.0 
t3 46 4.5 0.7 4.8 4.0-5.0 
t6 37 4.6 0.7 5.0 4.5-5.0 
Satisfaction with information on 
vitamins, herbal medicines and 
complementary treatment options 
(VC) 
t0 47 3.6 1.2 3.7 2.7-4.7 
t3 45 3.7 1.3 4.0 2.7-5.0 
t6 37 4.0 1.1 4.0 3.7-5.0 
Satisfaction with information sources 
(RS) 
t0 47 4.6 0.5 4.8 4.3-5.0 
t3 46 4.6 0.6 5.0 4.3-5.0 
t6 37 4.7 0.4 5.0 4.5-5.0 
Overall satisfaction (OV) 
t0 49 4.2 0.7 4.3 3.8-4.9 
t3 46 4.3 0.7 4.7 3.7-4.9 
t6 37 4.5 0.5 4.5 4.3-5.0 
4.3.7 Hand-foot syndrome (HFS) 
In the group of initially adherent patients the median severity grade of the adverse drug reaction 
HFS was zero at t1 and t2 and increased to 1 at t3, t4, t5, and t6. Figure 4-17 shows the results of 
the questionnaire on HFS as a boxplot. 
Capecitabine treatment was temporarily discontinued in 39.7% (23/58) of initially adherent 
patients. The most common reasons for temporary capecitabine discontinuation were HFS 
(10/23, 43.5%) and hospital stays (5/23, 21.7%). Other reasons (8/23, 34.8%) were e.g. femur 
fracture, abdominal influenza or selective internal radiation therapy. 
Figure 4-18 illustrates the cumulative proportion of initially adherent patients who had to reduce 
their capecitabine dose (22/58, 37.9%). The period between the first day of capecitabine 
treatment and the day of the physicians’ decision to reduce the dose was assessed. Performed 
dose reductions were mostly due to HFS (19/22, 86.4%), the common adverse drug reaction of 
capecitabine. Three exceptions were observed; in one patient the dose was reduced due to 
diarrhea, in another patient due to gastric phlegmon, and in the third patient due to bone pain. 
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Figure 4-17: HFS severity grades of initially adherent patients under treatment with 
capecitabine at t1, t2, t3, t4, t5 and t6 
 
Figure 4-18: Time to dose reduction [days] of capecitabine in initially adherent patients; 
vertical lines represent censored data 
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4.3.8 Pharmacist’s working time 
Pharmacist’s working time needed for the provision of modular medication management was 
documented regarding the duration of interviews and rework (see Table 4-16). The initial 
patient conversation differed from the follow-up patient interviews. This was because contents 
such as the course of the study, aims, outcome assessment, and time schedule were explained in 
detail. Basically, the first counselling session took place before the start of the patient’s 
capecitabine therapy (t0). If required, more than one interview was conducted. Nine patients had 
more than one conversation with the study pharmacist at that time point (seven patients had two, 
one patient had three and one patient had four conversations). 
Table 4-16: Duration and rework of the initial counselling conversation with initially adherent 
patients (n=58, 70 conversations) 
Duration [min] Rework [min] 
Mean 29 8 
Median 25 6 
SD 16 9 
Range 8-90 0-60 
IQR 16-35 2-11 
Conversations per patient ranged from 1.1 in cycle 3 to 1.6 in cycle 6, compare Table 4-17. 
Table 4-18 shows information on the duration and rework of patient interviews during the 
course of the modular medication management. Median duration of patient interviews ranged 
from 2 minutes during cycle 5 to 8 minutes during cycle 1 and 2. 
Table 4-17: Number of patient interviews during the course of the study 
 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
n 58 56 50 45 41 38 
Conversations 88 75 56 61 44 62 
Conversations/patient 1.5 1.3 1.1 1.4 1.1 1.6 
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Table 4-18: Duration and rework of follow-up counselling conversations with initially adherent 
patients 
  Duration [min] Rework [min]   Duration [min] Rework [min] 
t1 
n 58 58 
t4 
n 45 45 
Mean 12 4 Mean 8 3 
Median 8 0 Median 6 0 
SD 13 12 SD 8 16 
Range 0-52 0-62 Range 0-29 0-120 
IQR 3-17 0-1 IQR 0-12 0-1 
t2 
n 56 56 
t5 
n 41 41 
Mean 12 3 Mean 7 3 
Median 8 0 Median 2 0 
SD 17 7 SD 11 11 
Range 0-105 0-34 Range 0-58 0-60 
IQR 4-13 0-2 IQR 0-11 0-1 
t3 
n 50 50 
t6 
n 38 38 
Mean 7 1 Mean 9 2 
Median 5 0 Median 6 0 
SD 9 3 SD 13 8 
Range 0-43 0-15 Range 0-68 0-60 
IQR 0-7 0-1 IQR 0-13 0-0 
4.3.9 Patient evaluation 
The questionnaire on patient evaluation asked patients for their assessment of the therapy 
outcome compared with their expectations, assessment of adverse drug reactions compared with 
their expectations, and their overall assessment regarding treatment. More than half of initially 
adherent patients evaluated the outcome of their capecitabine therapy as much better (10/39, 
25.6%) and slightly better (10/39, 25.6%) than expected. Only 2/39 (5.1%) patients assessed 
therapy outcome as much worse than expected. The adverse drug reactions of capecitabine were 
evaluated even better. 13/39 (33.3%) patients stated that they perceived adverse drug reactions 
as much better than expected and 10/30 (25.6%) as slightly better. 2/39 (5.1%) found toxicity 
much worse than expected. Figure 4-19 visualises these results. 
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Assessment of therapy outcome 
compared with expectations 
Assessment of adverse drug reactions 
compared with expectations 
  
Figure 4-19: Initially adherent patients’ evaluation of two different aspects of the capecitabine 
treatment; assessed at t6; n=39 
Overall, capecitabine treatment was rated as very good and excellent by 16 of 39 patients 
(41.0%), see Figure 4-20. 
Tabulated results of the questionnaire on patient evaluation are presented in Appendix D, Table 
D-7. 
 
 
Figure 4-20: Initially adherent patients’ overall assessment of capecitabine treatment assessed 
at t6; n=39 
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4.4 Initially non-adherent patients 
Initially non-adherent participants were observed for a median time of 118.0 days (mean 103.5 
days; SD 32.1; range 35.0-140.0; IQR=96.0-126.0). 
4.4.1 Adherence support 
Various adherence-enhancing strategies were utilised by the application of module 3 (adherence 
support). Table 4-19 lists the different measures and the number of patients receiving these 
strategies. Treatment diaries (n=11) and patient education regarding treatment efficacy (n=7) 
were used most frequently. 
Table 4-19: Adherence-enhancing strategies applied in module 3 (n=15; more than one 
strategy could be applied to one patient) 
Strategy n 
Entry in treatment diary  11 
Patient education regarding 
importance of adherence 7 
Reminder card  4 
Link to daily activity  2 
Information on process of 
drug supply  1 
Reminder by mobile phone  0 
Figure 4-21 illustrates the number of adherence-enhancing strategies per patient. 1.7 strategies 
per patient were applied on average. 
 
Figure 4-21: Absolute frequency of the number of adherence-enhancing strategies applied to 
initially non-adherent patients 
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Figure 4-22 shows the percentage of days with intentional, unintentional, or unknown non-
adherence. In total, 155 non-adherent days were found in 15 initially non-adherent patients 
receiving adherence support. The study pharmacists assessed the type of non-adherence 
according to patients’ statements during counselling sessions or patient documentation (e.g. in 
the treatment diary). However, it was not always possible to find a reason for non-adherence. 
Thus, not every non-adherent day could be classified as either intentionally or unintentionally 
non-adherent. 
 
Figure 4-22: Percentage of days with intentional, unintentional and unknown non-adherence 
in 15 patients 
Most common reasons for intentional non-adherence were nausea and emesis and averseness to 
medication. Further details are shown in Table 4-20. Most of unintentionally non-adherent days 
were due to miscellaneous errors. Non-performance of the seven-day treatment break, belated 
begins of the capecitabine intake period, and over-adherence are examples for non-adherence 
falling in this category. Further unintentional barriers to sufficient medication taking behaviour 
were forgetfulness and too short intake intervals. External circumstances were the reason for 
two unintentionally non-adherent days: one patient had a collapse that made it impossible for 
him to take capecitabine and another patient ordered capecitabine belatedly and the community 
pharmacy did not have it on stock. 
25.8%
34.2%
40.0%
Intentional (40/155 days)
Unintentional (53/155 days)
Unknown (62/155 days)
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Table 4-20: Reasons for intentional and unintentional non-adherence observed in initially non-
adherent patients (n=15) 
 No. of days No. of patients 
Reasons for intentional non-adherence   
Nausea and emesis 17 1 
Averseness to medication 17 2 
„Compensation“ for non-adherence in 
treatment break 3 1 
Hand-foot syndrome 1 1 
Constipation 1 1 
Bad general condition 1 1 
Reasons for unintentional non-adherence   
Miscellaneous errors 22 7 
Forgetfulness 15 6 
Too short intake interval 14 6 
External circumstances 2 2 
4.4.2 Daily adherence 
Figure 4-23 compares median baseline daily adherence and median daily total adherence during 
cycle 1 of initially non-adherent patients. As discussed more explicitly later in this chapter, 
baseline daily adherence was found to be slightly lower than daily total adherence during 
cycle 1. 
 
Figure 4-23: Baseline daily adherence versus daily total adherence during cycle 1 of initially 
non-adherent patients (n=15) 
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Figure 4-24 shows individual daily total adherence profiles of initially non-adherent patients 
during the course of the study calculated for intake plus rest period. Adherence varied widely 
between patients but also from cycle to cycle in the same patients. Reasons for non-adherence 
are discussed in chapter 4.4.1. 
Three patients refused to receive modular medication management provided by the study 
pharmacists. Two patients expressed that they would not need any support and would get along 
with the situation themselves. These patients’ daily total adherence accounted for >90% 
throughout all observed capecitabine cycles. A further patient stated that the comprehensive 
care of his daughter was sufficient and no further support was required. Daily total adherence 
was >90% during the observation period except in cycle 5 (85.7%). 
 
Figure 4-24: Individual daily total adherence of initially non-adherent patients during the 
course of the study; cycle 1: n=15, cycle 2: n=15, cycle 3: n=13, cycle 4: n=12, cycle :5 n=12, 
cycle 6: n=8; the black line represents the median daily total adherence 
Average daily total adherence accounted for 80.8% during the first cycle and was found to be 
greater than 90% during the application of the adherence support module. Table 4-21 presents 
the according results. 
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Table 4-21: Daily total adherence of initially non-adherent patients (calculation based on 
intake and rest period) 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
Cycle 1 15 80.8 85.7 17.6 28.6-92.9 85.0-90.5 
Cycle 2 15 93.7 95.2 8.8 71.4-100.0 95.0-100.0 
Cycle 3 13 90.7 95.2 13.6 59.1-100.0 90.5-100.0 
Cycle 4 12 92.1 95.2 7.0 76.2-100.0 90.5-95.2 
Cycle 5 12 92.7 95.2 7.2 79.2-100.0 88.1-97.6 
Cycle 6 8 90.5 97.6 15.1 57.1-100.0 85.7-100.0 
Median daily total adherence increased from 85.7% in cycle 1 to 97.6% in cycle 6, see Figure 
4-25. Some patients exhibited outliers and extreme values during the different cycles. Reasons 
for non-adherence are discussed in chapter 4.4.1. 
 
Figure 4-25: Daily total adherence of initially non-adherent patients during cycle 1 to 6 
Considering daily intake adherence, variability is higher compared to daily total adherence, see 
Figure 4-26. However, the median of both adherence measures accounted for <90% during the 
first cycle and clearly increased over time. Only few outliers and extreme values can be 
observed. More detailed information on daily intake adherence can be found in Appendix E, 
Table E-1. 
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Figure 4-26: Daily intake adherence [%] of initially non-adherent patients during cycle 1 to 6 
Median daily break adherence of initially non-adherent patients was higher than the median of 
all other adherence parameters, compare Figure 4-27. However, the interquartile range during 
cycle 1 and 4 was relatively large, 85.7% to 100.0% in both cycles. More detailed information 
on daily break adherence is tabulated in Appendix E, Table E-2. 
Figure 4-28 illustrates the percentage of patients who showed a daily total adherence equal or 
greater than 90% during the different cycles. The results indicate a clear effect of adherence 
support. In cycle 2 the number of adherent patients was twice as high as in cycle 1 and remained 
more or less constant in the later cycles. After completion of the sixth cycle, daily total 
adherence of six out of eight (75.0%, CI 46.0%-91.3%) initially non-adherent patients 
accounted for ≥90%. Since the CI includes 80% which was the cut-off value used for sample 
size determination of initially non-adherent patients, it could not be confirmed in this study that 
>80% of initially non-adherent patients were adherent after the intervention. In Appendix E, 
Table E-3 the percentage of participants who showed a daily total adherence =100%, ≥90% and 
80%, respectively, during the different cycles is illustrated. 
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Figure 4-27: Daily break adherence [%] of initially non-adherent patients during cycle 1 to 6 
 
Figure 4-28: Percentage of initially non-adherent patients exhibiting a daily total 
adherence ≥90% during intake and rest periods of cycle 1 to 6; the numbers inside the boxes 
show the exact percentage (first row) and absolute patient numbers (second row) 
Figure 4-29 shows the percentage of initially non-adherent patients with a daily intake 
adherence ≥90% over the cycles. In contrast to the initially adherent patients, the fractions of 
patients exhibiting a daily total adherence ≥90% and a daily intake adherence ≥90% did not 
exhibit major differences. 
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Figure 4-29: Percentage of initially non-adherent patients exhibiting a daily intake adherence 
≥90% during the intake periods of cycle 1 to 6; the numbers inside the boxes show the exact 
percentage (first row) and absolute patient numbers (second row) 
Considering intra-individual differences of daily total adherence between the end of study and 
baseline, it becomes obvious that most initially non-adherent patients’ adherence improved. The 
adherence of 11 patients improved, maximum increases were 31.0%, 42.9%, and 71.4%. Four 
patients’ adherence diminished by 1.4%, 9.5%, 14.3%, and 27.9%. Figure 4-30 illustrates these 
findings. 
 
Figure 4-30: Intra-individual difference in daily total adherence [%] between the last and first 
capecitabine cycle of initially non-adherent patients (n=15); every rhombus represents one 
patient 
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Each capecitabine cycle completed by an initially non-adherent patient was defined as either 
adherent (≥90%) or non-adherent (<90%) and plotted in Figure 4-31. The fact that six initially 
non-adherent patients showed a daily total adherence of ≥90% during cycle 1 is explained in 
chapter 3.6 and 3.7.2. 46.7% of the patients (7/15) were non-adherent at least during one cycle 
(except cycle 1). Three of 15 patients (20.0%) were non-adherent during one cycle and two 
cycles, respectively. Maximum number of non-adherent cycles per patient was three (1/15 
patients, 6.7%). From cycle 2 onwards, 53.3% (8/15) did adhere during all completed cycles. 
Seven of 15 of all initially non-adherent patients (46.7%) were prescribed less than six 
capecitabine cycles (see 4.4.4). 
 
Figure 4-31: Individual daily total adherence of initially non-adherent patients; green bars 
indicate adherent cycles (daily total adherence ≥90%), and red bars non-adherent cycles 
(daily total adherence <90%); non-complete bars imply treatment duration of less than six 
cycles, for information on reasons for shortened prescription of capecitabine see 4.4.4 
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Influence of gender 
No statistically significant difference in terms of daily total adherence was observed between 
initially non-adherent women and men, compare Table 4-22. In both gender groups, the 
minimum values were observed during the first capecitabine cycle, both mean and median daily 
total adherence accounted for <90%. From the second cycle on, median daily total adherence 
was found to be ≥90%. However, mean daily total adherence of male patients was <90% in 
cycle 3, 5, and 6. Thus, a marginal trend to a better adherence in female patients was seen. 
Influence of tumour entity 
At no time point a statistically significant difference regarding daily total adherence between 
patients with breast, colorectal or other cancer was observed, apart from t1 (p value=0.046, 
Mann-Whitney-U test). At t1 median daily total adherence of breast cancer patients accounted 
for 90.5%, whereas colorectal cancer patients’ exhibited a median value of 85.0%. Table 4-23 
shows the results in detail. 
Influence of therapy regimen 
At t1, t2, t3, t5, and t6 no statistically significant difference could be seen between patients who 
received capecitabine as a single agent therapy and patients who were prescribed capecitabine in 
combination with one or more further anti-cancer agents. However, the difference between these 
two patient subgroups was statistically significant at t4 (p value=0.044, Mann-Whitney-U test). 
Mean daily total adherence of patients treated with capecitabine as monotherapy was 96.0%, the 
median accounted for 95.2%. Patients who were treated with more than one anti-cancer agent 
showed a mean daily total adherence of 88.2% and the median was 90.5%. Details are listed in 
Table 4-24. 
Influence of treatment intention 
Differences concerning daily total adherence between patients who were treated with a curative 
or palliative intention were not found to be statistically significant (see Table 4-25). 
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Table 4-22: Daily total adherence [%] of initially non-adherent female and male patients 
during the course of the study 
 Female Male p value* 
t1 
n 10 5 
0.758 
Mean  83.0 76.4 
Median 87.3 85.7 
SD 12.1 27.0 
IQR 85.0-90.5 85.0-90.0 
Range 57.1-91.7 28.6-92.9 
t2 
n 10 5 
0.565 
Mean  92.1 97.1 
Median 95.2 95.2 
SD 10.4 2.6 
IQR 87.5-100.0 95.2-100.0 
Range 71.4-100.0 95.0-100.0 
t3 
n 8 5 
1.000 
Mean  91.8 89.0 
Median 95.2 95.2 
SD 12.0 17.2 
IQR 92.7-97.6 90.5-100.0 
Range 63.0-100.0 59.1-100.0 
t4 
n 7 5 
0.497 
Mean  93.3 90.5 
Median 95.2 90.5 
SD 5.8 8.9 
IQR 90.5-95.2 90.5-95.2 
Range 81.8-100.0 76.2-100.0 
t5 
n 7 5 
0.203 
Mean  95.2 89.2 
Median 95.2 90.5 
SD 4.7 9.0 
IQR 95.2-100.0 81.0-95.2 
Range 85.7-100.0 79.2-100.0 
t6 
n 4 4 
0.758 
Mean  94.1 86.9 
Median 97.6 95.2 
SD 9.0 20.3 
IQR 88.1-100.0 73.8-100.0 
Range 81.0-100.0 57.1-100.0 
* Mann-Whitney-U test 
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Table 4-23: Daily total adherence [%] of initially non-adherent patients with breast cancer, 
colorectal cancer and other cancer entities1 during the course of the study 
 Breast cancer Colorectal cancer Other1 p value* 
t1 
n 7 7 1 
0.046 
Mean  85.0 74.9 92.9 
Median  90.5 85.0 92.9 
SD  12.4 22.1 n.a. 
IQR  85.7-90.5 64.3-85.7 n.a. 
Range  57.1-91.7 28.6-90.0 n.a. 
t2 
n 7 7 1 
0.683 
Mean  90.7 96.6 95.0 
Median  100.0 95.2 95.0 
SD  12.5 2.4 n.a. 
IQR  76.2-100.0 95.2-100.0 n.a. 
Range  71.4-100.0 95.0-100.0 n.a. 
t3 
n 5 7 1 
0.237 
Mean  90.7 95.2 59.1 
Median  95.2 95.2 59.1 
SD  15.7 3.9 n.a. 
IQR  95.2-100.0 90.5-100.0 n.a. 
Range  63.0-100.0 90.5-100.0 n.a. 
t4 
n 5 6 1 
0.612 
Mean  91.6 92.9 90.5 
Median  95.2 95.2 90.5 
SD  5.8 8.9 n.a. 
IQR  90.5-95.2 90.5-100.0 n.a. 
Range  81.8-95.2 76.2-100.0 n.a. 
t5 
n 5 6 1 
0.093 
Mean  97.1 91.3 79.2 
Median  95.2 92.9 79.2 
SD  2.6 7.0 n.a. 
IQR  95.2-100.0 85.7-95.2 n.a. 
Range  95.2-100.0 81.0-100.0 n.a. 
t6 
n 3 4 1 
0.478 
Mean  93.7 85.7 100.0 
Median  100.0 92.9 100.0 
SD  11.0 19.4 n.a. 
IQR  81.0-100.0 73.8-97.6 n.a. 
Range  81.0-100.0 57.1-100.0 n.a. 
* Kruskal-Wallis-H test 
1Other cancer entity: oesophageal cancer 
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Table 4-24: Daily total adherence [%] of initially non-adherent patients who received 
capecitabine as single agent or in combination during the course of the study (n=15) 
 Single agent Combination p value* 
t1 
n 7 8 
0.351 
Mean  74.8 86.0 
Median  85.7 89.5 
SD  23.4 9.2 
IQR 57.1-90.5 85.0-91.1 
Range 28.6-90.5 64.3-92.9 
t2 
n 7 8 
0.227 
Mean  94.6 93.0 
Median  100.0 95.1 
SD  10.4 7.8 
IQR 95.2-100.0 91.3-97.6 
Range 71.4-100.0 76.2-100.0 
t3 
n 6 7 
0.418 
Mean  91.5 90.0 
Median  95.2 95.0 
SD  14.2 14.2 
IQR 95.2-100.0 90.5-100.0 
Range 63.0-100.0 59.1-100.0 
t4 
n 6 6 
0.044 
Mean  96.0 88.2 
Median  95.2 90.5 
SD  3.6 7.7 
IQR 95.2-100.0 81.8-95.2 
Range 90.5-100.0 76.2-95.2 
t5 
n 6 6 
0.181 
Mean  96.0 89.4 
Median  95.2 90.5 
SD  3.6 8.6 
IQR 95.2-100.0 81.0-95.2 
Range 90.5-100.0 79.2-100.0 
t6 
n 5 3 
0.525 
Mean  94.3 84.1 
Median  100.0 95.2 
SD  8.5 23.5 
IQR 90.5-100.0 57.1-100.0 
Range 81.0-100.0 57.1-100.0 
* Mann-Whitney-U test 
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Table 4-25: Daily total adherence [%] of initially non-adherent patients who received 
capecitabine with a curative or palliative treatment intention during the course of the study 
(n=15) 
 Curative intention Palliative intention p value* 
t1 
n 3 12 
0.424 
Mean  85.5 79.6 
Median  85.7 89.4 
SD  0.4 19.7 
IQR 85.0-85.7 74.6-90.5 
Range 85.0-85.7 28.6-92.9 
t2 
n 3 12 
0.598 
Mean  96.8 93.0 
Median  95.2 95.2 
SD  2.7 9.7 
IQR 95.2-100.0 91.3-100.0 
Range 95.2-100.0 71.4-100.0 
t3 
n 3 10 
0.663 
Mean  93.7 89.8 
Median  95.2 95.2 
SD  2.7 15.5 
IQR 90.5-95.2 90.5-100.0 
Range 90.5-95.2 59.1-100.0 
t4 
n 3 9 
0.847 
Mean  90.5 92.7 
Median  95.2 95.2 
SD  12.6 5.2 
IQR 76.2-100.0 90.5-95.2 
Range 76.2-100.0 81.8-100.0 
t5 
n 3 9 
0.209 
Mean  88.9 94.0 
Median  90.5 95.2 
SD  7.3 7.1 
IQR 81.0-95.2 95.2-100.0 
Range 81.0-95.2 79.2-100.0 
t6 
n 2 6 
0.076 
Mean  73.8 96.0 
Median  73.8 100.0 
SD  23.6 7.6 
IQR 57.1-90.5 95.2-100.0 
Range 57.1-90.5 81.0-100.0 
* Mann-Whitney-U test 
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MEMS®- versus self-assessed adherence 
The percentage of initially non-adherent patients whose MEMS®-assessed daily total adherence 
accounted for >85.7% was relatively low and varied from 26.7% in cycle 1 to 80.0% in cycle 2. 
Values during cycles 3 to 6 were 76.9%, 66.7%, 33.3%, and 75.0%, compare Figure 4-32. 
Despite the impaired MEMS®-assessed adherence, interestingly adherence self-assessment was 
found to be high, see Figure 4-33. Almost 100.0% of the patients stated that their adherence 
accounted for >85.7% during all observed capecitabine cycles. 
 
Figure 4-32: Percentage of initially non-adherent patients within MEMS®-assessed daily 
intake adherence ranges during the course of the study 
 
Figure 4-33: Percentage of initially non-adherent patients within self-assessed daily intake 
adherence ranges during the course of the study 
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However, the difference between MEMS®- and self-assessed total adherence during the total 
study period was not significant (p value=0.050, Wilcoxon test). Mean self-assessed total 
adherence was 95.9% and the median was 100.0%. Mean MEMS®-assessed daily adherence 
during the whole observation period was 89.7% and the median was 89.1%. Table 4-26 depicts 
the respective details. Altogether, adherence self-assessment of initially non-adherent patients 
does not seem to be objective. 
Table 4-26: MEMS®-assessed [%] versus self-assessed total adherence [%] during the whole 
study period (cycle 1 to 6) assessed at t6 in initially non-adherent patients 
MEMS®-assessed daily 
adherence [%] 
Self-assessed total adherence 
[%] p value* 
n 15 11 
0.050 
Mean 89.7 95.9 
Median 89.1 100.0 
SD 5.0 9.2 
IQR 86.4-94.2 95.0-100.0 
Range 78.6-96.9 70.0-100.0 
* Wilcoxon test 
4.4.3 Overall adherence 
Overall adherence of initially non-adherent patients under basic pharmaceutical care, adverse 
event management and adherence management was high. Mean overall adherence ranged from 
93.8% in cycle 1 to 102.7% in cycle 3, median overall adherence from 96.2% in cycle 1 to 
100.0% in cycle 2, 3, and 4. Logically, lowest values were observed during the first completed 
capecitabine cycle. More detailed information on data shown in Figure 4-34 are tabulated in 
Appendix E, Table E-4. Regarding overall adherence, it has to be kept in mind that over-
adherence (too many container openings at one point) might compensate under-adherence 
(missing openings at another time). 
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Figure 4-34: Overall adherence [%] of initially non-adherent patients during cycle 1 to 6 
4.4.4 Persistence 
All initially non-adherent patients persisted with their oral anti-cancer treatment during the 
whole period they were prescribed capecitabine. No patient performed an unauthorised 
discontinuation of his capecitabine treatment. 
In five of 15 initially non-adherent patients capecitabine was discontinued prematurely due to 
tumour progression. The chronological sequence of treatment discontinuations is illustrated in 
Figure 4-35. Since treatment in ten patients was not discontinued prematurely by the physicians, 
their data were censored (eight patients completed six capecitabine cycles as planned, one 
patient completed five cycles as planned, and one patient died during the second cycle). 
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Figure 4-35: Duration of capecitabine prescription [days] for initially non-adherent patient, 
n=15; short vertical lines indicate censored patient data 
4.4.5 Dosing intervals 
The administration of capecitabine is supposed to take place twice per day separated by twelve 
hours. During the study period 1906 dosing intervals were recorded in initially non-adherent 
patients and the median dosing interval accounted for 12:00 hours. Dosing intervals ≥24 hours 
were not considered in this analysis. More detailed information on the registered dosing 
intervals is shown in Table 4-27. 
Table 4-27: Dosing intervals [hours] <24 hours recorded by MEMS® in initially non-adherent 
patients (n=15) 
Dosing intervals [hours] 
n 1906 
Mean 11:58 
Median 12:00 
SD 2:46 
IQR 10:15-13:38 
Range 0:16-23:42 
Furthermore, classified dosing intervals were analysed (see Table 4-28). For this consideration, 
a range of 10 to 14 hours was defined. More than half of all registered dosing intervals (58.3%) 
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in initially non-adherent patients was within this range and was, therefore, regarded as adherent. 
Percentages of the dosing intervals <10 hours and >14 hours were lower and roughly equal 
(21.8% and 19.9%). 
Table 4-28: Classified dosing intervals <24 hours recorded by MEMS® in initially non-adherent 
patients (n=15) 
 Number of dosing intervals Proportion [%] 
<10 hours 415 21.8 
10-14 hours 1111 58.3 
>14 hours 380 19.9 
Total 1906 100.0 
Figure 4-36 shows the results of the analysis of dosing intervals as a histogram. The main peak 
of the dosing intervals was situated at approximately twelve hours. However, the dosing 
intervals are relatively broad distributed within the range of approximately 8 and 16 hours. 
 
Figure 4-36: Frequency of dosing intervals in initially non-adherent patients 
  
24 
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4.4.6 Quality of life 
EORTC QLQ-C30 questionnaire 
Initially non-adherent patients had lower median values of functional scales at t0 compared to 
the reference values of the QLQ-C30 scoring manual [114]. However, during the course of the 
study the median score of the dimensions physical functioning, role functioning, emotional 
functioning, and social functioning increased. Cognitive functioning remained constant at t0, t3, 
and t6. Nevertheless, the level of the reference values was not reached. For details see Table 
4-29. Reference values can be accessed in Appendix D, Table D-5. 
Table 4-29: EORTC QLQ-C30 (modified version 3.0) functional scales at t0, t3 and t6 in initially 
non-adherent patients (n=15) 
QLQ-C30 dimension n Mean SD Median IQR 
Physical functioning (PF2) 
t0 13 60.0 21.8 53.3 46.7-73.3 
t3 11 65.5 23.1 73.3 40.0-86.7 
t6 12 62.8 26.1 60.0 40.0-86.7 
Role functioning (RF2) 
t0 13 39.7 33.0 33.3 16.7-66.7 
t3 11 48.5 34.5 33.3 33.3-66.7 
t6 12 54.2 39.6 50.0 25.0-100.0 
Emotional functioning (EF) 
t0 13 46.8 28.6 41.7 33.3-58.3 
t3 11 55.3 23.1 50.0 41.7-66.67 
t6 11 51.5 35.5 50.0 16.7-100.0 
Cognitive functioning (CF) 
t0 13 70.5 27.3 66.7 50.0-100.0 
t3 11 62.1 29.9 66.7 50.0-83.3 
t6 11 65.2 20.4 66.7 50.0-83.3 
Social functioning (SF) 
t0 13 42.3 24.2 33.3 33.3-50.0 
t3 11 47.0 31.5 33.3 16.7-66.7 
t6 11 57.6 31.9 66.7 33.3-83.3 
The median values of the symptom scales nausea and vomiting, pain, constipation, diarrhoea, 
and financial difficulties at t0 of initially non-adherent patients were in the same range as the 
reference values of the QLQ-C30 scoring manual [114]. Since the symptom scale ‘HFS’ was 
added to the questionnaire in the present study, no reference values are available. Worse fatigue, 
dyspnoea, insomnia, and appetite loss compared to the reference were observed. The global 
health status was lower compared to the reference values of the QLQ-C30 scoring manual 
[114]. However, it remained constant at t0, t3, and t6. Detailed information on the symptom 
scales and the global health status at the three different measuring points is tabulated in Table 
4-30. For details on the reference values see Appendix D, Table D-5. 
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Table 4-30: EORTC QLQ-C30 (modified version 3.0) symptom scales and global health status 
at t0, t3 and t6 in initially non-adherent patients (n=15) 
QLQ-C30 dimension/QoL n Mean SD Median IQR 
Fatigue (FA) 
t0 13 67.5 23.3 66.7 44.4-88.9 
t3 11 59.6 33.4 66.7 33.3-100.0 
t6 12 60.2 28.6 61.1 33.3-83.3 
Nausea and Vomiting (NV) 
t0 13 5.1 8.0 0.0 0.0-16.7 
t3 11 13.6 23.4 0.0 0.0-50.0 
t6 11 13.6 20.8 0.0 0.0-16.7 
Pain (PA) 
t0 13 34.6 39.9 16.7 0.0-66.7 
t3 11 40.9 36.8 33.3 0.0-66.7 
t6 12 47.2 38.8 41.7 8.3-83.3 
Dyspnoea (DY) 
t0 12 38.9 42.2 33.3 0.0-83.3 
t3 11 36.4 40.7 33.3 0.0-66.7 
t6 12 38.9 31.2 33.3 16.7-66.7 
Insomnia (SL) 
t0 13 53.8 39.8 66.7 33.3-100.0 
t3 11 39.4 36.0 33.3 0.0-66.7 
t6 12 50.0 38.9 50.0 16.7-83.3 
Appetite loss (AP) 
t0 13 38.5 40.5 33.3 0.0-66.7 
t3 11 33.3 29.8 33.3 0.0-66.7 
t6 12 44.4 38.5 50.0 0.0-66.7 
Constipation (CO) 
t0 13 20.5 34.8 0.0 0.0-33.3 
t3 11 18.2 34.5 0.0 0.0-33.3 
t6 11 36.4 40.7 33.3 0.0-66.7 
Diarrhoea (DI) 
t0 13 10.3 28.5 0.0 0.0-0.0 
t3 11 6.1 20.1 0.0 0.0-0.0 
t6 11 12.1 27.0 0.0 0.0-0.0 
Financial difficulties (FI) 
t0 13 28.2 42.7 0.0 0.0-33.3 
t3 11 36.4 37.9 33.3 0.0-66.7 
t6 11 27.3 36.0 0.0 0.0-66.7 
Hand-foot syndrome (HFS) 
t0 12 25.0 32.2 0.0 0.0-66.7 
t3 11 42.4 44.9 33.3 0.0-100.0 
t6 11 39.4 38.9 33.3 0.0-66.7 
Global health status/ 
QoL (QL2) 
t0 13 42.3 20.8 50.0 25.0-50.0 
t3 11 53.0 23.4 50.0 33.3-75.0 
t6 11 50.0 31.8 50.0 16.7-83.3 
EQ-5D questionnaire 
The results of the descriptive system of the EQ-5D-3L questionnaire for the initially non-
adherent patients are shown in Table 4-31. Most patients reported to have no problems with 
‘self-care’; the proportion was high throughout the study period. However, it slightly decreased 
from 100.0% at t0 to 91.7 at t3 and t6. The percentage of patients reporting level 1 for the 
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dimension ‘mobility’ increased from 57.1% at t0 to 66.7% at t3 and decreased to 58.3% at t6. The 
proportion of patients reporting level 2 or 3 (some or extreme problems) for the dimensions 
‘usual activities’ and ‘pain/discomfort’ increased over time. The percentage of patients reporting 
no problems concerning the dimension ‘anxiety/depression’ slightly increased from 35.7% at t0 
to 41.7% at t3 and t6. 
Table 4-31: Proportion of patients [%] reporting level 1, 2 or 3 of the EQ-5D-3L descriptive 
system at t0, t3 and t6 concerning the five EQ-5D dimensions 
EQ-5D dimension n Level 1 Level 2 Level 3 
Mobility 
t0 14 57.1 42.9 0.0 
t3 12 66.7 33.3 0.0 
t6 12 58.3 41.7 0.0 
Self-care 
t0 14 100.0 0.0 0.0 
t3 12 91.7 8.3 0.0 
t6 12 91.7 8.3 0.0 
Usual activities 
t0 14 42.9 57.1 0.0 
t3 12 41.7 58.3 0.0 
t6 12 33.3 66.7 0.0 
Pain/discomfort 
t0 14 57.1 42.9 0.0 
t3 12 41.7 41.7 16.7 
t6 12 41.7 50.0 8.3 
Anxiety/depression 
t0 14 35.7 64.3 0.0 
t3 12 41.7 58.3 0.0 
t6 12 41.7 58.3 0.0 
Figure 4-37 visualises the proportion of patients reporting problems (level 2 plus level 3) 
concerning the five EQ-5D dimensions at the three different time points by means of a bar chart. 
Mean, standard deviation, median and interquartile range of the EQ-5D descriptive system at t0, 
t3 and t6 for initially non-adherent patients are tabulated in Appendix E, Table E-5. The median 
of the EQ-5D dimensions ‘usual activities’ and ‘anxiety/depression’ was found to account for 
level 2 at all time points. Regarding the dimensions ‘mobility’ and ‘self-care’, the median was 
on level 1 at all three time points. ‘Pain/discomfort’ increased from level 1 to level 2 at t3 and t6.  
The mean EQ-5D VAS value of initially non-adherent patients increased from 58.1 at t0, to 63.3 
at t3 and decreased to 57.7 at t6, see Table 4-32. 
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Table 4-32: EQ-5D-3L VAS values at t0, t3 and t6 (n=15) 
 n Mean SD Median IQR 
t0 14 58.1 17.4 50.0 50.0-70.0 
t3 12 63.3 26.3 65.0 45.0-80.0 
t6 12 57.7 23.4 50.0 44.5-74.5 
 
 
Figure 4-37: Proportion of patients [%] reporting problems concerning the five 
EQ-5D dimensions (sum of proportion of patients reporting level 2 and 3) 
4.4.7 Patient satisfaction with information 
The Likert-scale of the PSCaTE questionnaire ranged from strongly disagree (1) to strongly 
agree (5). Median scoring of patient satisfaction with information on cancer therapy, adverse 
effects, information sources and overall satisfaction of initially non-adherent patients was high 
at t0 (in the median 4.0 to 4.3). Merely patient satisfaction with information on complementary 
treatment options was found to be lower (median 2.3). Patient satisfaction increased for all five 
dimensions during the course of the modular medication management and even median 
satisfaction with information on complementary treatment options accounted for 4.0 at t6. The 
respective details are shown in Table 4-33 and presented additionally as boxplots in 
Appendix E, Figures E-1, E-2 and E-3. 
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Table 4-33: Patient satisfaction with information of initially non-adherent patients (n=15) at t0, 
t3 and t6 
PSCaTE dimension n Mean  SD Median IQR 
Satisfaction with information on 
cancer therapy (CT) 
t0 13 4.2 0.7 4.2 4.0-4.6 
t3 11 4.4 0.8 4.6 4.0-5.0 
t6 12 4.7 0.5 4.9 4.5-5.0 
Satisfaction with information on 
adverse effects (SE) 
t0 13 4.3 0.8 4.3 4.0-5.0 
t3 11 4.5 0.6 4.5 4.3-5.0 
t6 12 4.6 0.5 4.7 4.3-5.0 
Satisfaction with information on 
vitamins, herbal medicines and 
complementary treatment options 
(VC) 
t0 13 2.8 1.5 2.3 1.7-4.0 
t3 11 3.3 1.4 3.3 2.3-4.7 
t6 12 3.9 1.0 4.0 3.7-4.7 
Satisfaction with information sources 
(RS) 
t0 13 4.4 0.5 4.3 4.0-5.0 
t3 11 4.5 0.5 4.8 4.3-5.0 
t6 12 4.7 0.3 4.8 4.5-5.0 
Overall satisfaction (OV) 
t0 13 3.9 0.7 4.0 3.4-4.5 
t3 11 4.2 0.7 4.3 3.8-4.9 
t6 12 4.5 0.5 4.5 4.2-4.9 
4.4.8 Hand-foot syndrome (HFS) 
Patient information regarding severity grades of the hand-foot syndrome during the different 
capecitabine cycles are shown as boxplots in Figure 4-38. Median HFS severity grade increased 
from 0 at t1 to 1 at all other time points. 
Three of 15 (20.0%) initially non-adherent patients had to discontinue their capecitabine 
treatment temporarily. Reasons for these treatment breaks were HFS, hospital stay, and 
worsening of general condition. 
Figure 4-39 shows the cumulative proportion of initially non-adherent patients whose 
capecitabine dose had to be reduced (5/15, 33.3%). All dose reductions were due to HFS. 
Results 101 
 
Figure 4-38: HFS severity grades of initially non-adherent patients under treatment with 
capecitabine at t1, t2, t3, t4, t5 and t6 
 
Figure 4-39: Time to dose reduction [days] of capecitabine in initially non-adherent patients; 
vertical lines represent censored data 
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4.4.9 Pharmacist’s working time 
Pharmacist’s working time needed for modular medication management was documented 
regarding the duration of interviews and rework. In terms of initially non-adherent patients, it 
has to be considered that the time needed for patient interviews and rework in the context of 
module 3 (adherence support) is included in the data shown in Table 4-34 and Table 4-36. The 
median duration of the initial patient interview accounted for 30 minutes (Table 4-34). One 
initially non-adherent patient had four discussions with the study pharmacist before the start of 
his capecitabine treatment. 
Table 4-34: Duration and rework of the initial counselling conversation with initially non-
adherent patients (n=15, 18 conversations) 
Duration [min] Rework [min] 
Mean 36 12 
Median 30 7 
SD 27 16 
Range 10-107 0-60 
IQR 17-40 2-14 
The number of conversations per patient ranged from one in cycle 4 up to two conversations in 
cycle 5 and 6 (compare Table 4-35). Information on the duration and rework of follow-up 
patient interviews conducted during the course of the modular medication management at t1, t2, 
t3, t4, t5, and t6 are shown in Table 4-36. Median duration of follow-up patient interviews ranged 
from four minutes in cycle 4 to eight minutes in cycle 1 and 2. 
Table 4-35: Number of patient conversations during the course of the study 
 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
n 15 15 13 12 12 8 
Conversations 24 21 18 8 22 14 
Conversations/patient 1.6 1.4 1.4 0.7 1.8 1.8 
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Table 4-36: Duration and rework of follow-up counselling conversations with initially non-
adherent patients 
  Duration [min] Rework [min]   Duration [min] Rework [min] 
t1 
n 15 15 
t4 
n 12 12 
Mean 14 2 Mean 7 1 
Median 11 0 Median 4 0 
SD 16 5 SD 8 1 
Range 0-60 0-20 Range 0-23 0-5 
IQR 4-22 0-1 IQR 0-14 0-0 
t2 
n 15 15 
t5 
n 12 12 
Mean 13 1 Mean 13 1 
Median 9 0 Median 12 0 
SD 18 2 SD 13 1 
Range 0-67 0-8 Range 0-40 0-3 
IQR 0-16 0-1 IQR 0-20 0-2 
t3 
n 13 13 
t6 
n 8 8 
Mean 15 2 Mean 8 2 
Median 6 0 Median 8 0 
SD 18 5 SD 11 4 
Range 0-50 0-20 Range 0-40 0-15 
IQR 0-36 0-2 IQR 0-11 0-1 
4.4.10 Patient evaluation 
Twelve initially non-adherent patients filled in the questionnaire on patient evaluation. 66.7% 
(8/12) assessed the therapy outcome of their oral chemotherapy as expected. Two of 12 patients 
(16.7%) evaluated the outcome as slightly worse and 1/12 patients (8.3%) as much worse than 
expected. Assessment of adverse drug reactions of capecitabine compared with the patients’ 
expectations was distributed all over the Likert scale. Thirty-three percent (4/12) evaluated 
experienced adverse drug reactions as they expected them before, 2/12 (16.7%) stated ‘slightly 
better’ and the same number of patients stated ‘slightly worse’. For details see Figure 4-40. 
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Assessment of therapy outcome 
compared with expectations 
Assessment of adverse drug reactions 
compared with expectations 
  
Figure 4-40: Initially non-adherent patients’ evaluation of two different aspects of the 
capecitabine treatment assessed at t6; n=12 
Overall assessment of treatment was mostly fair (4/12, 33.3%) and good (4/12, 33.3%), see 
Figure 4-41.  
Details on the results of the questionnaire on patient evaluation are accessible in Appendix E, 
Table E-6. 
 
 
Figure 4-41: Initially non-adherent patients’ overall assessment of capecitabine treatment 
assessed at t6; n=12 
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4.5 Further analyses in the entire patient cohort 
4.5.1 Relationship between overall adherence and hand-foot syndrome 
Since the occurrence of hand-foot syndrome (HFS) is not likely to be confounded by cancer 
entity, the entire patient cohort was analysed in terms of an existing relationship between HFS 
and overall adherence. Since a possible drug over-consumption also is reflected by the 
calculation of overall adherence, this adherence parameter was chosen for the analysis of the 
relationship between adherence and HFS. In order to revise the assumption that the cancer type 
is not likely to influence HFS, cancer entity as influencing factor on the occurrence of HFS was 
investigated additionally. 
Overall adherence (referring to the whole observation period) as continuous variable and 
dichotomised by median was not found to be connected to the occurrence of HFS in a 
statistically significant manner. HFS was classified into individual HFS grades (HFS grade 1 to 
3, or HFS grade 2 to 3). Table 4-37 shows the respective results. 
Table 4-37: Tests on significant relationship between overall adherence [%] and HFS 
Dependent variable Independent variable n p value 
Overall adherence [%] 
No HFS 16 
0.273* 
HFS max. grade 1 16 
HFS max. grade 2 25 
HFS max. grade 3 14 
Missing 2 
Overall adherence [%] 
No HFS grade 1-3 16 
0.301** HFS grade1-3 55 
Missing 2 
Overall adherence [%] 
No HFS grade 2-3 32 
0.583** HFS grade2-3 39 
Missing 2 
Overall adherence dichotomised by 
median [<100% / ≥100%] 
No HFS grade 1-3 16 
0.165*** HFS grade 1-3 55 
Missing 2 
Overall adherence dichotomised by 
median [<100% / ≥100%] 
No HFS grade 2-3 32 
0.309*** HFS grade 2-3 39 
Missing 2 
* Kruskal-Wallis-H test 
** Mann-Whitney-U test 
*** Chi-square test 
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No difference in time to first occurrence of HFS grade 1 to 3 between patients whose overall 
adherence accounted for greater or equal the median (black line) and patients with an overall 
adherence of less than the median (dotted line) could be observed (p value=0.458, log-rank test). 
Figure 4-42 illustrates this finding by means of a Kaplan-Meier plot. Triangles and rhombi 
mean censored data (either patients who did not experience HFS at all until the end of the sixth 
cycle or patients who completed less than six cycles). Regarding time to first occurrence of HFS 
grade 2 to 3, no statistically significant difference between the two described overall adherence 
groups was found either (p value=0.202, log-rank test), see Figure 4-43. 
 
Figure 4-42: Time to first occurrence of HFS grade 1-3 during the study period of patients 
showing an overall adherence ≥ median and < median, respectively (median=100%); 
p value=0.458, log-rank test; numbers in the legend represent the number of studied patients 
No statistically significant effect of overall adherence parameters on time to HFS was observed 
by means of Cox regression models. Table 4-38 and Table 4-39 summarise three models each 
for time to first occurrence of HFS grade 1 to 3 and grade 2 to 3, respectively. The effect of 
tumour entity on time to HFS was investigated in order to verify the assumption that occurrence 
of HFS is not likely to be confounded by cancer entity (see 3.9). A statistically not significant 
result in time to occurrence of HFS grade 1 to 3 and grade 2 to 3 indicate the correctness of the 
assumption. 
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Therefore, the conducted analyses suggest that a significant association between overall 
adherence and the occurrence of HFS is unlikely. 
 
Figure 4-43: Time to first occurrence of HFS grade 2-3 during the study period of patients 
showing an overall adherence ≥ median and < median, respectively (median=100%); 
p value=0.202, log-rank test; numbers in the legend represent the number of studied patients 
Table 4-38: Cox regression models for time to first occurrence of hand-foot syndrome grade 1-3 
(enter method) 
Covariates n HR 95%-CI b p 
Overall adherence [%] 71 0.992 0.905-1.088 -0.008 0.870 
Overall adherence dichotomised      
≥100.0% 38 0.847 0.499-1.437 -0.166 0.538 
<100.0%* 33     
Tumour entity      
Breast cancer 28 1.053 0.445-2.495 0.052 0.906 
Colorectal cancer 31 1.390 0.606-3.185 0.329 0.437 
Other cancers* 12    0.557 
n: number of patients; HR: hazard ratio; 95%-CI: 95%-confidence interval for hazard ratio; p: p value of the 
‘likelihood ratio’-test; b: coefficient estimated by Cox regression; * reference group in case of categorical 
variables 
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Table 4-39: Cox regression models for time to first occurrence of hand-foot syndrome grade 2-3 
(enter method) 
Covariates n HR 95%-CI b p 
Overall adherence [%] 71 1.030 0.918-1.156 0.030 0.612 
Overall adherence dichotomised      
≥100.0% 38 1.476 0.774-2.814 0.389 0.237 
<100.0%* 33     
Tumour entity      
Breast cancer 28 2.130 0.616-7.363 0.756 0.232 
Colorectal cancer 31 2.579 0.769-8.648 0.947 0.125 
Other cancers* 12    0.301 
n: number of patients; HR: hazard ratio; 95%-CI: 95%-confidence interval for hazard ratio; p: p value of the 
‘likelihood ratio’-test; b: coefficient estimated by Cox regression; * reference group in case of categorical 
variables 
4.5.2 Potential predictors of adherence 
There was no indication for a relationship between patients’ daily total adherence during the 
first cycle and their age (Spearman’s r=0.009, p=0.941). The age of the entire patient cohort 
ranged from 36 to 90 years. It was observed that those three participants who showed the lowest 
adherence results during cycle 1 (28.6%, 57.1%, and 64.3%) were of a relatively high age (90, 
75, and 79 years), see Figure 4-44. 
 
Figure 4-44: Relationship of daily total adherence during cycle 1 [%] and age [years]; n=73 
A relationship between daily total adherence during cycle 1 and participants’ gender was not 
found either (p=0.891, Mann-Whitney-U test). In addition, there was not any significant 
association between daily total adherence and any of the further socio-demographic and disease-
related characteristics. Appendix F, Tables F-1, F-2 and F-3 contain detailed information on the 
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relationship and correlation, respectively, between daily total adherence during cycle 1 and all 
potential influencing factors and covariates, respectively, tested. 
Spearman correlation of daily total adherence during cycle 1 and the covariate EORTC QLQ-
C30 scale ‘social functioning’ revealed a statistically significant association (Spearman’s 
r=0.285, p=0.023). However, on close examination it became obvious that outliers biased the 
result and no actual relationship between these two variables exists, see Figure 4-45. 
 
Figure 4-45: Relationship of daily total adherence during cycle 1 [%] and the EORTC QLQ-
C30 scale ‘social functioning’; n=63 
Correlation of daily total adherence during cycle 1 and the covariate PSCaTE dimension VC 
(satisfaction with information on vitamins, herbal medicines and complementary treatment 
options) revealed a result that was close to statistically significant (Spearman’s r=0.239, 
p=0.066). The same applied to the correlation of the mentioned adherence parameter with 
distance to patients’ treatment site (Spearman’s r=-0.225, p=0.075). However, the same 
phenomenon was observed and outlier values biased the finding as described above. 
Corresponding scatter diagrams clarified this circumstance and can be accessed in Appendix F, 
Figures F-1 and F-2. 
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5 Discussion 
The future of pharmacy is based on presenting the beneficial effects of pharmaceutical care 
services on patient outcomes [115]. In this study, we applied a systematic screening for non-
adherent patients at an early stage of their capecitabine chemotherapy in order to provide a 
patient-tailored modular medication management. The results indicate that specific adherence 
support might improve adherence of initially non-adherent patients to capecitabine and that 
initially adherent patients’ medication taking behaviour persists over time under basic 
pharmaceutical care and adverse event management. 
5.1 Study set-up 
Study design 
The present study utilised a prospective, multi-centred, two-arm observational cohort study 
design. All patients received modular medication management consisting of basic 
pharmaceutical care and adverse event management. Adherence screening gave information 
about patient adherence during the first capecitabine cycle. Only initially non-adherent patients 
received special adherence support accompanying their anti-cancer treatment. 
Previous studies conducted at the Department of Clinical Pharmacy, University of Bonn, also 
utilised a prospective, multi-centred observational cohort design. However, a preceding control 
group was used instead of two study arms. The impact of pharmaceutical care provided by study 
pharmacists on various outcome parameters was evaluated. In each of the earlier studies the 
control group received standard care provided by health care professionals of the respective 
study centre and intervention group patients additionally received pharmaceutical care provided 
by study pharmacists. Beneficial effects of pharmaceutical care on nausea and emesis, 
adherence, cost-effectiveness, quality of life, and patient satisfaction with information were 
shown [55–62]. These findings built the basis for the present study. As benefits of 
pharmaceutical care on patient adherence have been shown previously [55–62], this study 
focused on resource-saving adherence management (early adherence screening and specific 
adherence support). Since patients were purposely separated according to their baseline daily 
adherence, randomisation of study participants in terms of receipt of the adherence support 
intervention was not applicable in the present study. 
The pharmaceutical care intervention applied was complex because it implied changes in the 
traditional interactions between pharmacist, physician, nurse, and patient, and contained an 
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altered organisation and process of patient care. [116]. The definition of clear outcomes is 
particularly important in the design of such a study which has the aim to evaluate the benefit of 
pharmaceutical care services [117]. In studies evaluating complex interventions, the 
combination of one single primary outcome with some secondary outcomes is the most 
straightforward way for statistical analysis. Moreover, appropriate subgroup analyses should be 
incorporated [116]. Any analysis of quality should consider all three quality measures, structure, 
process, and outcomes. No isolated measure is able to describe the quality of care provided. 
Important structural inputs are e.g. patient profiles. Medication history taking, monitoring, and 
patient counselling on the correct way to use treatment are examples for crucial process 
activities. Outcomes are both intended endpoints of care and unintended consequences (e.g., 
adverse drug reactions) [115]. In Germany, the additional evaluation of subjective endpoints 
(e.g., quality of life, patient expectations) is increasingly demanded [118]. The combination of 
outcome parameters which has been chosen to be assessed in the present study meet the 
demands mentioned above, and therefore the outcomes are valid for the evaluation of benefits of 
pharmaceutical care service. 
Study realisation 
Patients who are treated at the same treatment site – be it an oncology outpatient ward or 
practice – usually initiate conversations with each other and exchange their experiences 
regarding received treatments and patient care. Initially adherent patients did not receive 
module 3 (adherence support) during the course of the present trial. Since patient counselling 
sessions of the modules ‘basic pharmaceutical care’ and ‘adverse event management’ were 
scheduled after every conducted capecitabine cycle as well as adherence support visits, a 
perceived disadvantage was avoided. Consequently, initially adherent patients did not get the 
impression to receive less intense patient care provided by the study pharmacists and less 
information concerning their cancer treatment. 
Modular medication management was mainly provided by one study pharmacist (the author of 
this thesis). However, a second study pharmacist was involved in patient care for four patients. 
To diminish the influence of the individual competences and skills of the study pharmacists, the 
process of medication management was standardised where possible. All patient conversations 
were held and documented in a structured way using predefined documentation forms 
(pharmaceutical care plan, consultation documentation forms etc. which can be found in 
Appendix C). It was defined beforehand which exact situations required a contact with the 
responsible physician. Furthermore, every patient received the same standard components of 
care like an interaction check and a medication plan. The kind of written information material 
handed out to every patient at the beginning of study participation was exactly determined in 
advance. 
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During the accomplishment of the present study the study pharmacists provided broad 
pharmaceutical information to patients and health care professionals. To improve patient care 
and guarantee high quality pharmaceutical care services, relevant evidence was searched 
according to the concept of evidence-based medicine. The five-step approach to effectively 
practice evidence-based medicine was taken into account (formulation of clinical question, 
search of evidence, critical appraise of evidence, integration of critical appraisal with 
physician’s expertise and individual patient, evaluation and improvement of personal approach) 
[119]. Basically, information given during the course of pharmaceutical care was provided 
orally or in written form depending on the particular situation taking into account that provision 
of written information in addition to oral information is essential for the content’s sustainability 
[120]. 
In the present study, the two clinical pharmacists provided pharmaceutical care and performed 
all activities concerning data collection and analysis of the results. Thus, they were both 
practitioners and researchers. This set-up might possibly imply conflicting interests. A more 
appropriate approach would have been a strict separation of the delivery of modular medication 
management and research and evaluation of this service. Moreover, it would have been 
reasonable if the person who analysed the results would not have been aware of patients’ 
baseline adherence and group assignment. Due to personnel and budget constraints it was not 
possible to realise these demands. However, every effort was taken to minimise possible bias 
caused by the study pharmacists. Standard procedures for the analysis of MEMS® profiles were 
defined beforehand and analysis of questionnaires was carried out in the exact same manner 
consistently. In the event of controversial results, a group of experts of the Department of 
Clinical Pharmacy, University of Bonn, was consulted. The group discussed the debatable result 
in detail and a majority decision was made. Furthermore, patients filled in the questionnaires 
unobserved and independently, only in very rare cases the study pharmacists provided minor 
help in terms of completion of the questionnaire (e.g., if a patient had problems to understand 
individual questions or to read the questionnaire). Even though the mentioned limitations exist, 
standardised procedures were utilised in terms of methods of data collection and analysis of the 
results in order to ensure a robust and reliable evaluation of study endpoints. 
Feasibility of modular medication management applied in this study was not distinctively 
investigated and proven by scientific approaches. However, experience gained by the study 
pharmacists shall not be missing at this point. The conduction of modular medication 
management implied a close collaboration between the pharmacists and other health care 
providers like mainly physicians and nurses. During the accomplishment, it became apparent 
that it takes time to implement such a complex pharmaceutical care intervention and to establish 
a successful multidisciplinary collaboration based on mutual trust. Doucette et al. described that 
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trustworthiness is crucial in the development of collaborative relationships and also, to facilitate 
open communication between health care professionals. As time passes and the pharmacist is 
able to demonstrate his expertise by the quality of recommendations he gives, the physicians 
increasingly trust the pharmacist’s competence. This is especially the case when useful 
recommendations are made consistently over time. Moreover, the relationship is more likely to 
become collaborative when pharmacists and physicians jointly determine specific roles. In 
addition, the extent of professional interactions between physician and pharmacist has been 
described to be significantly associated with collaborative patient care. At marginal levels of 
cooperation, most multidisciplinary communications were initiated by the pharmacist. As the 
pharmacist’s role increased, the physician began to address the pharmacist for opinions, 
updates, and other information [121]. During the conduction of the present trial, especially 
trustworthiness and professional interaction have been experienced to foster collaboration 
between pharmacists and other health care providers. Possibly, routine face-to-face interactions 
contributed to a trust-based relationship [122]. 
Time or the lack of it is another limiting factor in the feasibility of pharmaceutical care services 
[123–126]. Analysis of pharmacist’s working time gave information about additional 
expenditure of time caused by an implementation of pharmaceutical care concepts. In the 
present study, pharmacist’s working time was assessed in terms of duration of patient interviews 
and rework. Rework included activities like preparation of the counselling sessions, post 
processing, literature search, interaction checks, generation of medication plans, and discussions 
with other health care professionals. Initially, a raised expenditure of time has to be taken into 
account. However, the median duration of follow-up interviews ranged from 2 to 12 minutes. 
These results are in line with previous findings and show that additional expenditure of time for 
the conduction of pharmaceutical care is kept within reasonable dimensions [57, 61, 95]. 
Patient recruitment 
A major limitation of our study is the relatively small number of initially non-adherent patients. 
Instead of the required sample size of 30 initially non-adherent patients, only 15 patients could 
be enrolled during the study period. Previous data suggested a distribution of 60% initially 
adherent and 40% initially non-adherent patients [57]. The actual distribution in our patient 
population, however, was 80% to 20%. This has to be considered before interpreting data of the 
initially non-adherent patients. However, a clear trend towards an improved adherence over time 
was observed. Further multicenter studies are needed to be able to generalise the findings. 
Apart from the proportion of initially non-adherent patients which has been different than 
expected, patient recruitment was connected with several difficulties. Especially in the early 
stages of the project it was difficult to sustain a fluent recruitment process. This might be 
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explained by lack of time in daily routine of the study centers [127]. Patient recruitment 
improved during the course of the study. Possibly, it took some time for collaborating health 
care professionals to bear the announcement of eligible patients to the study pharmacists in 
mind and to get familiar with changed processes of patient care. Nevertheless, it seems possible 
that collaborating physicians might not have announced every eligible patient to the study 
pharmacists. Possibly, a certain pre-selection of study participants by the collaborating 
physicians happened (knowingly or unknowingly). Data on the total number of cancer patients 
treated in the respective study centres during the study period are not available. Especially 
information on the number of eligible patients who were not announced to the study 
pharmacists would be of particular interest for further analysis. One oncology outpatient ward 
requires further explanation. This centre recruited the vast majority of study participants (54 of 
73). Therefore, one of the two study pharmacists spent a lot of time at that site becoming a 
constantly integrated member of the respective health care team. Accordingly, it is likely that 
most eligible patients of this centre were included in the study. This can be explained by the 
constant awareness of the physicians about the study due to the presence of the study 
pharmacist. Due to personnel constraints it was not possible to integrate a pharmacist in the 
cancer care team of each study centre. However, this seems to be an effective measure to 
improve patient recruitment. 
It is known that one possible reason for participant recruitment problems is a smaller percentage 
of patients agreeing to participate than expected [127]. In this study, eight patients refused to 
participate. The most common reason was perceived additional stress during the study period in 
addition to their mentally and/or physically impaired condition. Moreover, 11 patients did not 
meet the inclusion criteria. Five patients were not capecitabine-naïve, four patients participated 
in another trial and two patients were not able to understand and speak German. Concerning the 
present study, participation in another trial precluded the use of the MEMS® containers. Since 
the other study’s protocol demanded a return of the empty and whole capecitabine blister packs, 
it was not possible to handle the blister packs as usual in this study (reduce them to small pieces 
and store them in the MEMS® container). Language difficulties as well as competing research 
are known recruitment problems [127]. 
Patient population 
Although randomisation of patients was not applicable in the present study and patients were 
separated intentionally according to their baseline adherence, comparable patient groups were 
created in terms of general participant characteristics. No statistically significant differences 
concerning socio-demographic and disease-related variables were found. The observed median 
age of patients treated with capecitabine (initially adherent: 62 years, initially non-adherent: 65 
years) is consistent with data from previous studies which reported a median age of 61 to 71 
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years [19, 22, 61, 128, 129]. Hence, initially non-adherent patients were in the median four 
years older than initially adherent patients. Moreover, initially non-adherent patients took a 
median number of two additional orally administered drugs more (5 versus 3). All initially non-
adherent patients (15/15) took at least one additional drug, whereas the relative frequency 
distribution of initially adherent patients under additional oral treatment was 88% (50/57). Since 
an older age and a cancer diagnosis are usually connected with a higher medication usage, this 
finding is reasonable and in line with the results of a study from 2010 [130], in which 112 
patients older than 65 years and newly diagnosed with breast, colorectal or lung cancer, 
lymphoma or multiple myeloma were surveyed. At baseline, the majority of these patients 
(92%, 103/112) were taking medications and the median number of medications per patient was 
five. Although no statistically significant difference between the adherence groups studied in the 
present study in terms of age and additional drugs was discovered, this result indicates a slight 
trend towards lower adherence in patients with increasing age and number of additional drugs. 
Study drop-outs and missing data 
The EMA recommends the usage of an intention-to-treat analysis (analysis of all patients based 
on initial treatment group allocation) in order to minimise bias due to inconsistencies between 
treatment groups. Intention-to-treat analysis is especially recommended in terms of analysing 
the results of a randomised controlled trial in order to ensure group consistency and, thus, to 
achieve best possible internal validity [131]. The present study, however, is a non-randomised 
cohort study and in this case intention-to-treat analysis is not as essential as in randomised 
controlled trials. Five study drop-outs were recorded who were not analysed, one patient 
withdrew informed consent, two patients did not use the MEMS® container and two patients 
died before the containers could be read out. Thus, a classification as either initially adherent or 
non-adherent of the latter four patients was impossible which, however, represented the 
prerequisite for their assignment to one of the two study arms. Patients who dropped out of the 
present study because of other reasons than the reasons mentioned above were included in 
analysis. Other reasons for a shortened observation period included premature discontinuations 
of capecitabine treatment by the physician (due to tumour progression, adverse drug reaction, 
hospital admission, toxicity of a co-administered drug, or patient’s wish to stop treatment), a 
planned treatment period of less than six cycles, the death of a patient, or the patient’s wish to 
quit the study participation. Nevertheless, the number of study drop-outs who were not analysed 
was relatively low, so that it did not represent a difficulty in the present study. Therefore, per-
protocol-analysis was used. 
In the present study, missing data could not be avoided completely. As recommended by the 
EMA [131], every effort was undertaken to fulfill all the requirements of the protocol 
concerning data collection and management. A close contact between study pharmacists and 
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participating patients on a regular basis ensured the minimisation of missing data. Furthermore, 
the integration of one study pharmacist in the health care team of the study centre which 
recruited most participants contributed to the completion of collected data. In reality, however, 
missing data will almost always occur to some extent [131]. In the event of missing patient data 
in the present study (e.g., missing questionnaires, periods of MEMS® container non-usage), 
available data of the respective participant were analysed. Since the amount was not substantial, 
missing data did not represent a problem. 
5.2 Adherence measurement 
Adherence screening 
For the classification of patients as initially non-adherent or adherent, daily adherence of the 
first drug intake period plus the first day of the therapy-free interval assessed by MEMS® was 
used. Consideration of the whole capecitabine cycle would have provided a more complete 
picture of the participant’s adherence during the first cycle. However, this was not feasible. In 
order to initiate adherence support before the start of cycle 2, an exact appointment on day 21 of 
the first cycle for group allocation would have been necessary. A belated start of the adherence-
supporting module would have biased the results of initially non-adherent patients. 
Although the presented approach was suitable to discriminate between adhering and non-
adhering patients it would be easier to identify non-adhering patients by means of possible 
predictors. With knowledge of adherence predictors a screening method without electronic 
monitoring could be developed, e.g. by a specific questionnaire. In general, numerous factors 
associated with non-adherence to oral anti-cancer drugs have been identified like e.g. side 
effects, forgetfulness, or disliking aspects of treatment [85, 132]. On the basis of our data, it was 
not possible to predict adherence from socio-demographic or disease-related characteristics, e.g. 
age. Indeed, we observed that the three patients exhibiting the lowest baseline adherence during 
cycle 1 (28.6%, 57.1%, and 64.3%) were of a relatively old age (90, 75, and 79 years). 
Moreover, initially non-adherent patients were in the median older than initially adherent 
patients (65 versus 62 years). Although it has been described previously that older age was 
associated with poor adherence to oral anti-cancer treatment [85, 132–134], however, it cannot 
be concluded that adherence decreases with increasing age as there were also elderly patients 
exhibiting high adherence. These findings are in line with the findings of Partridge et al. who 
did not find an association of adherence and age [86]. Furthermore, Bhattacharya et al. did not 
identify significant associations between self-reported adherence to capecitabine and experience 
of side effects, beliefs about capecitabine, or satisfaction with information. However, the 
generalisability of this study was limited by a relatively small sample size as well [89]. 
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Therefore, larger multi-centre studies are necessary to identify predictors of non-adherence to 
capecitabine.  
The current study suggests an association between the adherence status at the beginning of the 
oral anti-cancer treatment and the treatment setting. Sixty patients (51 initially adherent/nine 
initially non-adherent) were recruited on two oncology outpatient wards and 13 patients (seven 
initially adherent/six initially non-adherent) in two oncology practices (p value=0.021, Fisher’s 
exact test). One oncology practice recruited six initially adherent and six initially non-adherent 
participants and the other practice recruited one initially adherent patient. Thus, relatively more 
initially non-adherent patients were recruited in private oncology practices than in oncology 
outpatient wards (46% versus 15%). According to the study design, adherence status was not 
known at time of recruitment. It seems reasonable that the larger oncology outpatient wards 
basically recruited more patients during the study period than the collaborating oncology 
practices. However, it is remarkable that the distribution of initially adherent and non-adherent 
patients recruited from the different settings is that diverse. It has been described previously that 
the private community-based treatment sector (versus an academic setting) is a factor which is 
significantly associated with poor patient adherence to physician’s prescription directives 
regarding chemotherapy [85, 135]. On the other hand, no statistically significant relationship 
between daily total adherence during cycle 1 and the patients’ treatment setting could be 
observed. It has to be taken into account that this differing distribution might have occurred 
randomly due to the small sample size of 15 initially non-adherent patients. However, the result 
might indicate an interesting trend. 
Other potential factors with a negative influence on adherence also include a prolonged 
travelling time for patients to their treatment site [63], complex treatment regimens and multiple 
co-medication [63, 136], low level of education [63], longer time since cancer diagnosis, and 
living alone [132]. Focusing on the studied patient cohort, initially non-adherent patients 
travelled a longer median time to reach their treatment site than initially adherent patients (28 
versus 20 minutes), and took a higher median number of additional regularly and orally 
administered drugs (5 versus 3). A lower percentage of initially non-adherent patients than 
initially adherent patients was treated with capecitabine as a single-agent treatment (47% versus 
60%) and had a university/college degree (7% versus 14%). Median time since diagnosis was 
longer in initially non-adherent patients (16 versus 13 months) and a higher proportion of 
initially non-adherent patients lived on their own (20% versus 14%). Although the differences 
between the two adherence groups regarding the mentioned socio-demographic or disease-
related characteristics were not statistically significant and no significant relationships between 
daily total adherence during cycle 1 and the mentioned variables were found, these results may 
be considered as trends. Nevertheless, the small sample size of the studied patients limits the 
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validity of the observed results. Therefore, larger multi-centre studies are necessary to identify 
precise and specific predictors of non-adherence to capecitabine. If predictors were identified a 
more user-friendly adherence screening method than the measurement with MEMS® (e.g., 
specific questionnaires like MARS) could be developed and MEMS® measurement could be 
replaced. However, as long as the respective evidence is not available, assessment of adherence 
by means of MEMS® would be necessary. 
Subgroup analyses of daily total adherence results were conducted in terms of gender, tumour 
entity, treatment regimen, and treatment intention groups. Regarding initially adherent patients, 
no statistically significant differences of daily total adherence between particular subgroups 
were observed, apart from the difference between patients who were treated with single agent 
versus combination therapy in cycle 6. Patients who received single agent capecitabine 
exhibited a higher adherence. Accordingly, a statistically significant difference between these 
two regimen groups was shown in initially non-adherent patients at t4. Additionally, a trend 
towards better adherence of patients treated with capecitabine monotherapy could be observed 
during most other cycles. These findings are consistent with previous research showing that 
complex treatment regimens negatively affect adherence [63, 136]. However, this result was 
only observed in individual cycles and it would be interesting to see if this finding would be 
confirmed by the assessment of a larger patient population. A marginal trend towards higher 
adherence in female initially non-adherent patients could be observed. However, the studied 
patient cohort was small and the difference was not statistically significant. Concerning this 
matter, previous research presented conflicting results. On the one hand, adherence of HIV-
seropositive patients with antiretroviral therapy was lower among women than among men 
[137]. On the other hand, a patient-related determinant associated with higher non-adherence to 
imatinib therapy was found to be male sex [132]. 
Effect of modular medication management 
Mean daily total adherence of initially adherent participants under modular medication 
management (without receiving adherence support) was high throughout all six observed cycles; 
it ranged from 96.7% to 98.9%. 
All but one patient showed an adherence of ≥90% after the sixth cycle (36/37, CI 88.8%-
99.4%). Thus, the current study proved that >75% of initially adherent patients were adherent 
after the modular medication management. The present data demonstrate that one of the 
postulated working hypotheses (patients with a baseline adherence of >90% do not require 
adherence support) is correct. Initially non-adherent patients’ mean daily total adherence during 
cycle 1 accounted for 80.8%. During the course of cycle 2 to 6 this adherence parameter ranged 
from 90.5% to 93.7%. These patients received adherence support in addition to basic 
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pharmaceutical care and adverse event management. Seventy-five percent (6/8, CI 46.0%-
91.3%) of initially non-adherent patients exhibited an adherence of ≥90% after the sixth cycle. 
Consequently, the hypothesis that >80% of these patients were adherent after the modular 
medication management (including the adherence support module) was not confirmed. Despite 
the small sample size of 15 initially non-adherent patients, a trend towards an improved 
adherence under medication management including adherence support over time was, however, 
observed. Nevertheless, large multi-centre studies are needed to provide more generalisable 
findings concerning the development of initially adherent and non-adherent patients’ adherence 
under medication management. 
Correct interpretation of adherence results is dependent on the exact way of calculating the 
respective adherence parameter, e.g. daily adherence, overall adherence, variability of dosing 
intervals (compare 3.7.2) [138]. Moreover, adherence results are dependent on the method used 
for measuring. Self-reports tend to overestimate adherence and have been criticised as too 
subjective [67, 73, 75]. The present results confirm that both initially adherent and non-adherent 
patients overestimate their adherence compared to the electronic adherence measurement. The 
observed discrepancy of the two measures was more pronounced in the group of initially non-
adherent patients exhibiting a MEMS®-assessed daily total adherence between 33% and 80% 
during cycles 2 to 6. Patient self-report revealed higher results, 83% to 100% of the patients 
stated that their adherence was high (correct intake on 13 of 14 days). Concerning initially 
adherent patients, MEMS®-assessed daily intake adherence was high throughout the whole 
treatment period, self-assessed daily intake adherence, however, was even higher. When 
evaluating the treatment period as a whole, the difference between initially non-adherent 
patients’ statement (mean 95.9%) and electronic monitoring (mean 89.7%) was not statistically 
significant (p value=0.050, Wilcoxon test). In initially adherent patients the difference was 
marginal (97.9% versus 97.7%). Therefore, electronic monitors like MEMS® provide a more 
objective impression even though expensive and complex to handle [67, 73, 75]. Consequently, 
comparison of adherence results from different studies that used different parameters and 
measuring methods might remain vague and methodologically flawed. This applies to the 
present study, as further studies that used the same approach are missing. Most studies which 
investigated adherence to capecitabine assessed medication taking behaviour by means of 
patient self-reports (one study in combination with MEMS®, another study combined with pill 
counts). These studies did not imply the concept of pharmaceutical care and adherence 
parameters were defined diversely. Generally, patient adherence was found to be relatively high 
even without the provision of pharmaceutical care services [81, 88–91]. However, individual 
patients who possibly showed poor adherence were not identified and analysed separately as it 
was the case in the present study. Since the number of non-adherers to capecitabine seems to be 
generally low, final adherence results are not influenced to a great extent. Results of the second 
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interim analysis of a German non-interventional study with capecitabine reported that the 
adherence rate of capecitabine intake was between 84.5% (cycle 1) and 73.2% (cycle 12) [104]. 
This seems lower compared to self-reported adherence results of the present study, but may be 
explained by the fact that the patients did not receive pharmaceutical care. 
The study conducted by Simons et al. measured adherence using MEMS® and calculated daily 
adherence as it was done in the present study. The results demonstrated a high mean daily 
adherence of patients under pharmaceutical care (96.8%) [57]. Daily adherence was not 
calculated for each capecitabine cycle but for the whole observation period. These findings are 
consistent with the present results showing a high mean daily adherence during the whole 
observation period (97.7%) and a high mean daily total adherence during cycle 1 (98.9%) in 
initially adherent participants under medication management. 
The adherence rates in this study are higher than those reported by Partridge et al. who found an 
average overall adherence measured by MEMS® (defined as the number of doses taken divided 
by the number of doses prescribed) between 70% to 80% [86]. Analysing our data the same 
way, overall adherence values ranged between 98.2% and 100.5% in initially adherent patients 
and between 93.8% and 102.7% in initially non-adherent patients. This might be explained by 
the fact that every participant of the present study received two medication management 
modules during all six cycles. In case of initially non-adherent patients, the provided adherence 
support might have increased adherence additionally. This finding is consistent with previous 
results from studies conducted at the Department of Clinical Pharmacy, University of Bonn. 
Under the provision of intensified pharmaceutical care to 48 breast and colorectal cancer 
patients, the intervention group showed an increased mean overall adherence in comparison to 
the control group [57]. In line with previous results [57, 86], non-persistence was not a problem 
in the studied group of patients. 
In terms of overall adherence, some values exceeded 100%. The phenomenon of over-adherence 
in the actual sense has been described as an intentional intake of more doses than prescribed 
[139, 140]. However, when analysing the MEMS® profiles of our studied patient cohorts it 
became apparent that an intentional intake of more capecitabine than prescribed could be 
precluded. These medication taking behaviours might rather be characterised as unintentional 
over-adherence. Two values were particularly conspicuous. One initially adherent patient 
exhibited an overall adherence of 154% in cycle 3 and one initially non-adherent patient’s 
overall adherence in cycle 3 accounted for 145%. The first patient mentioned took by mistake 
capecitabine for a period of three weeks instead of only for two with a subsequent week of 
treatment break. The latter patient took capecitabine during his intended treatment break as well. 
Further reasons for overall adherence values >100% were capecitabine intake events during the 
intended treatment break. Occasionally, patients forgot to stop capecitabine intake after 14 
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treatment days and took capecitabine on the first day of treatment break. Furthermore, it 
happened that patients started with their next cycle one day too early. Since over-adherence 
occurred to a certain extent in this study, patients should be educated carefully in terms of the 
complex treatment regimen of capecitabine. 
Seventy-two percent (5048/7064) of the registered dosing intervals performed by the group of 
initially adherent patients were within the range of 10 to 14 hours. This result is reasonable and 
in line with previous results regarding adherence to capecitabine. Simons et al. found that 82.0% 
(2187/2667) of the dosing intervals of patients who received pharmaceutical care were within 
the mentioned range compared to 64.4% (1221/1897) in patients who did not receive 
pharmaceutical care [57]. Initially non-adherent patients exhibited only 1111/1906 (58.3%) 
dosing intervals between 10 to 14 hours. Consequently, it may be concluded that it is 
particularly essential to counsel patients treated with capecitabine regarding the importance of 
adherence to the correct dosing interval. Regnier Denios et al. reported satisfactory adherence of 
patients under capecitabine but poor observance of the dosing schedule [90]. Accordingly, 
adherence of our studied patient cohorts was high and dosing intervals were found to be 
improvable. 
A factor which might have led to overestimation of adherence in our study is the so-called 
‘Hawthorne effect’. If patients are aware of being monitored for adherence, it is possible that 
they manipulate the MEMS® monitor in order to show a higher level of adherence than actually 
true. Moreover, patients might have been more adherent than they would have been without 
adherence monitoring. However, since all patients were subject to the Hawthorne effect inter-
individual comparisons should be valid. 
The fact that patients were defined as initially adherent or non-adherent on the basis of an 
empirical threshold value (90%) represents a limitation of the study. It is unknown which 
adherence rates are necessary to achieve therapeutic success. A definition of required adherence 
rates gained e.g. from clinical studies would be helpful to assess the clinical relevance of 
enhanced patient adherence. Despite extensive literature search, no information could be found 
on the question how much adherence is needed in order to maximise efficacy of capecitabine 
treatment. To date, few adherence-improving interventions were demonstrated to have an 
impact on clinical outcomes [141]. Wu et al. demonstrated that poor adherence was associated 
with an increased mortality in patients receiving polypharmacy. Regular telephone counselling 
provided by a pharmacist enhanced adherence and, therefore, reduced mortality [98]. It is 
known that pharmaceutical care is able to enhance patient adherence [57]. Future research 
should examine the effect of adherence to capecitabine on the course of disease, clinical 
outcomes, and mortality and, thus, examine clinical relevance of adherence-enhancing 
interventions. 
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Adherence management 
Even though daily total adherence could be improved in initially non-adherent patients, it has to 
be pointed out that this patient population did not reach the same adherence level as initially 
adherent patients. Moreover, inter-individual variability of adherence was higher. This finding 
suggests that a subgroup of patients with low adherence benefits from the adherence-enhancing 
intervention as suggested by Simons et al. [57]. However, a certain number of patients cannot 
be reached and shows a resistant medication taking behaviour. Reasons for intentional non-
adherence in those patients were difficulties in swallowing tablets due to nausea and emesis 
caused by capecitabine (despite the provision of antiemetic prophylaxis and treatment), 
averseness to medication, or ‘compensating’ intake for previous non-adherence during treatment 
break. Unintentional non-adherence was mainly based on forgetfulness. Further research should 
include a systematic approach to develop strategies for adherence management in those 
‘resistant’ patients. 
An intentional background was detected in 26% (40/155) of non-adherent days compared to 
34% (53/155) with unintentional non-adherence. However, reasons for the highest proportion of 
non-adherent days remained unknown (62/155, 40%) mainly because patients were not able to 
remember what had happened on that special day or period when they were asked by the study 
pharmacist (recall bias). Moreover, reasons for non-adherence were defined as unknown if the 
patients’ explanations did not match with the adherence profiles recorded by MEMS® (e.g. the 
patient reported that medication taking went without variations, but the profile displayed non-
adherent behaviour). This demonstrates that it is challenging to fully investigate every detail of 
the process of patients’ adherence. 
Per initially non-adherent patient 1.7 adherence-enhancing strategies were used during the 
accomplishment of the adherence-supporting module. Most frequently, treatment diaries and 
patient education regarding capecitabine efficacy were used. It has been described before that 
patient diaries and education as parts of a complex intervention to enhance adherence represent 
effective possibilities [77, 141]. 
Daily total adherence versus daily intake adherence 
Daily adherence during the intake periods of each cycle was generally lower compared to daily 
total adherence calculated on the basis of drug intake plus rest period. This implies that 
adherence to the regimen was better in the rest period when the drug should not be taken, i.e. 
not many patients took the drug by mistake. However, difficulties concerning the change of 
capecitabine intake to capecitabine-free period became apparent. Eight of 15 patients took 
capecitabine one day too long, too short or even completely ignored the break. From this finding 
we conclude that special attention has to be paid to the change of drug intake to drug-free days 
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during the first capecitabine cycle. Patients have to be educated in detail regarding this 
particularity of the capecitabine treatment regimen. 
5.3 Other endpoints 
Quality of life 
Health-related quality of life has been considered as an important outcome measure in clinical 
cancer research [142]. Chemotherapy, its related side effects and psychological distress 
diminish cancer patients’ quality of life [143, 144]. In the assessment of an oral anti-cancer 
treatment such as capecitabine, quality of life is an important endpoint. The current study used 
the generic questionnaire EQ-5D and the cancer-specific questionnaire EORTC QLQ-C30 at 
three time points to investigate quality of life under modular medication management. 
In initially adherent patients, it became apparent that no problems were mentioned in terms of 
‘mobility’, ‘self-care’, ‘anxiety/depression’. Slight deterioration was observed in the dimension 
‘usual activities’. In the dimension ‘pain/discomfort’ initially adherent patients had some 
problems throughout the observation period. Initially non-adherent patients remarked no 
problems in terms of ‘mobility’ and ‘self-care’. Concerning ‘usual activities’ and 
‘anxiety/depression’ they expressed to have had some problems during the course of therapy. 
‘Pain/discomfort’ was not perceived as a problem at t0, however at t3 and t6 patients had some 
problems. Thus, these results indicate a high and stable health state during the observation 
period although patients were treated with capecitabine. Data acquired by means of the EQ-5D 
visual analogue scale (VAS) also revealed high and stable quality of life values both among 
initially adherent and non-adherent patients. Remarkably, quality of life increased under 
modular medication management, an improvement in VAS values after the sixth cycle could be 
observed among initially adherent patients. Initially non-adherent patients’ median VAS value 
increased from t0 to t3 and decreased to the baseline value after the sixth cycle. As hypothesised, 
these findings suggest that the provision of modular medication management might stabilise 
health-related quality of life over time. This is in line with results gained from the study 
conducted by Döhler who found that pharmaceutical care for breast cancer patients contributed 
to the stabilization of the patient’s quality of life during cancer therapy [55]. 
Compared to the EORTC-QLQC30 reference values initially adherent patients had equal 
median symptom scale values, despite slightly worse symptoms in terms of fatigue, dyspnoea, 
and pain [114]. Median values did not vary remarkably during the course of the study, only 
slight variations were observed (pain got worse, dyspnoea better). An increase of HFS 
symptoms was observed in initially adherent patients. The symptom scale HFS was added to the 
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questionnaire for the present study, thus, no reference values were available. Since HFS is one 
of the most common side effects of capecitabine, this result is not surprising [11, 21, 22]. 
Nevertheless, median symptom scale values did not exceed a moderate level. On the whole, 
initially non-adherent patients showed median symptom scale values which tended be worse 
than the reference values [114]. Since it is known that side effects negatively affect adherence 
[145–147], it is possible that initially non-adherent patients’ medication taking behaviour has 
been influenced hereby. However, no statistically significant relationship between patients’ 
daily total adherence in cycle 1 and EQ-5D dimensions or EORTC QLQ-C30 scores were 
observed. Since the small sample size of this study might limit the validity of observed results, 
larger studies are needed to address this question. 
In general, functional scale values of initially adherent patients were comparable to the 
reference values of the QLQ-C30 scoring manual [114]. Physical and role functioning were 
slightly worse than the reference values but stable over the cycles. Emotional and social 
functioning as well as global health status increased to the level of the reference values at t6 
compared to the time-point of recruitment. Cognitive functioning decreased slightly but not 
below the reference value. In the median, initially non-adherent patients had worse functional 
scale values than the reference values. However, during the course of treatment physical, role, 
emotional, and social functioning increased. Global health status and cognitive functioning were 
stable at each point of measurement. Interestingly, median values concerning emotional 
functioning increased during the course of medication management both in the initially adherent 
and in the initially non-adherent patient group. This is in contrast to the work of Westfeld and 
Simons. In their studies the impact of pharmaceutical care on quality of life of breast and 
ovarian cancer patients under intravenous chemotherapy and of breast and colorectal cancer 
patients treated with capecitabine was assessed. A remarkable deterioration of emotional 
functioning was observed during the course of the study in the control and the intervention 
group [60, 61]. In accordance with median EQ-5D VAS results, median global health status of 
initially adherent patients increased to the level of the reference values [114] during the course 
of treatment. An increase is remarkable taking into account that patients were treated with a 
cytotoxic agent. Initially non-adherent patients’ global health was stable during the provision of 
medication management, as it was found by Simons [61]. 
A German non-interventional study which was conducted in association with the present study 
(see 3.2) found stable quality of life in metastatic breast cancer patients treated with 
capecitabine. The second interim analysis included QLQ-C30 data for 556 patients for up to 12 
cycles. Roughly, observed mean values of functional scales and global health status were about 
10 to 30 lower than the reference values, approximately 10 to 20 lower than the values of 
initially adherent patients and about 10 higher than initially non-adherent patients’ values. The 
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authors did not report symptom scales [104]. The majority of these patients did not receive 
medication management, apart from 25 patients who were analysed in both studies. It has to be 
taken into account that these moderate differences might have occurred randomly due to the 
relatively small sample size of the present study. However, future studies could focus on further 
investigation of the differing quality of life values in the described patient groups. 
In conclusion, quality of life of initially adherent patients treated with capecitabine was high and 
stable under the provision of modular medication management. Initially non-adherent patients’ 
quality of life was stable as well but lower. It has been shown previously that the global health 
status, nausea/vomiting and appetite loss of the EORTC QLQ-C30 questionnaire are 
beneficially influenced by pharmaceutical care [56]. But so far no significant impact of 
pharmaceutical care services on quality of life of patients under capecitabine treatment was 
shown, neither measured with the EQ-5D nor with the EORTC QLQ-C30 questionnaire [61, 
62]. Overall, previously observed quality of life of patients treated with capecitabine was high 
and stable as well [62]. 
In general, comparability of observed results with the reference values might be limited. Higher 
observed symptom scale values and lower observed functional scale values might be explained 
by the fact that EORTC QLQ-C30 reference values are based on baseline quality of life data 
only. These data were assessed before any kind of treatment had been initiated and included 
symptoms originating from the cancer only. Data from patients presently receiving therapy or 
who finished/paused treatment were excluded [114]. However, most patients surveyed in the 
present study (85%) were treated with a palliative intention. Thus, most likely many of them 
had received treatments before the initiation of capecitabine therapy (surgery, radiation, oral or 
intravenous anti-cancer drugs). Additionally, the reference patient cohort included only 12% 
breast and 8% colorectal cancer patients and only 14% were from Germany [114]. Most patients 
in our study suffered from breast or colorectal cancer and were German. 
The sample size of this study was small and heterogenous (different entities, treatment regimens 
etc.). These facts might limit the validity of the observed results. Therefore, larger studies of 
homogenous patient cohorts are required to confirm the beneficial effect of modular medication 
management on quality of life. Since quality of life is influenced by numerous factors such as 
adverse drug reactions, anxiety/depression, age, marital status, physical activity level, or 
race/ethnicity [143, 144, 148, 149], it is crucial that evaluations control for placebo effects and 
determinants of quality of life not related to cancer or its therapy [150]. 
Patient satisfaction with information 
Patients have specific information needs and information satisfaction has been shown to be an 
important predictor of overall quality of life in individuals with cancer. Thus, adequate 
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information provision is essential in cancer care [151]. Initially adherent and non-adherent 
patients showed a high median baseline satisfaction with information (≥4, apart from 3.7 and 
2.3, in both patient groups, respectively, regarding satisfaction with complementary treatments). 
Apart from initially adherent patients’ satisfaction with information sources (median t0: 4.3, t3: 
4.7, t6: 4.5), patient satisfaction improved in each dimension during the course of the study. 
Initially non-adherent patients basically showed marginally lower satisfaction with information 
throughout the study. The second interim analysis of the non-interventional study with 
capecitabine (ML 21725) which was associated to the present study in terms of breast cancer 
patients showed high patient satisfaction regarding information on cancer therapy and adverse 
effects (mean value ≥4) as well [104]. At first view this result is remarkable since these patients 
did not receive additional pharmaceutical care (despite those patients who were included in both 
studies). However, the final evaluation has not been published yet and since patient satisfaction 
with information on complementary treatment options, with information sources and overall 
satisfaction is not described, a comprehensive discussion is not possible at this point. Previous 
studies showed that the provision of pharmaceutical care to a cohort of breast and ovarian 
cancer patients and to a cohort of breast and colorectal cancer patients, respectively, had a 
significant beneficial effect on patient satisfaction with information. Patients of the respective 
control groups who received standard care by physicians and nurses were less satisfied with the 
information they received [56, 60, 61]. A study by Döhler investigated whether the continuous 
integration of a pharmacist in the cancer care team is capable to further increase patient 
satisfaction with information. This was, however, not the case [55]. Patient satisfaction with 
information measured in the present study was higher than in the three mentioned studies. Thus, 
modular medication management seems to be a suitable instrument for the stabilisation (and a 
slight increase) of patient satisfaction with information. 
Hand-foot syndrome (HFS) 
After each conducted capecitabine cycle occurrence and severity grade of HFS was measured 
using the questionnaire on HFS. Regarding initially adherent and initially non-adherent patients, 
the percentage of patients who experienced HFS grade 3 was reasonable (13/56, 23.2%; 1/15, 
6.7%). Only one initially adherent patient had to finally stop treatment because of HFS. 
However, every third patient had to reduce the capecitabine dose due to HFS (initially adherent 
patients: 32.8% (19/58), initially non-adherent patients: 33.3% (5/15)). Most frequently, 
temporary treatment discontinuation in initially adherent patients was due to HFS. This is 
consistent with Steffens et al. who reported that patients stated interruption of capecitabine 
therapy most frequently as a result of HFS [104]. Neither among initially adherent nor among 
initially non-adherent patients, median HFS grade exceeded 1. Since HFS grade 1 is well 
tolerable for patients, this is a pleasant result and might be explained by the provision of adverse 
128 Discussion 
event management to every patient. In the context of this module, patients were educated 
regarding HFS in detail. Prophylaxis, detection and treatment of this cutaneous toxicity were 
explicitly discussed. Although available recommendations for prophylactic and therapeutic 
interventions are empirical only, intensive education and monitoring of patients in terms of HFS 
seems to have a positive impact on the severity of HFS. Additionally, close contact and good 
communication between study pharmacist and attending physician might have accelerated an 
immediate HFS management. If recommended by the SPC (Fachinformation), a dose reduction 
or treatment interruption was prescribed and initiated immediately [12, 13]. Regarding initially 
adherent and initially non-adherent patients, 76.8% (43/56) and 80.0% (12/15) reported to have 
experienced any grade of HFS during the course of the study. The mentioned proportions are 
higher than in a previous study where a proportion of 53.5% patients under capecitabine 
treatment were found to suffer from HFS. In that study toxicity was assessed by clinicians [22]. 
Since occurrence and severity of HFS in the present study were assessed by patients themselves 
and not by their attending physician or nurse, results might be biased (in the direction of higher 
values than actually true). It is likely that patients did not strictly ignore adverse drug reactions 
of other co-administered anti-cancer drugs, e.g. peripheral neuropathy by oxaliplatin and skin 
alterations by cetuximab. Therefore, in the assessment of HFS, patients might have mixed up 
symptoms caused by different anti-cancer drugs. Moreover, previous work has demonstrated 
that patients more frequently report worse symptom severity than clinicians. Furthermore, 
patients tend to report adverse symptoms earlier in the course of treatment than their clinicians 
[152]. Despite this possible bias, occurrence and severity grades of HFS under adverse event 
management were found to be satisfying. 
Patient evaluation 
Oral anti-cancer treatment with capecitabine was evaluated by the patients after six cycles in 
terms of treatment success, adverse drug reactions and overall impression. More than half of 
initially adherent patients assessed their therapy outcome as better than they had expected it 
before starting their treatment (either slightly or much better). The same applies to the 
assessment of adverse drug reactions, 59% assessed experienced toxicity as better than 
expected. A good overall assessment (good, very good and excellent) was stated by 87%. The 
group of initially non-adherent patients had a worse impression of capecitabine therapy. 
Treatment outcome was assessed as better than expected by only 8%. Adverse drug reactions 
were perceived as better than expected by 42% and 58% stated good overall assessment. This 
finding might indicate that a higher degree of dislike of capecitabine therapy was present among 
initially non-adherent patients than among initially adherent patients. Atkins et al. studied non-
adherence to medication amongst 131 breast cancer patients and found out that those patients 
who disliked aspects of their actual medication (e.g. adverse drug reactions, difficulties 
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swallowing tablets, inconvenience) were significantly less likely to adhere [153]. Although 
adherence of initially non-adherent patients improved during later cycles in comparison to the 
first cycle, they did not reach the level of adherence found in initially adherent patients. 
Disliking aspects of the treatment might have contributed to a lower adherence among initially 
non-adherent patients. However, since patients’ perceptions to aspects of their capecitabine 
treatment was not assessed in a structured way in the present study, further research is needed to 
gain insight into patients’ attitudes towards capecitabine in association with their adherence. 
Relationship between overall adherence and hand-foot syndrome 
Previous research showed that the development of HFS under capecitabine treatment is 
associated with a better clinical outcome, more precisely with a longer overall survival [12, 13, 
43]. Hence, HFS might be regarded as a surrogate endpoint for the evaluation and monitoring of 
capecitabine efficacy [43]. We investigated the question whether the occurrence of HFS 
increases with increasing overall adherence. However, conducted analyses suggest that an 
association between overall adherence and the occurrence of HFS is unlikely. Moreover, no 
statistically significant difference in time to first occurrence of HFS grade 1 to 3 could be 
observed between patients exhibiting an overall adherence ≥100% (median) and <100%. The 
same applies to time to first occurrence of HFS grade 2 to 3. Overall adherence of 38 patients 
accounted for ≥100% and 31 patients were found to be in the range of 90.5% to 99.4%. Only 
two patients’ adherence was <90% (88.0% and 89.8%). Possibly, the range of adherence values 
was too small to observe an influence of overall adherence on the development of HFS. 
Additionally, the sample size might have been too small. Nevertheless, a trend towards an 
earlier occurrence of HFS grade 2 to 3 with increasing overall adherence was observed. 
According to this, final clarification has to be revealed by the conduction of further studies 
investigating a larger number of patients. 
5.4 Conclusion and perspectives 
In this study, a systematic screening for non-adherent patients at an early stage of their 
capecitabine chemotherapy was applied in order to provide a patient-tailored modular 
medication management. In summary, the results of this study demonstrate the potential of an 
early adherence screening for non-adherence and an individually applied modular medication 
management to use limited resources most efficiently. The provided adherence support 
improved the medication taking behaviour of initially non-adherent patients to oral 
chemotherapy. Moreover, the provision of basic pharmaceutical care as well as adverse event 
management was sufficient to maintain adherence in initially adherent patients for at least six 
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cycles. The identification of potential predictors of adherence would facilitate the utilisation and 
broad application of the proposed adherence screening and modular medication management. 
Multiprofessional, modular medication management seems to have a stabilising effect on 
quality of life and patient satisfaction with information. Additional expenditure of time for the 
provision of modular medication management by pharmacists was found to be reasonable. 
Initially adherent patients were satisfied with therapy outcome and side effects of capecitabine 
treatment and had a good overall impression. Initially non-adherent patients expressed lower 
satisfaction with their treatment. For future research, it would be interesting to investigate 
initially non-adherent patients’ reasons for this assessment and if there is a relationship of 
patients’ perceptions on capecitabine therapy and adherence. 
Incidence of HFS was found to be high among patients treated with capecitabine. Thus, further 
research concerning effective options for prophylaxis and treatment of this cutaneous toxicity is 
needed. This is especially required since this side effect can impair mobility and activities of 
daily living. Nevertheless, a general limitation of symptoms to a tolerable level under modular 
medication management was achieved. 
Since the small sample size of 15 initially non-adherent patients might limit the validity of the 
present findings, further studies with a larger sample size are required to verify the observed 
results. Moreover, reliable subgroup analyses could be conducted.  
No evidence-based information is available on the question how much adherence to 
capecitabine is needed to maximise efficacy. Thus, further research should urgently address this 
question. A well-founded knowledge regarding particular consequences of poor adherence 
would be very helpful for clinical practice and the development of patient-tailored care. 
For future research projects, a sustainable approach should be used. Upon completion of the 
present project it was not possible to continue modular medication management in the 
collaborating study centres seamlessly and implemented patient care was ceased without 
substitution. It should be aimed to integrate a clinical pharmacist in every cancer care team on a 
permanent basis. This would guarantee continuity of pharmaceutical care and enable 
advancement of services. Moreover, in this way the roles of the clinical pharmacist and the 
scientist could be separated which would be beneficial for the quality of acquired data.  
Despite the discussed limitations of the present study, the innovative approach used and the data 
obtained might build a useful base for further investigations of adherence-enhancing 
interventions. 
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6 Summary 
Capecitabine, an orally administered prodrug of fluorouracil, is given twice daily for 14 days 
followed by a seven day rest period. An adequate patient adherence is essential for treatment 
success. The early identification of potential non-adherers followed by adherence-enhancing 
measures may contribute to the effectiveness of oral anticancer drug therapy. 
The present study aimed at distinguishing initially adherent from non-adherent cancer patients 
treated with capecitabine and to enhance adherence of the latter patient group by providing 
specific adherence support. Moreover, it was aimed to investigate further patient-related 
endpoints under the provision of modular medication management. 
The study was conducted as a prospective, multi-centred observational cohort study. All 
participating patients received two pharmaceutical care modules consisting of oral and written 
information (basic pharmaceutical care and adverse event management). Daily adherence was 
assessed as primary endpoint using electronic monitoring (MEMS®) over a maximum period of 
six cycles. According to their daily adherence during the first treatment cycle, patients treated 
with capecitabine were identified as either initially non-adherent (<90% adherence) or initially 
adherent (≥90% adherence). Initially non-adherent patients received an additional adherence 
supporting module. Further adherence parameters were assessed. Secondary endpoints included 
quality of life, patient satisfaction with information, occurrence of hand-foot syndrome, 
pharmacist’s working time, and patients’ evaluation of capecitabine treatment. 
Seventy-three patients with various tumour entities were enrolled, 58 were initially adherent and 
15 non-adherent according to the above-mentioned definition. Median daily total adherence of 
initially non-adherent patients significantly increased from 85.7% to 97.6% during the 
observation period of six cycles. Throughout all cycles, median daily total adherence of initially 
adherent patients was 100.0%. Daily adherence was not associated with socio-demographic and 
disease-related factors. No patient was non-persistent. Median overall adherence of initially 
adherent patients accounted for 100% in all cycles. In initially non-adherent patients, this 
parameter was 96.2% in cycle 1 and increased in cycles 2 to 6. Initially adherent patients 
generated 7064 dosing intervals (median 11:59 hours) of which 72% were between 10 to 14 
hours. A quantity of 1906 dosing intervals was recorded in initially non-adherent patients 
(median 12:00 hours) of which 58% were in the range between 10 and 14 hours. Self-
assessment revealed a higher adherence than electronically measured, especially among initially 
non-adherent patients. Quality of life of initially adherent patients under modular medication 
management was high and stable, initially non-adherent patients’ values were lower but also 
stable over the cycles. Patient satisfaction with information was high and increased in all 
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dimensions during the observation period. Median HFS severity grade did not exceed a well 
tolerable level. Pharmacist’s working time for provision of medication management was kept 
within reasonable limits. Evaluation of treatment success, adverse drug reactions and overall 
impression of capecitabine by initially adherent patients was good, whereas initially non-
adherent patients expressed a worse impression. 
An early adherence screening effectively distinguishes between patients adhering and non-
adhering to capecitabine. The provision of specific adherence support can enhance adherence of 
initially non-adherent patients, whereas initially adherent patients remain adherent for at least 
six cycles without specific support. Our needs-based approach helps to use available resources 
for adherence management efficiently. Our results are in line with previous studies showing a 
beneficial impact of pharmaceutical care on patient-related endpoints like quality of life, patient 
satisfaction with information, and the severity grade of hand-foot syndrome. Since the small 
sample size of initially non-adherent patients limits the validity of the observed results, larger 
studies are required to verify these findings. 
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150 Appendix A 
 
Information brochure (example Johanniter Hospital Bonn, page 3)  
 
 
Appendix A 151 
 
Information brochure (example Johanniter Hospital Bonn, page 4)  
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EORTC QLQ-C30 questionnaire modified version 3.0 (page 3) 
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Appendix B 167 
 
EORTC QLQ-C30 questionnaire version 3.0 (page 2) 
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PSCaTE questionnaire version 1.1, 03/2006 (page 1) 
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Patient letter containing medication plan (page 1) 
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Patient letter containing medication plan (page 2) 
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First consultation documentation form (page 1) 
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Adherence support documentation form (cycle 1) 
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Adherence support documentation form (cycle 2-6) 
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Appendix D: Results of initially adherent patients 
Adherence 
Table D-1: Daily intake adherence [%] of initially adherent patients during cycle 1 to 6 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 58 98.8 100.0 2.8 90.9-100.0 100.0-100.0 
t2 56 95.8 100.0 9.0 50.0-100.0 92.9-100.0 
t3 48 94.9 100.0 8.7 66.7-100.0 92.9-100.0 
t4 45 95.8 100.0 7.4 68.8-100.0 92.9-100.0 
t5 39 95.8 100.0 8.3 62.5-100.0 92.9-100.0 
t6 37 96.7 100.0 7.9 57.1-100.0 92.9-100.0 
Table D-2: Daily break adherence [%] of initially adherent patients during cycle 1 to 6 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 58 99.2 100.0 3.2 85.7-100.0 100.0-100.0 
t2 54 99.2 100.0 3.2 85.7-100.0 100.0-100.0 
t3 47 100.0 100.0 0.0 100.0-100.0 100.0-100.0 
t4 40 98.9 100.0 3.5 85.7-100.0 100.0-100.0 
t5 40 99.6 100.0 2.6 83.3-100.0 100.0-100.0 
t6 32 99.6 100.0 1.8 92.9-100.0 100.0-100.0 
Table D-3: Number of initially adherent patients exhibiting a daily total adherence below 
100%, 90% and 80%, respectively, at t1, t2, t3, t4, t5 and t6 
Daily total adherence [%] n % Daily total adherence [%] n % 
t1 
=100% 45 77.6 
t4 
=100% 29 64.4 
<100% 13 22.4 <100% 16 35.6 
≥90 58 100.0 ≥90 42 72.4 
<90 0 0.0 <90 3 5.2 
≥80 58 100.0 ≥80 43 74.1 
<80 0 0.0 <80 2 3.4 
Missing 0 0.0 Missing 13 22.4 
t2 
=100% 38 67.9 
t5 
=100% 28 70.0 
<100% 18 32.1 <100% 12 30.0 
≥90 54 93.1 ≥90 38 65.5 
<90 2 3.4 <90 2 3.4 
≥80 55 94.8 ≥80 40 69.0 
<80 1 1.7 <80 0 0.0 
Missing 2 3.4 Missing 18 31.0 
t3 
=100% 30 62.5 
t6 
=100% 25 67.6 
<100% 18 37.5 <100% 12 32.4 
≥90 46 79.3 ≥90 36 62.1 
<90 2 3.4 <90 1 1.7 
≥80 47 81.0 ≥80 36 62.1 
<80 1 1.7 <80 1 1.7 
Missing 10 17.2 Missing 21 36.2 
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Table D-4: Overall adherence [%] of initially adherent patients during the course of the study 
Overall 
adherence n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 58 99.9 100.0 2.3 92.9-107.7 100.0-100.0 
t2 56 99.1 100.0 6.0 58.3-107.1 100.0-100.0 
t3 48 100.5 100.0 8.5 90.0-153.6 100.0-100.0 
t4 45 98.9 100.0 3.6 82.1-103.6 100.0-100.0 
t5 39 98.2 100.0 4.6 81.3-107.4 100.0-100.0 
t6 37 98.8 100.0 4.6 75.0-107.1 100.0-100.0 
Quality of life 
Table D-5: EORTC QLQ-C30 reference values for ‘all cancer patients: all stages’ 
 n Mean SD Median IQR 
Functional scales      
Physical functioning (PF) 10,158 76.7 23.2 80.0 66.7-93.3 
Role functioning (RF) 19,155 70.5 32.8 83.3 50.0-100.0 
Emotional functioning (EF) 23,024 71.4 24.2 75.0 58.3-91.7 
Cognitive functioning (CF) 23,094 82.6 21.9 83.3 66.7-100 
Social functioning (SF) 23,064 75.0 29.1 83.3 66.7-100 
Symptom scales/items      
Fatigue (FA) 22,945 34.6 27.8 33.3 11.1-55.6 
Nausea and vomiting (NV) 22,992 9.1 19 0.0 0.0-16.7 
Pain (PA) 22,989 27.0 29.9 16.7 0.0-50.0 
Dyspnoea (DY) 23,230 21.0 28.4 0.0 0.0-33.3 
Insomnia (SL) 23,241 28.9 31.9 33.3 0.0-33.3 
Appetite loss (AP) 23,241 21.1 31.3 0.0 0.0-33.3 
Constipation (CO) 23,241 17.5 28.4 0.0 0.0-33.3 
Diarrhoea (DI) 23,173 9.0 20.3 0.0 0.0-0.0 
Financial difficulties (FI) 23,124 16.3 28.1 0.0 0.0-33.3 
Global health status/QoL      
Global health status/QoL (QL) 19,237 61.3 24.2 66.7 50.0-83.3 
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Table D-6: Mean, standard deviation, median and interquartile range of the EQ-5D descriptive 
system at t0, t3 and t6 in initially adherent patients (n=58) 
EQ-5D dimension n Mean SD Median IQR 
Mobility t0 51 1.3 0.5 1.0 1.0-2.0 
Mobility t3 46 1.3 0.5 1.0 1.0-2.0 
Mobility t6 36 1.3 0.5 1.0 1.0-2.0 
Self-care t0 51 1.1 0.3 1.0 1.0-1.0 
Self-care t3 46 1.1 0.3 1.0 1.0-1.0 
Self-care t6 37 1.1 0.4 1.0 1.0-1.0 
Usual activities t0 51 1.5 0.6 1.0 1.0-2.0 
Usual activities t3 46 1.5 0.6 1.0 1.0-2.0 
Usual activities t6 37 1.6 0.5 2.0 1.0-2.0 
Pain/discomfort t0 51 1.6 0.6 2.0 1.0-2.0 
Pain/discomfort t3 46 1.5 0.5 2.0 1.0-2.0 
Pain/discomfort t6 37 1.6 0.5 2.0 1.0-2.0 
Anxiety/depression t0 51 1.5 0.5 1.0 1.0-2.0 
Anxiety/depression t3 46 1.3 0.5 1.0 1.0-2.0 
Anxiety/depression t6 37 1.2 0.4 1.0 1.0-1.0 
Patient satisfaction with information 
 
Figure D-46: Five dimensions of patient satisfaction with information of initially adherent 
patients assessed by means of the PSCaTE questionnaire at t0 
CT = Satisfaction with information on cancer therapy; SE = Satisfaction with information on adverse 
effects; VC = Satisfaction with information on vitamins, herbal medicines and complementary 
treatment options; RS = Satisfaction with information sources; OV = Overall satisfaction 
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Figure D-47: Five dimensions of patient satisfaction with information of initially adherent 
patients assessed by means of the PSCaTE questionnaire at t3 (abbreviations see below) 
 
Figure D-48: Five dimensions of patient satisfaction with information of initially adherent 
patients assessed by means of the PSCaTE questionnaire at t6 
CT = Satisfaction with information on cancer therapy; SE = Satisfaction with information on adverse 
effects; VC = Satisfaction with information on vitamins, herbal medicines and complementary 
treatment options; RS = Satisfaction with information sources; OV = Overall satisfaction 
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Patient evaluation 
Table D-7: Patient evaluation of the capecitabine treatment at t6 (n=58) 
 n % 
Assessment of therapy outcome 
compared with expectations 
Much worse 2 5.1 
Slightly worse 7 17.9 
As expected 10 25.6 
Slightly better 10 25.6 
Much better than expected 10 25.6 
Assessment of adverse drug reactions 
compared with expectations 
Much worse 2 5.1 
Slightly worse 6 15.4 
As expected 8 20.5 
Slightly better 10 25.6 
Much better than expected 13 33.3 
Overall assessment of treatment 
Poor 1 2.6 
Fair 4 10.3 
Good 18 46.2 
Very good 13 33.3 
Excellent 3 7.7 
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Appendix E: Results of initially non-adherent patients 
Adherence 
Table E-1: Daily intake adherence [%] of initially non-adherent patients during cycle 1 to 6 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 15 77.8 84.6 17.6 42.9-92.9 78.6-90.9 
t2 15 92.3 92.9 11.6 57.1-100.0 92.3-100.0 
t3 13 90.6 92.9 13.2 50.0-100.0 92.3-100.0 
t4 12 91.7 92.9 8.5 71.4-100.0 85.7-100.0 
t5 12 89.8 92.9 9.5 70.6-100.0 82.1-96.4 
t6 8 89.3 96.4 16.2 57.1-100.0 82.1-100.0 
Table E-2: Daily break adherence [%] of initially non-adherent patients during cycle 1 to 6 
 n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 15 85.7 85.7 25.3 0.0-100.0 85.7-100.0 
t2 15 97.1 100.0 8.0 71.4-100.0 100.0-100.0 
t3 12 98.8 100.0 4.1 85.7-100.0 100.0-100.0 
t4 12 93.2 100.0 10.8 71.4-100.0 85.7-100.0 
t5 12 98.8 100.0 4.1 85.7-100.0 100.0-100.0 
t6 7 98.0 100.0 5.4 85.7-100.0 100.0-100.0 
Table E-3: Number of initially non-adherent patients exhibiting a daily total adherence below 
100%, 90% and 80%, respectively, at t1, t2, t3, t4, t5 and t6 
Daily total adherence [%] n % Daily total adherence [%] n % 
t1 
=100 0 0.0 
t4 
=100 2 16.7 
<100 15 100.0 <100 10 83.3 
≥90 6 40.0 ≥90 10 66.7 
<90 9 60.0 <90 2 13.3 
≥80 12 80.0 ≥80 11 73.3 
<80 3 20.0 <80 1 6.7 
Missing 0 0.0 Missing 3 20.0 
t2 
=100 6 40.0 
t5 
=100 3 25.0 
<100 9 60.0 <100 9 75.0 
≥90 12 80.0 ≥90 9 60.0 
<90 3 20.0 <90 3 20.0 
≥80 13 86.7 ≥80 11 73.3 
<80 2 13.3 <80 1 6.7 
Missing 0 0.0 Missing 3 20.0 
t3 
=100 4 30.8 
t6 
=100 4 50.0 
<100 9 69.2 <100 4 50.0 
≥90 11 73.3 ≥90 6 40.0 
<90 2 13.3 <90 2 13.3 
≥80 11 73.3 ≥80 7 46.7 
<80 2 13.3 <80 1 6.7 
Missing 2 13.3 Missing 7 46.7 
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Table E-4: Overall adherence [%] of initially non-adherent patients during the course of the 
study 
Overall 
adherence n Mean [%] Median [%] SD [%] Range [%] IQR [%] 
t1 15 93.8 96.2 8.4 71.4-107.1 90.0-100.0 
t2 15 100.6 100.0 4.4 92.9-110.7 96.4-103.6 
t3 13 102.7 100.0 13.4 92.9-144.8 96.4-103.6 
t4 12 99.4 100.0 7.3 89.3-114.3 92.9-103.6 
t5 12 97.0 98.2 4.3 89.3-103.6 92.9-100.0 
t6 8 96.0 100.0 12.4 67.9-110.7 94.7-100.0 
Quality of life 
Table E-5: Mean, standard deviation, median and interquartile range of the EQ-5D descriptive 
system at t0, t3 and t6 in initially non-adherent patients (n=15) 
EQ-5D dimension n Mean SD Median IQR 
Mobility t0 14 1.4 0.5 1.0 1.0-2.0 
Mobility t3 12 1.3 0.5 1.0 1.0-2.0 
Mobility t6 12 1.4 0.5 1.0 1.0-2.0 
Self-care t0 14 1.0 0.0 1.0 1.0-1.0 
Self-care t3 12 1.1 0.3 1.0 1.0-1.0 
Self-care t6 12 1.1 0.3 1.0 1.0-1.0 
Usual activities t0 14 1.6 0.5 2.0 1.0-2.0 
Usual activities t3 12 1.6 0.5 2.0 1.0-2.0 
Usual activities t6 12 1.7 0.5 2.0 1.0-2.0 
Pain/discomfort t0 14 1.4 0.5 1.0 1.0-2.0 
Pain/discomfort t3 12 1.8 0.8 2.0 1.0-2.0 
Pain/discomfort t6 12 1.7 0.7 2.0 1.0-2.0 
Anxiety/depression t0 14 1.6 0.5 2.0 1.0-2.0 
Anxiety/depression t3 12 1.6 0.5 2.0 1.0-2.0 
Anxiety/depression t6 12 1.6 0.5 2.0 1.0-2.0 
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Patient satisfaction with information 
 
Figure E-1: Five dimensions of patient satisfaction with information of initially non-adherent 
patients assessed by means of the PSCaTE questionnaire at t0 (abbreviations see below) 
 
Figure E-2: Five dimensions of patient satisfaction with information of initially non-adherent 
patients assessed by means of the PSCaTE questionnaire at t3  
CT = Satisfaction with information on cancer therapy; SE = Satisfaction with information on adverse 
effects; VC = Satisfaction with information on vitamins, herbal medicines and complementary 
treatment options; RS = Satisfaction with information sources; OV = Overall satisfaction 
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Figure E-3: Five dimensions of patient satisfaction with information of initially non-adherent 
patients assessed by means of the PSCaTE questionnaire at t6 
CT = Satisfaction with information on cancer therapy; SE = Satisfaction with information on adverse 
effects; VC = Satisfaction with information on vitamins, herbal medicines and complementary 
treatment options; RS = Satisfaction with information sources; OV = Overall satisfaction 
Patient evaluation 
Table E-6: Patient evaluation of the capecitabine treatment at t6 
 n % 
Assessment of therapy outcome 
compared with expectations 
Much worse 1 8.3 
Slightly worse 2 16.7 
As expected 8 66.7 
Slightly better 0 0.0 
Much better than expected 1 8.3 
Assessment of adverse drug reactions 
compared with expectations 
Much worse 1 8.3 
Slightly worse 2 16.7 
As expected 4 33.3 
Slightly better 2 16.7 
Much better than expected 3 25.0 
Overall assessment of treatment 
Poor 1 8.3 
Fair 4 33.3 
Good 4 33.3 
Very good 2 16.7 
Excellent 1 8.3 
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Appendix F: Results of the entire cohort 
Table F-1: Relationship between daily total adherence during cycle 1 [%] and various binary 
or nominal influencing factors at t0 
Influencing factor (binary or nominal) at t0 n p value 
Age dichotomised by median >62 years 35 0.677*  62 years 38 
Sex female 54 0.891* male 19 
Marital status 
Married/partner 41 
0.895** 
Single 9 
Divorced 4 
Widow 11 
Missing 8 
Current living situation 
Living alone 11 
0.469** With family/partner 53 Living in institution 1 
Missing 8 
Education 
Elementary school 9 
0.529** 
Secondary school 6 
O-levels 18 
Journeyman 5 
A-levels 8 
Master of a trade 4 
Bachelor 3 
University/College 9 
Higher university degree 2 
Missing 9 
Current employment situation 
Housewife/-man 6 
0.333** 
Public servant 2 
Pensioner 34 
Employee 15 
Self-employed 6 
Worker 1 
Missing 9 
Therapy at time of inclusion single agent 42 0.187* combination 31 
Treatment setting Oncology outpatient ward 60 0.171* Oncology practice 13 
Tumour entity 
Breast cancer 28 
0.142** Colorectal cancer 32 
Other 13 
Treatment intention curative 12 0.272* palliative 61 
Responsibility for 
pharmacotherapy 
Independently 59 
0.785** 
Partner/family 4 
Nursing service 1 
Other 1 
Missing  8 
Activity in support group 
Yes 6 
0.874* No 57 
Missing 10 
* Mann-Whitney-U test     ** Kruskal-Wallis-H test 
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Table F-2: Relationship between daily total adherence during cycle 1 [%] and various ordinal 
influencing factors at t0 
Influencing factor (ordinal) at t0 n 
p value 
(Kruskal-
Wallis-H) 
Spearman correlation 
Correlation 
coefficient p value 
Classified number 
of additional drugs  
≤5 55 
0.969 0.018 0.877 6-10 12 >10 5 
Missing 1 
Classified distance 
to therapy site 
[minutes] 
<15 10 
0.111 -0.216 0.087 
15-29 31 
30-44 21 
≥45 2 
Missing 9 
Classified time 
since diagnosis  
<½ year 18 
0.838 0.014 0.906 ½ to 2 years 26 >2 years 28 
Missing 1 
EQ-5D dimension      
Mobility 
No problems 44 
0.476 -0.145 0.249 Some problems 20 Extreme problems 1 
Missing 8 
Self-care 
No problems 59 
0.556 0.074 0.560 Some problems 6 Extreme problems 0 
Missing 8 
Usual activities 
No problems 34 
0.689 0.053 0.675 Some problems 27 Extreme problems 4 
Missing 8 
Pain/ 
discomfort 
No problems 31 
0.247 0.179 0.154 Some problems 31 Extreme problems 3 
Missing 8 
Anxiety/ 
depression 
No problems 33 
0.130 -0.202 0.107 Some problems 31 Extreme problems 1 
Missing 8 
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Table F-3: Spearman correlation of daily total adherence during cycle 1 [%] and various 
covariates at t0 
Covariate at t0 n 
Correlation 
coefficient p value 
Age [years] 73 0.009 0.941 
Distance to therapy site [minutes] 64 -0.225 0.075 
Number of additional drugs 72 -0.088 0.463 
Time since diagnosis [months] 73 -0.082 0.488 
EQ-5D-3L VAS score  64 0.027 0.832 
PSCaTE scale    
Satisfaction with information on cancer therapy (CT)  61 0.125 0.336 
Satisfaction with information on adverse effects (SE)  62 0.117 0.364 
Satisfaction with information on vitamins, herbal 
medicines and complementary treatment options (VC)  60 0.239 0.066 
Satisfaction with information sources (RS)  60 0.109 0.406 
Overall satisfaction (OV) 62 0.206 0.109 
EORTC QLQ-C30 score    
Global health status/QoL (QL2)  63 0.120 0.349 
Physical function (PF2) 63 0.095 0.459 
Role function (RF2)  62 0.112 0.387 
Emotional function (EF)  63 0.218 0.085 
Cognitive function (CF)  63 0.123 0.339 
Social function (SF)  63 0.285 0.023 
Fatigue (FA) 63 -0.165 0.197 
Nausea and vomiting (NV)  63 0.034 0.794 
Pain (PA) 63 -0.026 0.839 
Dyspnoe (DY)  62 -0.024 0.852 
Insomnia (SL)  63 -0.198 0.121 
Appetite loss (AP)  63 -0.207 0.103 
Constipation (CO)  63 -0.016 0.902 
Diarrhea (DI)  62 0.077 0.552 
Financial difficulties (FI)  63 -0.073 0.571 
Hand-foot syndrome (HFS)  62 -0.069 0.596 
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Figure F-1: Relationship of daily total adherence during cycle 1 [%] and the PSCaTE 
dimension VC (Satisfaction with information on vitamins, herbal medicines and 
complementary treatment options); n=60 
 
 
Figure F-2: Relationship of daily total adherence during cycle 1 [%] and distance to 
treatment site [min]; n=64 
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